CERTIFICATE OF MAILING BY "EXPRESS M

"Express Mail" Mailing Label Number EL870637462US

Date of Deposit: March 1, 2002

CTU RECEIPCTATO O 1 MAR 2002

I hereby certify that this paper of fee and the papers indicated as being attached hereto are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 C.F.R. §1.10 on the date indicated above and are addressed to the Commissioner of Patents and Trademarks, P.O. Box 2327, BOX PCT, Arlington, VA 22202.

Alicia Bradbury (Typed or printed name of person mailing) (Signature of person mailing)				
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. §371 ATTORNEY DOCKET NUMBER 24747-1104US				
INTERNATIONAL APPLICATION NO. PCT/NZ00/00174	INTERNATIONAL FILING DATE 04 September 2000	PRIORITY DATE CLAIMED 02 September 1999		
TITLE: NUCLEOTIDE SEQUENCES ENCODING AN INSECTICIDAL PROTEIN COMPLEX FROM SERRATIA				
APPLICANTS FOR DO/EO/US: Travis Robert Glare, Mark Robin Holmes Hurst, Trevor Anthony Jackson				
Applicant herewith submitsto the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. X This is a FIRST submission of items concerning a filing under 35 U.S.C. §371. 2. This is a SECOND OR SUBSEQUENT submission of items concerning a filing under 35 U.S.C. §371.				
3. This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).				
 4. \(\) A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. \(\) A copy of the International Application as filed (35 U.S.C. §371(c)(2)): a. \(\) is transmitted herewith (required only if not transmitted by the International Bureau). b. \(\) has been transmitted by the International Bureau. c. \(\) is not required, as the application was filed in the United States Receiving Office (RO/US). 				
 A translation of the International Application into English (35 U.S.C. §371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3)): a. □ are transmitted herewith (required only if not transmitted by the International Bureau). b. □ have been transmitted by the International Bureau. c. □ have not been made; however, the time limit for making such amendments has NOT expired. d. □ have not been made and will not be made. 				
 A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. §371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)). 				
Items 11 to 16 concern other documents or information included:				
11. An Information Disclosure Statement under 37 C.F.R. §§1.97 and 1.98. 12. A DECLARATION and POWER OF ATTORNEY with claim under 35 U.S.C. §119 for benefit of priority to Application Serial No. New Zealand Patent No. 337610 will be submitted				
13. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 14. A substitute specification. 15. A change of power of attorney and/or address letter. 16. □ Other items of information:				
A SEQUENCE LISTING and DISK copy thereof with Verified Statement.				

17. The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO International preliminary examination fee paid to PTO (37 CFR 1.482) No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) Neither international preliminary examination fee paid to USPTO (37 CFR 1.482) International search fee (37 CFR 1.445(a)(2)) paid to USPTO International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482) International preliminary examination fee paid to USPTO (37 CFR 1.482)	PTO USE ONLY			
Search Report has been prepared by the EPO or JPO \$890.00 International preliminary examination fee paid to PTO (37 CFR 1.482) \$710.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$740.00 Neither international preliminary examination fee paid to USPTO (37 CFR 1.482) \$1040.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Articles 33(2)-(4) \$100.00				
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$ 740.00 Neither international preliminary examination fee paid to USPTO (37 CFR 1.482) *1040.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) *1040.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) *100.00				
international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$ 740.00 Neither international preliminary examination fee paid to USPTO (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1040.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Articles 33(2)-(4) \$ 100.00				
one international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1040.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Articles 33(2)-(4) \$100.00				
and all claims satisfied provisions of PCT Articles 33(2)-(4) \$ 100.00				
ENTER APPROPRIATE BASIC FEE AMOUNT = \$ 890.00				
\$ 130.00 Surcharge of \$130.00 for furnishing the oath or declaration later than 20 X 30 months for the earliest claimed priority date (37 CFR 1.492(e)).				
Claims Number Filed Number Extra Rate				
Total claims 48 28 18 \$ 504.00				
Independent claims 1 0 84 \$ 0.00				
Multiple dependent claims 0 280 \$ 0.00				
BASED UPON ENTRY OF THE ATTACHED PRELIMINARY AMENDMENT TOTAL OF ABOVE CALCULATIONS = \$.00				
Reduction by 1/2 for filing small entity .00				
SUBTOTAL = \$.00	,			
Processing fee of \$130.00 for furnishing the English translation later than20 30 months for the earliest claimed priority date (37 CFR 1.492(f)).				
TOTAL NATIONAL FEE = \$1,524.00				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment accompanied by an appropriate cover sheet (37 CFR 3,28, 3.31) \$40.00 per property.				
TOTAL FEES ENCLOSED = \$1,524.00				
Amount to be: refunded	\$			
charged	\$			
a. X A check in the amount of \$1,524.00 to cover the above fees is enclosed. A duplicate of this sheet is enclosed. b. X Please charge Deposit Account No. 50-1213 for the above fees or for any amount due that is not covered by the enclosed check or if the enclosed check is in the wrong amount, post-dated or otherwise improper. A duplicate of this sheet is enclosed. c. X The Commissioner is hereby authorized to charge any other fees that may be required, or credit any overpayment to Deposit Account No. 50-1213 is enclosed. SEND ALL CORRESPONDENCE TO: Stephanie Seidman Heller Ehrman White & McAuliffe LLP 4350 La Jolla Village Drive, 7th Floor San Diego, CA 92122 Telephone: (858) 450-8400 Facsimile: (858) 587-5360				

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Glare et al.

Serial No.:

10/070,489

Filed: March 1, 2002

For:

NUCLEOTIDE **SEQUENCES ENCODING**

AN INSECTICIDAL PROTEIN **COMPLEX**

FROM SERRATIA

Confirmation No.:6955

Art Unit:

Unassigned

Examiner:

Unassigned

CERTIFICATE OF MAILING BY "EXPRESS MAIL" "Express Mail" Mailing Label Number

EV175670072US

Date of Deposit September 17, 2002

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 C.F.R. §1.10 on the date indicated above and addressed

Commissioner for Patents

U.S. Patent and Trademark Office

Box Missing Parts

P.O. Box 2327

Arlington, VA 22202, on this date.

AMENDMENT IN RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Box Missing Parts

Commissioner for Patents U.S. Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

Dear Sir:

Responsive to the Notice to File Missing Parts of Nonprovisional Application and the Raw Sequence Listing Error Report, mailed June 19, 2002, please amend the application as follows:

IN THE SEQUENCE LISTING:

Please replace the sequence listing in the above-captioned application with the attached replacement SEQUENCE LISTING. A disk copy of the SEQUENCE LISTING accompanies this response.

REMARKS

A check for the fee for a one month extension of time accompanies this response. The Commissioner is authorized to charge any additional fee that may be due in connection with this paper or with this application during its entire pendency may be charged to Deposit Account No. 50-1213. If a Petition for extension of time is needed, this paper is to be considered such Petition.



USSN 10/070,489 Glare et al. AMENDMENT IN RESPONSE TO NOTICE TO COMPLY

Attached herewith is a copy of the Notice to File Missing Parts of a Nonprovisional Application mailed June 19, 2002 and the Raw Sequence Listing Error Report, paper and disk copies of the replacement Sequence Listing, and a Verified Statement that the content of the paper and computer readable copies are the same.

The replacement Sequence Listing differs from the Sequence Listing as originally filed in that the replacement Sequence Listing is prepared in FastSEQ for Windows Version 4.0 and reflects corrections made in response to the Raw Sequence Listing Error Report, as follows:

The General Information section has been amended to include the application number.

In SEQ ID NO. 1, an inadvertently added amino acid number under stop codon had been deleted, subsequent amino acid numbers have been adjusted and numbers indicating the position of the amino acids have been realigned.

In SEQ ID NO. 5, the numbers indicating the position of the amino acids have been realigned.

These corrections are formal and responsive to the Raw Sequence Listing Error Report and the Notice to File Missing Parts mailed June 19, 2002, and thus no new matter has been added.

Respectfully submitted,

HELLER EHRMAN WHITE & McAULIFFE LLP

By:

Stephanie L. Seidman Registration No. 33,779

Attorney Docket No. 24747-1104US Address all correspondence to: Heller Ehrman White & McAuliffe LLP 4350 La Jolla Village Drive, 7th Floor San Diego, California 92122-1246

Telephone: (858)450-8400 Facsimile: (858)587-5360 EMAIL: sseidman@HEWM.com

107070489091702

ROCOPCT/PTO 17 SEP 2002

PATENT APPLICATION Attorney Docket No. 24747-1104US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Glare et al.

Docket No.:

24747-1104US

Filed:

March 1, 2002

For:

NUCLEOTIDE SEQUENCES ENCODING AN INSECTICIDAL

PROTEIN COMPLEX FROM SERRATIA

VERIFIED STATEMENT PURSUANT TO 37 § C.F.R. 1.821(f)

I, Megha Bhumralkar, the undersigned, a Patent Scientific Advisor, in the patent practice group of Stephanie Seidman, Esq., declare that I personally prepared the computer-readable copy of the Sequence Listing set forth in above-entitled Application. The computer-readable file is titled 1104SEQ.US2 on the disk provided herewith.

I further declare that the computer-readable form of the SEQUENCE LISTING is identical to the written form of the replacement sequence listing and that the sequence listing does not contain matter that goes beyond the scope of the disclosure contained in the above-identified Application.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Dated at San Diego, California this 1st day of August, 2002.

Megha Bhumralkar
Patent Scientific Advisor to
Stephanie L. Seidman
Registration No. 33,779
Attorney for Applicant

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Glare et al.

National Stage of International Appln. No.:

PCT/NZ00/00174

Filed: 04 September 2000

Filed: herewith

For: I

NUCLEOTIDE SEQUENCES ENCODING AN

INSECTICIDAL PROTEIN COMPLEX FROM

SERRATIA

Group Art Unit: unassigned

Examiner: unassigned

ATTACHMENT TO THE PRELIMINARY AMENDMENT MARKED UP PARAGRAPHS AND CLAIMS (37 CFR §1.121)

IN THE CLAIMS

Please amend claims 8, 15 and 34 as follows:

- 8. (Amended) A purified and isolated nucleic acid molecule [as claimed in any one] of [claims] claim 4[through 6].
- 15. (Amended) A polypeptide resulting form the transformation or transfection of a host cell with a recombinant expression vector [as claimed in any one] of <u>claim</u> [claims] 12 [through 14].
- 34. (Amended) An insecticidal composition [as claimed in] of claim 32,[or 33] wherein the composition further comprises additional pesticides[, including compounds known to possess herbicidal, fungicidal, insecticidal or nematicidal activity].

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

I hereby certify that this paper and the attached papers are being deposited with the United States

Postal "Express Mail Post Office to Addressee" Service under 37 C.F.R. §1.10 on the date indicated above and addressed to: Commissioner of Patents

and Trademarks, P.O. Box 2327, BOX PCT,

"Express Mail" Mailing Label Number

Date of deposit March 1, 2002

EL870637462US

Arlington, VA 22202.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Glare et al.

National Stage of International Appln. No.:

PCT/NZ00/00174

Filed:

04 September 2000

Filed: herewith

For: NUCLEOTIDE SEQUENCES ENCODING AN

INSECTICIDAL PROTEIN COMPLEX FROM

SERRATIA

Group Art Unit: unassigned

Examiner: unassigned

PRELIMINARY AMENDMENT

BOX PCT Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Preliminary to the examination of the above-captioned application, please amend the application as follows:

IN THE CLAIMS:

Please add claims 42-48 as follows:

- 42. (New) A purified and isolated nucleic acid molecule of claim 5.
- 43. (New) A purified and isolated nucleic acid molecule of claim 6.
- 44. (New) An insecticidal composition of claim 33, wherein the composition further comprises additional pesticides.
- 45. (New) The insecticidal composition of claim 34, wherein an additional pesticide comprises a compound that has herbicidal, fungicidal, insecticidal or nematicidal activity.
- 46. (New) The insecticidal composition of claim 44, wherein an additional pesticide comprises a compound that has herbicidal, fungicidal, insecticidal or nematicidal activity.
- 47. (New) A polypeptide resulting form the transformation or transfection of a host cell with a recombinant expression vector of claim 13.

National Stage of International Appln. No.: PCT/NZ00/00174 GLARE *et al.*PRELIMINARY AMENDMENT

- 48. (New) A polypeptide resulting form the transformation or transfection of a host cell with a recombinant expression vector of claim 14. Please replace claims 8, 15 and 34 with amended claims 8, 15 and 34 as follows:
 - 8. (Amended) A purified and isolated nucleic acid molecule of claim 4.
- 15. (Amended) A polypeptide resulting form the transformation or transfection of a host cell with a recombinant expression vector of claim 12.
- 34. (Amended) An insecticidal composition of claim 32, wherein the composition further comprises additional pesticides.

IN THE SPECIFICATION

Between the Title and "Technical Field", on page 1 of the specification, insert:

—This application is the National Stage of International Application. No. PCT/NZ00/00174, filed 04 September 2000. Benefit of priority under 35 U.S.C. §365(b) to New Zealand application no. 337610, filed 02 September 1999 is claimed herein.—

REMARKS

Any fees that may be due in connection with filing this paper or this application during its pendency may be charged to Deposit Account No. 50-1213.

Claims 1-48 are presently pending. The claims are amended and new claims 42-48 added herein to delete multiple dependencies. The specification is amended to reflect the priority claim. Therefore, no new matter has been added nor have any amendments that alter the scope of the claims been introduced.

It is respectfully requested that any references of record in the International stage of prosecution of this application be made of record in this application.

Included as an attachment is a marked-up version of the amended claims pursuant to 37 C.F.R. §1.121.

National Stage of International Appln. No.: PCT/NZ00/00174 GLARE *et al.* PRELIMINARY AMENDMENT

* * *

In view of the above amendments and remarks, reconsideration and allowance of the application are respectfully requested.

Respectfully submitted,
HELLER EHRMAN WHITE & McAULIFFE LLP

By:

Stephanie Seidman

Registration No. 33, 779

Attorney Docket No. 24747-1104US

Address all correspondence to:
Stephanie Seidman
HELLER EHRMAN WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, 7th Floor
San Diego, CA 92122
Telephone: 858 450-8400

Facsimile: 858 587-5360 email:sseidman@HEWM.com

WO 01/16305

5

10

15

20

10/070489 PCT/NZ00/0017489 Rec'd PCT/PTO 01 MAR 2002

NUCLEOTIDE SEQUENCES

TECHNICAL FIELD

The present invention concerns novel nucleotide sequences encoding insecticidal proteins from the Enterobacteriaceae, Serratia entomophila and Serratia proteamaculans, and the use of said nucleotide sequences and insecticidal proteins.

BACKGROUND ART

Some Serratia entomophila and Serratia proteamaculans strains in New Zealand are known to cause a disease in the major scarab pest, Costelytra zealandica (New Zealand grass grub). The disease was first discovered and described by Trought and Jackson (1982) and was later named amber disease after the distinctive colour of affected insects (Stucki et al. 1984). One species capable of causing the disease, Serratia entomophila, was developed into a commercially-available product ("Invade") in 1989.

The disease is highly host specific, only know to infect a single indigenous species of New Zealand scarab larva. The disease appears unique among insects and results not from rapid invasion of the haemocoel, but from a slow colonisation of the gut. The disease has a distinct phenotypic progression, with infected hosts ceasing feeding within 2-5 days of ingesting pathogenic cells. The normally black gut clears around this time (Jackson et al. 1993) and the levels of the major gut digestive enzymes (trypsin and so forth) decreases sharply (Jackson, 1995). The clearance of the gut results in a characteristic amber colour of the infected hosts. The larvae may remain in this state for a prolonged period (1-3 months) before bacteria eventually invade the haemocoel, causing rapid death.

The finding of a plasmid that apparently encoded the disease was reported in Glare et al. (1993) by showing a correlation between pADAP presence and disease occurrence in

bacterial strains. This was further confirmed by Glare et al. (1996) who showed that transfer of the plasmid from pathogenic to non-pathogenic strains resulted in a change to pathogenic.

Grkovic et al. (1995) showed that disruption of the plasmid by transposon insertion could alter pathogenicity without fully defining the area containing the gene cassette. By marker exchange, they showed that a 10.5kb *Hin*dIII (pGLA20) construct from pADAP encoded some functions of amber disease. However, the clone did not contain all disease encoding plasmid-borne regions.

5

10

15

20

25

Another region involved in amber disease encoding was located by Nunez-Valdez and Mahanty (1996). They located a locus, *amb2*, by transposon mutagensis and searching a cosmid genomic library. This region was chromosomally located and was involved in antifeeding in the larvae of *Costelytra zealandica*. However, the current applicant's research has demonstrated that the *amb2* region is located on pADAP remote from the virulence gene and is probably regulatory in function.

Insecticidal toxins which share some protein homology to the Serratia insecticidal proteins of the present invention have been recently discovered (PCT/US96/18803; PCT/US97/07657) by a group at Wisconsin University (Blackburn et al. 1998; Bowen et al. 1998; Bowen and Ensign 1998). These insecticidal toxins are produced from a gene region in Photorhabdus luminescens which resembles the Serratia virulence region in the clustering of the genes and at the protein level, but has very little DNA homology with the Serratia genes. They have shown high molecular weight proteins from Photorhabdus luminescens are insecticidal to a number of insects from different orders. The lack of DNA homology over the majority of the region, as opposed to protein homology, between the Serratia genes and Photorhabdus genes suggests that these proteins have evolved as a result of convergent evolution leading to the formation of a distinct protein family with a

PCT/NZ00/00174 Received 5 October 2001

common function.

The present applicant has now found that three regions of the pADAP plasmid are required

for full insecticidal function. Sequence analysis of these three regions has shown that the

present applicant has isolated and identified a novel toxin from Serratia species that

belongs to a new family of insecticidal toxins. It is broadly to this toxin that the present

invention is directed.

5

10

15

20

DISCLOSURE OF INVENTION

According to a first aspect of the present invention, there is provided an isolated nucleic

acid molecule comprising a nucleotide sequence of SEQ ID NO: 1 which encodes an

insecticidal protein complex, or a functional fragment, neutral mutation, or homolog

thereof which have at least 75% nucleic acid homology to SEQ ID NO: 1 and are capable

of hybridising with said nucleic acid molecule under stringent hybridisation conditions.

The invention also provides an isolated nucleic acid molecule comprising the nucleotide

sequence 1995-18937 of SEQ ID NO: 1 which encodes an insecticidal protein complex, or

a functional fragment, neutral mutation, or homolog thereof capable of hybridising with

said nucleic acid molecule under standard hybridisation conditions.

The invention also provides an isolated nucleic acid molecule comprising one or more of

the nucleotide sequences 2411-9547, 9589-13883 or 14546-17467 of SEQ ID NO: 1 which

encode insecticidal proteins, or a functional fragment, neutral mutation, or homolog thereof

capable of hybridising with said nucleic acid molecule under standard hybridisation

conditions.

Preferably the nucleic acid molecule comprises all of nucleotide sequences 2411-9547,

9598-13884 and 14546-17467 of SEQ ID NO: 1.

3

AMENDED SHEET

The invention further relates to an isolated nucleic acid molecule comprising a sequence of SEQ ID NO: 1, nucleotides 1955-18937 of SEQ ID NO: 1 or one or more of nucleotides 2411-9547, 9598-13884 or 14546-17467 of SEQ ID NO: 1, operably linked to at least one further nucleotide sequence which encode an insecticidal protein. For example, the at least one further nucleotide sequence may be the nucleotide sequence which codes for the *Bacillus* delta endo toxins, vegatative insecticidal proteins (vips), cholesterol oxidases, *Clostridium bifermentens* mosquitocidal toxins and/or *Photorhabadus luminescens* toxins and so forth.

The nucleic acid molecule may comprise DNA, cDNA or RNA.

5

Preferably said fragment, neutral mutation or homolog thereof is capable of hybridising to said nucleic acid molecule under stringent hybridisation conditions.

The invention further relates to nucleic acid molecules which hybridise to the nucleotide sequence of SEQ ID NO: 1, or nucleotides 1955-18937, 2411-9547, 9598-13884 or 14546-17467 of SEQ ID NO: 1 if there is at least 75% or greater identity between the sequences.

The nucleic acid molecule may be isolated from Serratia entomophila or Serratia proteamaculans strains.

Also provided by the present invention are recombinant expression vectors containing the nucleic acid molecule of the invention and hosts transformed with the vector of the invention capable of expressing a polypeptide of the invention.

The vector may be selected from any suitable natural or artificial plasmid/vector. For example, pUC 19 (Yannish-Perron et al. 1995), pProEX HT (GibcoBRL, Gaithersburg, MD, USA), pBR322 (Bolivar et al. 1977), pACYC184 (Chang et al. 1978), pLAFR3 (Staskowicz et al. 1987), and so forth.

In a further aspect, the invention provides a method of producing a polypeptide of the invention comprising the steps of:

- (a) culturing a host cell which has been transformed or transfected with a vector as defined above to express the encoded polypeptide or peptide; and
- 5 (b) recovering the expressed polypeptide or peptide.

10

An additional aspect of the present invention provides a ligand that binds to a polypeptide of the invention. Most usually, the ligand is an antibody or antibody binding fragment. Such ligands also form a part of this invention.

According to a further aspect of the present invention there are provided probes and primers comprising a fragment of the nucleic acid molecule of the invention capable of hybridising under stringent conditions to a native insecticidal gene sequence. Such probes and primers are useful, for example, in studying the structure and function of this novel gene and for obtaining homologs of the gene from bacteria other than *Serratia* sp.

According to a still further aspect of the present invention there is provided a polypeptide

15 having insecticidal activity encoded by the nucleic acid molecule of the invention, or a
functional fragment, neutral mutation or homolog thereof.

The polypeptide may comprise the amino acid sequence of SEQ ID NO: 1 or a functional fragment, neutral mutation or homolog thereof.

The polypeptide may comprise amino acids 32-5118 of SEQ ID NO: 1.

The polypeptide may comprise at least one amino acid sequence of SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5 or SEQ ID NO: 6.

Preferably the polypeptide comprises amino acid sequence SEQ ID NO: 4; SEQ ID NO: 5

and SEQ ID NO: 6.

More preferably the polypeptide comprises all of SEQ ID NOs: 2-6.

Conveniently, the polypeptide of the invention is obtained by expression of a DNA sequence coding therefore in a host cell or organism.

- The polypeptide may comprise the amino acid sequence of SEQ ID NO: 1 linked to at least one further amino acid sequence encoding an insecticidal protein. For example, the at least one further amino acid sequence may be the amino acid sequence which codes for *Bacillus* delta endo toxins, vegatative insecticidal proteins (vips), cholesterol oxidases, *Clostridium bifermentens* mosquitocidal toxins and/or *Photorhabadus luminescents* toxins etc.
- The invention further relates to polypeptides comprising at least 50%, preferably 60%, more preferably 70% and most preferably 90-95% or greater identity to SEQ ID NO: 1.
 - The polypeptide may be produced by expression of a vector comprising the nucleic acid molecule of the invention or a functional fragment, neutral mutation or homolog thereof, in a suitable host cell.
- According to a further aspect, there is provided an insecticidal composition comprising at least the polypeptide of the invention and an agriculturally acceptable carrier such as would be known to a person skilled in the art. More than one polypeptide of the invention can of course, be included in the composition. In addition, the composition may comprise one or more additional pesticides, for example, compounds known to possess herbicidal, fungicidal, insecticidal or nematicidal activity.

The composition may further comprise other known insecticidally active agents, such as *Bacillus* delta endo toxins, vegatative insecticidal proteins (vips), cholesterol oxidases, *Clostridium bifermentens* mosquitocidal toxins and/or *Photorhabadus luminescents* toxins

WO 01/16305

5

10

15

20

PCT/NZ00/00174

and so forth.

According to a further aspect, there is provided a method of combating pests, especially insects at a locus or host for the pest infested with or liable to be infested therewith, said method comprising applying to a locus, host and/or the pest, an effective amount of the polypeptide of the invention that has functional insecticidal activity against said pest.

According to a further aspect the invention provides a method of inducing amber disease or like condition in insects comprising delivery to an insect an effective amount of the polypeptide of the invention that has functional insecticidal activity against said insect.

The insect may be selected from the order comprising Coleoptera (such as the black beetle, Heteronychus arator (F.), or the black vine weevil, Otiorhynchus sulcatus (F.)); Dictyoptera (eg. The German cockroach, Blattella germanica (L.), or the subterranean termite Coptotermes spp,); Diptera (eg. the housefly Musca domestica L. or the blowfly Lucillia cuprina (Wiedermann); Orthoptera (eg. The black field cricket Telleogryllus commodus (Walker) or the migratory locust Locusta migratoria L.); Hymenoptera (eg. The German wasp, Vespula germanica F.)); Hemiptera (such as the green vegetable bug Nezara viridula (L.) or the green peach aphid Myzus persicae (Sulzer)) the Lepidoptera (eg. the tomato fruitworm, Helicoverpa armigera (Walker), or the codling moth, Laspeyresia pomonella (L.)).

The insecticidal polypeptide may be delivered to the insect orally either as a solid bait matrix, as a sprayable insecticide sprayed onto a substrate upon which the insect feeds, applied directly to the soil subsurface or as a drench or is expressed in an transgenic plant, bacterium, virus or fungus upon which the insect feeds, or by any other suitable method which would be obvious to a person skilled in the art.

According to a further aspect, the invention provides a transgenic plant, bacterium virus or

fungus, incorporating in its genome, a nucleic acid molecule of the invention providing the plant, bacterium virus or fungus with an ability to express an effective amount of an insecticidal polypeptide.

DEFINITIONS AND METHODS

10

20

The following definitions and methods are provided to better define the present invention and to guide those of ordinary skill in the art in the practice of the present invention.

Definitions of common terms in molecular biology may also be found in Lewin, *Genes V*, Oxford University Press: New York, 1994.

The term "native" refers to a naturally-occurring nucleic acid or polypeptide, including, wild-type sequence and alleles thereof.

A "homolog" has at least one of the biological activities of the nucleic acid or polypeptide of the invention and comprises at least 50-70% identical amino acid or nucleic acid sequence thereto, preferably 75-85% and most preferably 90-95% identical amino acid or nucleic acid sequence thereto.

The term "neutral mutation" means a mutation, (that is - a change in the nucleotide or polypeptide sequence such as by deletion, substitution, inversion or insertion, any of which have no effect on the function of the encoded protein).

As indicated above, also possible are variants of the polypeptide or peptide that differ from the native amino acid sequence by insertion, substitution or deletion of one or more amino acids. Where such a variant is desired, the nucleotide sequence of the native DNA is altered appropriately. This alteration can be made through elective synthesis of the DNA, or by modification of the native DNA by, for example, site specific or cassette mutagenesis. Preferably, where portions of cDNA or genomic DNA require sequence modifications, site-

specific primer directed mutagenesis is employed using techniques standard in the art.

In a further aspect, the present invention consists in replicable transfer vector suitable for use in preparing a polypeptide of the invention. These vectors may be constructed according to techniques well known in the art, or may be selected from cloning vectors available in the art.

The cloning vector may be selected according to the host or host cell to be used. Useful vectors will generally have the following characteristics:

(a) the ability to self-replicate;

5 ----

20

- (b) the possession of a single target for any particular restriction endonuclease; and
- 10 (c) desirably, carry genes for a readily selectable marker such as antibiotic resistance.

Two major types of vector possessing these characteristics are plasmids and bacterial viruses (bacteriophages or phages). Presently preferred vectors include plasmids pMOS-Blue, pGem-T and pUC8.

The nucleic acids of the present invention can be free in solution, or attached by conventional means to a solid support, or present in an expression vector or any other type of plasmid.

The term "isolated" means substantially separated or purified away from contaminating sequences in the cell or organism in which the nucleic acid naturally occurs and includes nucleic acids purified by standard purification techniques as well as nucleic acids prepared by recombinant technology and those chemically synthesised.

The terms "DNA construct" means a construct incorporating the nucleic acid molecule of the present invention, or a fractional fragment, neutral mutation or homolog thereof in a

position whereby the protein coding sequence is under the control of an operably linked promoter capable of expression in a plant cell. Such promoters are well known in the art.

A fragment of a nucleic acid molecule according to the present invention is a portion of the nucleic acid that is less than full length and comprises at least a minimum length capable of hybridising specifically with a nucleic acid molecule according to the present invention (or a sequence complementary thereto) under stringent conditions as defined below. A fragment according to the present invention has at least one of the biological activities of the nucleic acid or polypeptide of the present invention.

5

10

15

20

25

Nucleic acid probes and primers can be prepared based on nucleic acids according to the present invention (for example, the sequence of SEQ ID NO: 1). A "probe" comprises an isolated nucleic acid attached to a detectable label or reporter molecule well known in the art. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes.

"Primers" are short nucleic acids, preferably DNA oligonucleotides 15 nucleotides or more in length, which are annealed to a complementary target DNA strand by nucleic acid hybridisation to form a hybrid between the primer and the target DNA strand, then extended along the target DNA strand by a polymerase, preferably a DNA polymerase. Primer pairs can be used for amplification of a nucleic acid sequence, (for example, by the polymerase chain reaction (PCR) or other nucleic acid amplification methods well known in the art). PCT-primer pairs can be derived from the sequence of a nucleic acid according to the present invention, (for example, by using computer programs intended for that purpose such as Primer (Version 0.5© 1991, Whitehead Institute for Biomedical Research, Cambridge, MA)).

Methods for preparing and using probes and primers are described, for example, in Sambrook et al. *Molecular Cloning: A Laboratory Manual*, 2nd ed, vol. 1-3, ed Sambrook

et al. Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY, 1989.

5

20

Probes or primers can be free in solution or covalently or noncovalently attached to a solid support by standard means.

The term "operably linked" means a first nucleic acid sequence linked to a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein coding regions, in reading frame.

The DNA molecules of the invention may be expressed by placing them in operable linkage with suitable control sequences in a replicable expression vector. Control sequences may include origins of replication, a promoter, enhancer and transcriptional terminator sequences, amongst others. The selection of the control sequence to be included in the expression vector is dependent on the type of host or host cell intended to be used for expressing the DNA.

A "recombinant" nucleic acid is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids (for example, by genetic engineering techniques).

Techniques for nucleic acid manipulation are described generally in, for example, Sambrook et al. (1989).

Large amounts of a nucleic acid according to the present invention can be produced by recombinant means well known in the art or by chemical synthesis.

Natural or synthetic nucleic acids according to the present invention can be incorporated into recombinant nucleic acid constructs, typically DNA constructs, capable of introduction into and replication in a host cell. Usually the DNA constructs will be suitable for replication in a unicellular host, such as *E. coli* or other commonly used bacteria, but can also be introduced into yeast, mammalian, plant or other eukaryotic cells.

Preferably, such a nucleic acid construct is a vector comprising a replication system recognised by the host. For the practice of the present invention, well known compositions and techniques for preparing and using vectors, host cells, introduction of vectors into host cells and so forth., are employed, as discussed, *inter alia*, in Sambrook et al (1989).

- A cell, tissue, organ, or organism into which has been introduced a foreign nucleic acid, such as a recombinant vector, is considered "transformed" or "transgenic". The DNA construct comprising a DNA sequence according to the present invention that is present in a transgenic host cell, particularly a transgenic plant, is referred to as a "transgene". The term "transgenic" or "transformed" when referring to a cell or organism, also includes;
- 15 (1) progeny of the cell or organism, and

5

(2) plants produced from a breeding program employing such a "transgenic" plant as a parent in a cross and exhibiting an altered phenotype resulting from the presence of the recombinant DNA construct.

Generally, procaryotic, yeast, insect, or mammalian cells are useful hosts. Also included within the term hosts are plasmid vectors. Suitable procaryotic hosts include *E. coli, Bacillus* species and various species of *Pseudomonas*. Commonly used promoters such as β-lactamase (penicillinase) and lactose (lac) promoter systems are all well known in the art. Any available promoter system compatible with the host of choice can be used. Vectors used in yeast are also available and well known. A suitable example is the 2 micron origin

WO 01/16305

15

20

25

PCT/NZ00/00174

of replication plasmid.

Similarly, vectors for use in mammalian cells are also well known. Such vectors include well known derivatives of SV-40, adenovirus, retrovirus-derived DNA sequences, *Herpes simplex* virus, and vectors derived from a combination of plasmid and phage DNA.

Further eucaryotic expression vectors are known in the art (for example in P.J. Southern and P. Berg, J. Mol. Appl. Genet. 1 327-341 (1982); S. Subramani et al., Mol. Cell. Biol. 1, 854-864 (1981); R.J. Kaufmann and P.A. Sharp, "Amplification and Expression of Sequences Cotransfected with a Modular Dihydrofolate Reducase Complementary DNA Gene, J. Mol. Biol. 159, 601-621 (1982); R.J. Kaufmann and P.A. Sharp, Mol. Cell. Biol. 159, 601-664 (1982); S.I. Scahill et al., "Expressions and Characterisation of the Product of a Human Immune Interferon DNA Gene in Chinese Hamster Ovary Cells," Proc. Natl. Acad. Sci. USA. 80, 4654-4659 (1983); G. Urlaub and L.A. Chasin, Proc. Natl. Acad. Sci. USA. 77, 4216-4220, (1980).

The expression vectors useful in the present invention contain at least one expression control sequence that is operatively linked to the DNA sequence or fragment to be expressed. The control sequence is inserted in the vector in order to control and to regulate the expression of the cloned DNA sequence. Examples of useful expression control sequences are the <u>lac</u> system, the <u>trp</u> system, the <u>trc</u> system, major operator and promoter regions of phage lambda, the glycolytic promoters of yeast acid phosphatase, (for example, Pho5), the promoters of the yeast alpha-mating factors, and promoters derived from polyoma, adenovirus, retrovirus, and simian virus (for example, the early and late promoters of SV-40), and other sequences known to control the expression of genes of prokaryotic and eucaryotic cells and their viruses or combinations thereof.

In the construction of a vector it is also an advantage to be able to distinguish the vector incorporating the foreign DNA from unmodified vectors by a convenient and rapid assay.

Reporter systems useful in such assays include reported genes, and other detectable labels which produce measurable colour changes, antibiotic resistance and the like. In one preferred vector, the β -galactosidase reporter gene is used, which gene is detectable by clones exhibiting a blue phenotype on X-gal plates. This facilitates selection. In one embodiment, the β -galactosidase gene may be replaced by a polyhedrin-encoding gene; which gene is detectable by clones exhibiting a white phenotype when stained with X-gal.

5

10

15

20

25

This blue-white colour selection can serve as a useful marker for detecting recombinant vectors.

Once selected, the vectors may be isolated from the culture using routine procedures such as freeze-thaw extraction followed by purification.

For expression, vectors containing the DNA of the invention to be expressed and control signals are inserted or transformed into a host or host cell. Some useful expression host cells include well-known prokaryotic and eucaryotic cells. Some suitable prokaryotic hosts include, for example, *E. coli*, such as *E. coli*, S G-936, *E. coli* HB 101, *E. coli* W3110, *E. coli* X1776, *E. coli*, X2282, *E. coli* DHT and *E. coli* MR01, *Pseudomonas*, *Bacillus*, such as *Bacillus subtilis* and *Streptomyces*. Suitable eucaryotic cells include yeast and other fungi, insect, animal cells, such as COS cells and CHO cells, human cells and plant cells in tissue culture.

Depending on the host used, transformation is performed according to standard techniques appropriate to such cells. For prokaryotes or other cells that contain substantial cell walls, the calcium treatment process (Cohen, S N *Proceedings, National Academy of Science, USA* 69 2110 (1972)) may be employed. For mammalian cells without such cell walls the calcium phosphate precipitation method of Graeme and Van Der Eb, *Virology* 52:546 (1978) is preferred. Transformations into plants may be carried out using *Agrobacterium tumefaciens* (Shaw et al., Gene 23:315 (1983)) or into yeast according to the method of Van

5

10

20

Solingen et al. J. Bact. 130:946 (1977) and Hsiao et al. Proceedings, National Academy of Science, 76:3829 (1979).

Upon transformation of the selected host with an appropriate vector the polypeptide, or peptide encoded can be produced, often in the form of fusion protein, by culturing the host cells. The polypeptide, or peptide, of the invention may be detected by rapid assays as indicated above. The polypeptide, or peptide, is then recovered and purified as necessary. Recovery and purification can be achieved using any of those procedures known in the art, for example by absorption onto the elution from an anion exchange resin. This method of producing a polypeptide, or peptide, of the invention constitutes a further aspect of the present invention.

Host cells transformed with the vectors of the invention also form a further aspect of the present invention.

Methods for chemical synthesis of nucleic acids are well known and can be performed, for example, on commercial automated oligonucleotide synthesisers.

The term "stringent conditions" is functionally defined with regard to the hybridisation of a nucleic acid probe to a target nucleic acid (for example, to a particular nucleic acid sequence of interest) by the hybridisation procedure discussed in Sambrook et al. (1989) at 9.52-9.55 and 9.56-9.58.

Regarding the amplification of a target nucleic acid sequence (for example,. by PCR) using a particular amplification primer pair, stringent conditions are conditions that permit the primer pair to hybridise only to the target nucleic acid sequence to which a primer having the corresponding wild type sequence (or its complement) would bind.

Nucleic acid hybridisation is affected by such conditions as salt concentration, temperature, or organic solvents, in addition to the base composition, length of the complementary

strands, and the number of nucleotide base mismatches between the hybridising nucleic acids, as will be readily appreciated by those skilled in the art.

When referring to a probe or primer, the term "specific for (a target sequence)" indicates that the probe or primer hybridises under stringent conditions only to the target sequence in a given sample comprising the target sequence.

The term "protein (or polypeptide)" refers to a protein encoded by the nucleic acid molecule of the invention including fragments, mutations and homologs having the same biological activity (for example, insecticidal activity). The polypeptide of the invention can be isolated from a natural source, produced by the expression of a recombinant nucleic acid molecule or be chemically synthesised.

Peptides having substantial sequence identity to the above-mentioned peptides can also be employed in preferred embodiments. Here, "substantial sequence identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 80% sequence identity, preferably at least 90% sequence identity, more preferably at least 95% sequence identity or more. Preferably, residue positions that are not identical differ by conservative amino acid substitutions. For example, the substitution of amino acids having similar chemical properties such as charge or polarity are not likely to effect the properties of a protein. Examples include glutamine for asparagine, or glutamic acid for aspartic acid.

BRIEF DESCRIPTION OF DRAWINGS

5

10

15

20

The invention will be further defined by reference to the specification and the following examples and figures herein.

shows restriction maps of clones used to isolate the pathogenic region and maps of the two pathogenic variants pMH32 and pMH41, in accordance

WO	01/1	6305
----	------	------

5

PCT/NZ00/00174

with a preferred embodiment of the present invention; and

- shows deletion derivatives used in the study, restriction maps of the mutated constructs and recombinants, the phenotype of each mutation, the schematic diagram of the sequenced region, and a nucleotide sequence in accordance with a preferred embodiment of the present invention; and
- Figure 3 shows hydrophobicity plots of SepC and its closest homologue TccC, in accordance with a preferred embodiment of the present invention; and
- Figure 4 shows the comparison of protein sequences of the SepA and P. luminescens toxins, TcdA, TcaB and TccB Putative RGD motif is boxed, plus the site of proteolytic cleavage is illustrated, in accordance with a preferred embodiment of the present invention; and
 - Figure 5 shows the comparison of protein sequences of the SepC and P. luminescens toxin TccC, in accordance with a preferred embodiment of the present invention; and
- shows the plasmid pADAP, in accordance with a preferred embodiment of the present invention.

BEST MODES FOR CARRYING OUT THE INVENTION

The invention will be further defined by reference to the specification and the following examples and figures herein in the ensuing description by way of example only where:

- Figure 1 shows restriction maps of clones used to isolate the pathogenic region and maps of the two pathogenic variants pMH32 and pMH41, where:
 - (A) Is the pADAP HindIII clone pGLA-20 showing locations of the pGLA-20 mutations -

10, -13, and 35, which when recombined back into pADAP and bioassayed against grass grub, result in either a pathogenic phenotype, shown by full flag, or a healthy but non-feeding phenotype indicated by half filled flag. Map of pBG35 showing relative position of pGLA-20-35 mutation and the location of the 2.2kb *Eco*Ri used as a probe to screen the pADAP *Bam*HI library; and

(B) Illustrated restriction enzyme maps of the pathogenic clones pMH32 and pMH41, area of deletion is indicated by Δ .

pBR322 vector DNA;

pLAFR3 vector DNA.

Restriction enzymes are abbreviated as follows: B, BamHI, Bg, BglII; E, EcoRI: H, HindIII; and X, XbaI.

Figure 2 shows:

(A) Which are Mini-Tn10 pACYC184 based deletion derivatives used in the study.

is the pACYC184 vector,

- 15 Δ indicates deletion + pathogenic,
 - loss of pathogenicity; and
 - (B) Illustrates restriction maps of the mutated constructs pBM32 and the pADK recombinants; and
 - (C) Where the phenotype of each mutant is indicated by flags.
- Blocked flags indicates mutations that did not affect the disease process.

Open flags indicate mutations that abolish disease symptoms.

Half-filled flags denote mutations that abolish visual disease symptoms but are unable to feed.

* indicates pADK mutations obtained by Grkovic et al. (1995).

Restriction enzymes are abbreviated as follows: B, BamHI, Bg, BglII; E, EcoRI; H, HindIII; and X, Xbal.

- (D) Is a schematic diagram of the sequenced region, where:
- Denotes sequenced region.

5

Arrows indicate ORFs and their direction

region homologous to spvB ... location of repeat.

10 (E) Is a nucleotide sequence of the 5 times 12bp repeat and the palindrome.

Restriction enzymes are abbreviated as follows: B, BamHI, Bg, BglII; E, EcoRI; H, HindIII; and X, Xbal.

In Figure 3 hydrophobicity plots of SepC and its closest homologue TccC are shown. The scale is disproportional to size and has a scanning window of 17 amino-acid residues.

Figure 4 shows the comparison of protein sequences of the SepA and P. luminescens toxins, TcdA, TcaB and TccB. Putative RGD motif is boxed. The site of proteolytic cleavage is reported by Bowen et al. (1998) (Residue 1933 of TcdA) is indicated by an arrow.

Figure 5 shows the comparison of protein sequences of the SepC and P. luminescens toxin

CC; and Figure 6 shows the plasmid pADAP.

5

15

20

PCT/NZ00/00174

PROTOCOL

Bacterial isolates and methods of culture

Table 1 lists bacterial isolates and plasmids used in the present invention. Bacteria were grown in LB broth or on LB agar (Sambrook et al. 1989), at 37° for *Escherichia coli* and 30°C for *S. entomophila*. Antibiotic concentrations used (μg/ml) for *Serratia* were kanamycin 100, chloramphenicol 90, tetracycline 30 and for *E. coli* strains were kanamycin 50, chloramphenicol 30, tetracycline 15, and ampicillin 100.

DNA isolation and manipulations

pADAP DNA was isolated from a 50ml overnight culture of bacteria using QIAGEN® plasmid maxi kit (Qiagen, Hilden, Germany), as per the manufacturer's instructions. Standard DNA techniques were carried out as described by Sambrook et al. (1989). Radioactive probes were made using the Amersham Megaprime DNA labeling system (Amersham, Buckinghamshire, UK). Southern and colony hybridisations were performed as outlined in Sambrook et al. (1989). The plasmid pADAP is shown in Figure 6.

pADAP BamHI library was constructed using a Sigma 'Gigapack®IIIXL packaging extract, as specified by the manufacturer (Stratagene, California, USA).

Introduction of plasmid DNA into E. coli and S. entomophilia

pLAFR3 based derivatives were introduced into *S. entomophilia* by tripartite matings on solid media as described previously (Finnegan & Sheratt, 1982) using the pRK2013 helper plasmid (Figorski & Helanski, 1979). pACYC184 and pBR322 based plasmids were electroporated into *E. coli* and *S. entomophilia* strains, using a Biorad Gene Pulser (2μF, 2.5KV, and 200 abns) (Dower et al. 1988).

WO 01/16305

5

10

15

20

PCT/NZ00/00174

Mutagenesis

Transposon insertions were generated in recombinant plasmids using the mini-*Tn10* derivative 103 (kanamycin resistant) as described by Kleckner et al. (1991). Insertions were recombined into pADAP by transforming A1MO2 (refer to Table 1) with the described construct. After growth in non-selective media, bacteria were screened for resistance to kanamycin and loss of the pLAFR3 tetracycline resistance marker.

Bioassay against Costelytra zealandica larvae

Infection of *C. zealandica* larvae was determined by a standard bioassay where the healthy larvae, collected from the field, were individually fed squares of carrot which had been rolled in colonies of bacteria grown overnight on solid media (resulting in approximately 10^5 cells/carrot square). Twelve, second or third instar larvae were used for each treatment. Inoculated larvae were maintained at 15° C, in ice-cube trays. Larvae were left feeding on treated carrot for 3-4 days, then transferred to fresh trays and provided with untreated carrot for 10-14 days. The occurrence of gut clearance and loss of feeding was recorded every 3-4 days. Strains were considered disease-causing if greater than 70% of larvae showed disease symptoms by day 14. Known pathogenic and non pathogenic controls were included in all bioassays. Typically cessation of feeding occurs within 2-3 days while clearance of the larvae gut may take 4-6 days.

Recovery of bacteria from larvae

To isolate bacteria from inoculated grubs, larvae were surface sterilised by submerging in 70% methanol for 30 seconds. The larvae were then shaken in sterile DH₂0, removed and individually macerated in a 1.5ml microcentrifuge tube. The macerate was serial diluted and plated on LB media containing antibiotics selective for the host *S. entomophilia* strain. To assess the stability of the bioassayed plasmid, colonies were patched onto a plate

containing antibiotics either selective for the recombinant plasmid or the *S. entomophilia* strain. Identity of plasmids in the recovered strain was checked by restriction enzyme profile.

Nucleotide Sequencing

15

20

25

A 9-kb BamHI –EcoRI fragment derived from the pBM32-8 mutation (Fig 2b) and the 8kb HindIII fragment of pBM32 were separately cloned into the appropriate site of the deletion factory plasmid pDELTA1. Deletions were generated using the Delection factoryTM system (GIBCO BRL, MD, USA), as outlined in the manufacturers instructions. To identify the precise location of mini-Tn10 mutations, the peripheral mini-Tn10 BamHI sites were used in conjunction with the BamHI sites of the pathogenic region to subclone the mini-Tn10 flanking regions into either pACYC184 or pUC19. Sequences were generated using the mini-Tn10 specific primer 5'ATGACAAGATGTGTATCCACC3' (Kleckner et al. 1991).

Plasmids for sequencing were prepared by Wizard® (Promega, Madison, USA) or Quantum Prep® (Bio-Rad, California, USA) miniprep kits. Sequences were determined on both strands, by using combinations of subcloned fragments, custom primers and deletion products derived from the deletion factory system (Gibco BRL, Madison, USA). The DNA was sequenced using either ³³P dCTP and the Thermosequenase cycle sequencing kit (Amersham, Buckinghamshire, UK), or by automated sequencing using an Applied Biosystem 373A or 377 autosequencer. Sequence data were assembled using SEQMAN (DNASTAR Inc., Madison, USA). ORF's were analysed by Gene Jockey. Databases at the National Center for Biotechnology Information were searched by using BLASTN and BLASTX via the www.ncbi.nlm.gov/BLAST. Searches for DNA palindromes, repeats and inverted repeats were undertaken using DNAMAN (Lynnon Biosoft, Quebec, Canada). Protein motifs were searched using Blocks (http://www.blocks.fhcrc.org/), ExPASy (http://www.expasy.ch/), and Gene Quiz (http://columba.ebi.ac.uk:8765/ggsrv/submit).

The sequences determined in this study have been deposited in Gene Bank under Accession Number AF1335182.

RESULTS

20

25

Cloning the disease encoding region from pADAP

Previously, Grkovic et al. (1995) have shown taht the pADK-13 mutation can be 5 complemented with the pADAP 11 kb HindIII fragment (pGLA-20). However, the pADK-10 mutation was unable to be complemented with pGLA-20. In an attempt to isolate the region that may complement the pADK-10 mutation the previously described pGLA-20 derived, pADK-35 null mutation (Grkovic et al. 1995) was used as a selective marker (Fig 10 1), to select the BgIII fragment encompassing both the pADK-10 and pADK-35 mutations. pADK-35 DNA was isolated and digested with the restriction enzyme $BgI\Pi$. The resultant digest was ligated into the BamHI site of bBR322 to form the construct pBG35 (containing 12.8kb $Bgl\Pi$ – mini-Tn10 fragment). pBG35 was placed separately in trans with pADK-10and pGLA-20, and the resultant strains bioassayed against grass grub larvae. Results 15 showed that pBG35 was able to complement the pADK-10 mutant, but was unable to induce any symptoms of amber disease when placed in trans with pGLA-20, indicating that there must be another region on pADAP needed to induce amber disease.

Restriction enzyme data of pGLA-20 and pBG35 suggested that the entire pathogenic region may reside within one of the large *Bam*HI fragments of pADAP. A cosmid *Bam*HI library of pADAP was made and screened using the 2.2kb *Eco*RI fragment derived from pBG35 (Fig 1) as the probe. Several probe positive clones were isolated; all shared similar restriction enzyme profiles. However, one (designated pMH32) was found to be smaller, measuring only 23kb in size compared with the 33kb of the other clones (eg. pMH41; Fig 1b). The difference between pMH32 and pMH41 was found to be a 10kb deletion at the left most end of pMH32 encompassing the one *Hind*III site (Fig 1). *E. coli* strains

containing pMH32 or pMH41 were bioassays against grass grub larvae and found to induce the full symptoms of amber disease (that is - gut clearance and antifeeding activity). However, about ten days after infection a proportion of grass grubs fed the *E. coli* strains were found to recover from a diseased to a healthy phenotype.

The plasmids pMH32 and pMH41 were subsequently introduced into a *S. entomophilia* strain cured of pADAP (5.6RC) and the strains bioassayed against grass grub larvae. The strains gave the same disease progression as wild type and no larvae recovered, suggesting that the region cloned in pMH32 contained all the pathogenic determinants of pADAP.

5

20

Effect of copy number and mini-Tn10 insertions in pBM32 on disease-causing ability

To facilitate mutagenesis and assess the effect of copy number on the disease process, the 23kb BamHI fragment from pMH32 was cloned into the medium copy plasmid pBR322 to give pBM32. A bioassay comparing the ability of pMH32 and pBM32 to induce amber disease against grass grub was undertaken. Results showed that there were no visual differences in the progression of amber disease between pBM32 and pMH32. The construct pBM32 was mutated with the mini-Tn10 transposon derivative 103, and insertions mapped (Fig 2b). Bioassays of E. coli strains containing plasmids of the resultant mutants, showed that the disease determinants were confined within a central 16.9kb region (nucleotides 1955-18937 of SEQ ID NO: 1).

All strains were non-pathogenic or fully pathogenic, and no partial disease phenotypes such as antifeeding, or gut clearance were noted.

To confirm that no sequences at either end of the cloned fragment influenced the disease process, several deletion plasmids were made (Fig 2a). The large fragments resulting from cleavage of the pBM32 -4, -8, -10, -20, -23, -24 and -35 plasmids with *BamHI* were cloned into the analogues site of pACYC184. The resultant plasmids were transformed into the

non-pathogenic S. entomophilia strain 5.6RKm and assessed for pathogenicity. This analysis confirmed that the central 16.9kb region (Fig 2a) was sufficient to induce the disease.

Effect of mini-Tn10 insertions in pADAP on disease-causing ability

15

20

Grkovic et al. (1995) recombined by marker exchange the pGLA-20 based mutations - 10 and -13 into pADAP (Fig 2a). When bioassayed, S. entomophilia strains containing either of these mutant plasmids caused a partial condition including cessation of feeding but not gut clearance or amber colouration. This was in contrast to the complete abolition of disease observed in pADAP-cured S. entomophilia strains containing mutant pBM32 plasmids with similar insertions.

To determine the disease phenotype of the pBM32-based insertions in a pADAP background, the pBM32 based insertions were transferred into pADAP. pBM32 -1, -2, -4, -5, -6, -8, -9, -10, -21, -24, -30, -31 and -35 DNA fragments containing the inserted transposon and flanking DNA were cloned as independent fragments into pLAFR3 and the inserts recombined back into pADAP by marker exchange (Fig 2c). The resultant recombinant *S. entomophilia* strains were checked by Southern analysis to confirm that recombination had occurred as expected and no pLAFR3 vector sequences were present (data not shown). Mutations that did not affect the disease process in pBM32 also had no effect when recombined back into pADAP. However, strains with the pADAP mutants that totally abolished the disease process when in the pBM32 clone caused non-feeding but not gut clearance of the grubs (Fig 2b, c). Hence, none of the pADAP recombinant strains completely abolished the disease process. This suggests that, while the 16.9kb fragment contains all genes required for pathogenicity, other genes contributing to the antifeeding effect are present on some other part of pADAP.

25 Assessment of plasmid stability during the course of the bioassay showed that greater than

90% of the recombinant Serratia strains contained the clone of interest.

Nucleotide Sequence Analysis of the pathogenic region

The large *Bam*HI fragment (18937 bp) derived from the pBM32-8 was sequenced on both strands using a combination of constructed detections, plasmid subclones and custom made primers. A total continuous sequence of 18937 bp has been deposited in Gene Bank (Accession Number AF135182). Structural analysis of the DNA sequence using DNAMAN showed that there was a 12-bp sequence repealed five times between positions 683 and 743. The repeat is flanked by an upstream 13 base pair palindrome (669-682-bp), and a degenerate 34-bp downstream palindrome (765-799-bp)(Fig 2d,e).

10 Translation of the nucleotide sequence revealed nine significant open reading frames (ORF's). These together with their putative ribosomal binding sites and their base composition are listed in Table 2. Eight of the ORF's were oriented in the same direction and the other two in the opposite direction (Fig 2d). Sequence similarity searches showed that the deduced products of seven of these ORF's shared similarity with known proteins (Table 3). Products of three of the ORF's showed similarity to different protein components of insecticidal toxins of *Photorhabadus luminescents* (Bowen et al. 1998).

These ORF's have been designated sep. (sepA, sepB and sepC) for Serratia entomophilia pathogenicity.

Similarities of deduced amino-acid sequences to proteins in current database

20 Results of database searches for homologues proteins are listed in Table 4.

With reference to Fig 2d and Table 4, the following protein similarities were identified:

The protein product of sepA, had high similarity to the P. luminescents insecticidal toxin complex protein TcbA, TcdA, TcaB and TccB. These proteins shared three significant

5

10

15

20

regions of predicted amino-acid similarity, at the amino-terminal region (SepA amino-acid residues (121-178), a central region (SepA amino-acid residues 960-1083) and, with greatest similarity, at the carboxyl terminus (SepA amino-acid residues 1630-2376) Fig. 4). However, there was little amino acid conservation around the putative proteolytic cleavage site of TcaB, TcbA and TcdA identified by Bowen et al. (1998). SepA also contained a region (residues 1057-1345) with weak similarity to the *Clostridium bifermentans* mosquitocidal toxin cbm71 (Barloy et al., 1996).

SepB and the *P. luminescens* insecticidal toxin complex protein TcaC shared similarity throughout their length, and both SepA and TcaC showed high amino-terminal similarity to the *Salmonella* virulence protein spvB (Gullig et al. 1992) (Fig. 5). The similarity of SepB and TcaC to SprB diminishes after SpvB amino acid residue 356.

SepC showed strong similarity to the amino-terminal of the insecticidal toxin complex protein TccC, up to amino-acid residue 663 of SepC. A number of putative bacterial cell wall proteins also have high similarity to SepC, including the wall associated protein precursor *B. subtilis* (WAPA) and members of the *E. coli Rhs* (recombinant hot spot) elements. Strong similarity of SepC was also observed with hypothetical wall-associated proteins from *Coxiella burnetti* and *Bacillus subtilis* (Table 4).

The translated sequences of ORF1 and ORF2 showed no similarity to sequences in the current databases. ORF3 shared significant similarity to the morphogenesis protein of the *Bacillus subtilis* bacteriophage B103, a member of bacteriophage muramidase-type lysis proteins (Pecenkova et al. 1996). However, relative to size, the gp19 protein of *S. typhimurium* phage ES18 (146 amino-acid residues) or the nucD/regB phage lysozymes of *S. marcescens* (179 amino-acid residues) are more similar. ORF4 showed similarity to *E. coli* bacteriophage N15gp 55 protein, a protein of unknown function (Zimmer et al. 1998).

25 Located in the same orientation as the sep genes and 134bp downstream of the SepC

5

10

15

20

25

termination codon is a 204 base pair region assigned ORF5, which has high similarity to a *S. typhimurium* revolvase/invertase protein. However ORF5 is disrupted by two stop codons at amino-acid residues 19 and 64, making it unlikely that an active resolvase/invertase protein, is encoded by this region. A 256-bp region of encompassed by ORF5 (17498-17754) showed high similarity (77% identity) to the region (AF020806; 1629-1885 bp) encoding *S. typhimurium* DNA invertase gene (Valdivia et al. 1997) suggesting a similar ancestral origin.

Downstream of ORF5 and oriented in the opposite direction from 18935-18163 was a 870 base pair region of DNA designated ORF6 whose product showed high amino-acid similarity over two different reading frames to the insertion element *IS*91 of *E. coli* (Mendiola et al. 1992). The translated sequence is interrupted at amino-acid residue 149 of the *IS*91 element and later resumed on a second reading frame, before its similarity switched back to the original reading frame. Swtiching of ORF's is a common feature of members of the *IS*3 family where the transposase is encoded by this overlapping ORF's (Prere et al. 1990). However, the switch back to the initial strand is atypical. ORF6 may therefore be a dysfunctional relic of an ancestral *IS* element. It is unknown whether ORF6 contains a ribosomal binding site as its predicted location would lie outside the sequenced region. There was no DNA similarity to the *IS*91 element.

Analysis for protein motifs showed that a tripeptide cell-binding motif Asp-Gly-Arg (RGD), implicated in the binding of various adhesion proteins produced by parasites and viruses to eukaryotic cells (Leininger et al. 1991), is present in SepA and the *P. luminescens* TcdA, and TcaB proteins (Fig. 4). The RGD motif is present in cell surface adhesions produced by the human pathogen *Bordetella pertussis*, namely the filamentous heamagglutinin (220 kDa) (Relman et al. 1989), and the outer membrane protein pertactin (69 kDa) (Leininger et al. 1991). These motifs have been implicated in enhancing the binding of *B. pertussis* to eukaryotic cells. Because the RGD motif found in SepA falls in a

region of high similarity between SepA and its *P. luminescens* counterparts, it may play a role in meditating the attachment of the protein and/or the bacteria to the insect cell wall.

The hydropathicity profile of each of the Sep proteins was examined using the Kyte and Doolittle algorithm (Kyte and Doolittle, 1982) and compared to the relevant *P. luminescens*5 homologues. None of the Sep proteins contained a positively charged amino terminus followed by a hydrophobic region, characteristic of a signal sequence (Gierasch, 1989). The profiles of SepA, TcbA and TcdA were very similar (data not shown) and each exhibited a steep hydrophilic peak at the carboxyl terminus (residues 2055-2061 of SepA), specifically the protein sequence RRRRE (Fig. 4). Although both SepB and TcaC shared similarity to the *Salmonella* virulence protein SpvB, the amino-terminil of SepB and TcaC were hydrophilic as opposed to the hydrophobic nature of SpvB. The profile of SepC and its *Photorhabadus* counterpart TccC differed in that SepC had a slightly hydrophilic aminoterminus, whereas TccC lacked a hydrophilic amino-terminus and had a significantly hydrophobic carboxyl terminus from amino-acid residue 717 onwards (Fig. 3).

Analysis to detect repetitive motifs characteristic of the RTX family of toxins (Welch, 1991) using DOTPLOT showed only *P. luminescens* TccC contained a plot characteristic of a repeat motif present at the carboxy terminal (data not shown).

Analysis of DNA composition (%GC) and similarity

20

25

Comparisons of the GC content (Table 3) showed that the SepA and SepB genes were more GC-rich than their P. luminescens counterparts, while SepC and tcaC had similar GC content. The high GC content of SepC may be attributed to the close relationship of these protein products to the rhs family of wall-associated proteins which have a GC-rich core of 62% (Wang et al. 1998). Comparisons of the GC content of the Sep genes with that of the S. entomophilia genome shows that they are rather similar, suggesting that the sep genes were not recently acquired by S. entomophilia.

Identification of mini-Tn10 location by sequence analysis

Analysis of the insertion points of the previously isolated mini-*Tn10* insertions (Fig. 2) within the putative ORF's (Table 4) revealed that ORF3 and ORF4 were interrupted by the -9, -23, -24 (ORF3) and -35 (ORF4) mutations. These insertions had no effect on the pathogenicity process, suggesting that ORF3 and ORF4 do not play a significant role in pathogenicity. However, the pADAP-35 mutation was at the 3' end of ORF4, resulting in the truncation of the final 11 amino-acid residues of ORF4 (Fig. 4), which may not have affected protein function. Further mutagenesis of ORF4 is therefore required to confirm that it has no role in pathogenicity. The mutations that caused loss of pathogenicity all resided within *SepA*, *SepB* or *SepC*. No mutation mapped to ORF1, ORF2 or ORF5.

Complementation analysis of the sep proteins

5

10

15

20

Following sequence data each of the Sep ORF's were excised as closely as possible with restriction enzymes, placed into pLAFR3 and placed in trans with the appropriate pADAP mutation. Complementation of SepA was undertaken through the use of the 8.5 kb HindIII clone (pMH45) which encompasses both ORF1 and SepA. SepB was excised as a 5.4 kb StuI fragment and SepC was excised as a 4.6 kb fragment using one of the peripheral; BamHI sites from the pBH32-13 mutation and the StuI site of pBM32 (Fig. 2b).

Complementation analysis showed that pLAFR3 based SepB and SepC are able to complement their mutated pADK- counterparts. Grkovic et al. (1995) had already previously shown that SepC could complement itself. However, this was achieved through using the entire 11 kb HindIII, pGLA-20 fragment.

Whether SepA is able to complement itself has yet to be fully established. It was found that ~98% of the pMH45 construct was lost during the course of the bioassay. This latter result was sporadic and occasionally a repeated experiment would show the presence of diseased

grubs. Analysis of the macerates of these grubs showed that pMH45 was present indicating that pMH45 can possible complement *SepA*. However before further complementation analysis of *SepA* can be undertaken, measures to ensure the complementation plasmids stability are needed.

5 DISCUSSION

10

15

20

25

The large conjugative plasmid, pADAP, of *S. entomophilia* encodes the genes responsible for cessation of feeding and gut clearance, characteristics of amber disease in the New Zealand grass grub *C. zealandica*. This plasmid is present in all *S. entomophilia* and *S. proteamaculans* strains capable of causing amber disease (Glare et al. 1993) and had been implicated in disease processes (Grkovic et al. 1995). The applicant has defined a 16.9 kb region of kADAP that is sufficient to confer pathogenicity towards *C. zealandica* on pADAP-cured strains of *S. entomophilia* and on strains of *E. coli*. Hence, the region confers all the essential pathogenicity genes of *S. entomophilia* responsible for amber disease. Nucleotide sequence and mutagenesis analysis of the region revealed three genes, *SepA*, *SepB* and *SepC*, that together are sufficient for pathogenicity. Mutations in any of the three genes completely abolished the disease process and partial disease states were not detected, suggesting that the three genes may interact to exert an effect.

The 23-kb region cloned into pBR322 to make pBM32 conferred pathogenicity in pADAP-cured *S. entomophilia* strains with all symptoms of amber disease being observed. Insertion mutants in pBM32 that abolished pathogenicity were transferred to pADAP. The resultant strains showed a partial disease phenotype, including anti-feeding but not gut clearance, suggesting that an additional anti-feeding gene may be present elsewhere on pADAP. The occurrence of two different anti-feeding genes on pADAP also supports data of Grkovic et al. (1995) who found that suppression of feeding was stronger in the wild-type pADK-6 strain, compared to the partial disease state (pADK-10, pADK-13) of

5

10

15

20

25

been isolated from the genomic DNA of *S. entomophilia* (Nunez-Valdez and Mahanty, 1996). Recent data indicate that the *amb2* locus resides at an as yet to be identified location on pADAP that is remote from the region identified herein (Hurst, unpublished data).

Sequence analysis and comparison of the products of the *sep* genes showed that they share significant similarity to the proteins TcbA (TcdA, TcaB, TccB), TcaC and TccC that comprise the toxin complexes of *P. luminescens*. Like the *P. luminescens* genes that *sep* genes of *Serratia* share a similar organisational pattern of three genes ordered in succession in the same orientation, and opposed by a terminil gene transcribed in the opposite direction. However, the order of sep genes differ, are slightly smaller in size, and comprise constituents of each of the *P. luminescens* loci tca (tcaB=sepA, tcaC=sepB), *luminescens* toxin gene tcd (Ensign et al. 1997) is also similar to SepA. The similarity shared between the *sep* and *tc* gene products suggests that they are members of a new family of insecticidal toxins. The lack of DNA similarity as opposed to protein similarity between *sep* and *P. luminescens* tc genes together with the differnce in GC content of the *sepA* and *sepB* genes compared to the tc genes, suggests that these genes were present in the common enterobacterial ancestor of *P. luminescens* and *S. entomophilia* and were not acquired by a more recent horizontal transfer event.

The *Photorhabadus* toxins were isolated as a composite of proteins which are hypothesised to interact synergistically to form a toxin complex. The toxins are also able to exert an anti-feeding effect (Bowen et al. 1998; Bowen and Ensign, 1998). This is consistent with the results we obtained with the *sep* mutants. pADAP-cured *S. entomophilia* strains containing the pathogenicity clone pBM32 exert an anti-feeding effect on the grass grub and individual mutations within any of the *sep* genes have an identical phenotype, completely abolishing pathogenicity. The *Photorhabadus* toxins have a wide host range, affecting Lepidoptera, Coleoptera and Dictyoptera and undergo post translational

5

10

15

20

25

proteolytic processing (Bowen et al. 1998). No similarities of sep proteins were found to the *Photorhabadus* toxin component TccA, and only the amino-terminus of TcaA shared similarity to SepA. This and the difference in the hydrophobicity profiles of SepC and TccC, may account for specificity of the sep proteins towards C. zealandica. However the sep proteins have yet to be purified and it is unknown whether the sep genes are expressed when S. entomophilia is ingested by other insects. Therefore the possibility that these newly-described toxins may exhibit a broader host range cannot be ruled out.

The *Photorhabdus* toxin TcbA shares weak similarity to the *Clostridium difficile A* and *B* toxins (Bowen, 1998), but no such similarities were found to *SepA*. *C. difficile A* and *B* toxins belong to the RTX (repeats in toxin) family of toxins which are noted for the presence of several carboxyl terminal repeats (von Eichel-Streiber et al. 1992). A search of the *sep* proteins and their *P. luminescens* homologues for protein repeats showed that only the *P. luminescens* TcaC protein contained a repeat-type signature. The TcaC carboxy-terminal repeat bears little resemblance in size or number of repeats found in RTX toxins (von Eichel-Streiber et al. 1992). *SepA* does not show weak similarity to the mosquitocidal toxin Cbm71 of *C. bifermentans* (Barloy et al. 1996). However when this region is compared with the relevant *Photorhabdus* homologues, it is a region with little similarity.

SepB has strong similarities to both P. luminescens TccC and the Salmonella virulence gene product SpvB (Gulig et al. 1992). SpvB is believed to enhance the survival of virulent Salmonella in macrophages (Libby et al. 1997). It has been suggested that TcaC may act by attacking insect haemocytes (Bowen et al. 1998). However, haemocytes reside within the insect haemocoel and S. entomophilia does not invade the haemocoel until late in the infection process (Jackson et al. 1993), suggesting that SepB may act in some other way. The similarity of SepB and TcaC is high to SpvB but diminishes ten amino-acid residues upstream of the proline-rich region found in SpvB that is postulated to divide the protein into separate domains (Roudier et al. 1992). This may indicate a vital role for the amino-

5

10

15

20

terminus of both SepB and SpvB in interacting with an evolutionarily-conserved eukaryotic protein.

The SepC protein shows high similarity to a family of cell wall-associated bacterial proteins such as the B. subtilis wall-associated protein (WAPA) and members of the E. coli rhs element family. The function of the Rhs proteins has yet to be established, but they are believed to be cell surface ligand-binding proteins (Hill et al. 1994). The Rhs proteins and the B. subtilis was-associated protein contain a characteristic repetitive peptide motif, but no such motif was observed in SepC. A feature of rhs elements is the presence of a downstream IS element (Wang et al. 1998). A degenerate IS91-type transposase element (ORF6) is present downstream of SepC. The IS91 element has been found associated with plasmids or chromosomal genes involved in α -haemolysin synthesis, and has been postulated to play a pivotal role in the spread of the α -haemolysin genes by means of the IS91-mediated recombinational activity (Zabala et al. 1984). It seems possible an IS element adjacent to SepC may have been involved in the acquisition of the sep genes by S. entomophilia.

Blackburn et al. (1998) undertook histological examinations of the lepidopteran *Manduca* sexta after treatment with the *P. luminescens* Tca toxin complex introduced by feeding or haemcoelic injection. They found blebbing of the midgut epithelium into the lumen, resulting in lysis and formation of cavities. Similar histological studies have been undertaken at various stages throughout the infection cycle of *S. entomophilia* in *C. zealandica*, and reveal a visible deterioration in the number of fat cells to almost minimal levels, and an emptying of the larval gut. However no blebbing of the midgut epithelium was observed (Jackson et al. 1993).

The S. entomophilia pathogenicity region endows pathogenicity on members of the Enterobacteraceae such as Klebsiella spp., Enterobacter agglomerans, E. coli, and Serratia

5

10

15

20

25

species (Glare et al. 1996). From this we can infer that the Sep proteins are the major virulence determinants, that the promoters of the sep genes are expressed constitutively or under the control of conserved regulatory genes, or a negative regulatory gene present in the pathogenicity region, and that export of the toxin proteins is carried out by a conserved chromosomally encoded system, or is an intrinsic property of the sep proteins. The Sep proteins have no obvious amino terminal signal sequences, a facet shared with E-Group colicins. The release of cloacin DF13 is mediated through a small lipoprotein designated BRP, for bacteriocin-release protein. Low level expression of BRP in conjunction with phospholipase A leads to the release of cloacin DF13, along with bacterial periplasmic proteins. However if expressed in high amounts, BRP causes cell death by cell lysis (vad der Wal, 1998). The close proximity and similar orientation pattern of ORF3 to the sep genes indicate that ORF3 may have an as yet to be determined important functional role. Protein similarity searches show that it has high similarity to the bacteriophage lysozyme family. In relation to amino-acid size, ORF3 closely resembles the LZBP22 lysozyme of the Salmonella P2 bacteriophage, a protein essential for the lysis of the bacterial cell wall (Rennell and Poteete, 1985). It is possible that ORF3 may facilitate the release of the sep proteins by lysing the bacterial cell wall. A low level expression of ORF3 might, as in the case of BRP, allow the passage of the sep proteins across the cell wall without causing cell death. The reason that the pBM32-9 and -24 mutations were unable to abolish the disease process could be due to a masking of ORF3 function by natural cell lysis of the bacteria.

A region of repetitive DNA was identified between nucleotides 683 to 743, centered within a 1.2-kb AT rich stretch of DNA that contains no potential ORF's. The repeat motif is flanked by an upstream 13-bp palindrome and a degenerate downstream 33-bp palindrome. Repeats have been found to be common sites for recombination (Allgood et al. 1988), or to facilitate the binding of proteins. A 66-bp DNA sequence termed the *rsk* element for reduced serum killing, of the *S. typhimurium* 95-kb virulence plasmid, comprises of a series

of direct 10-bp repeats with a 21 nucleotide periodicity. The *rsk* element is believed to titrate out a *trans*-acting factor, enhancing the expression of the *Salmonella* serum resistance gene (Vandenbosch et al. 1989). It is not known whether these repeats and/or flanking palindromes have a role in the pathogenicity process. The deletion derivative pAC24, which encompasses this region, was still pathogenic towards the grass grub. However, this deletion could also unknowingly remove the complete regulatory circuit of the pathogenicity region, leading to constitutive expression.

THE ARABINOSE EXPRESSION SYSTEM

Methodology

5

20

Using the polymerase chain reaction (PCR) the initiation codon ATG of the three *sep* genes (*sepA*, *sepB* and *sepC*) were individually placed into the unique *NdeI* site (restriction enzyme site CATGG) of the HIS-tag arabinose expression vector pAV2-10 (obtained from Chuck Shoemaker –AgResearch). Because large proteins i.e. greater than 50 kda are limited in their ability to bind to HIS tag affinity columns the carboxyl terminus of each of the Sep proteins did not need to be in frame with the HIS-tag site. Instead wild type DNA (non PCRd) containing a downstream chloramphenicol resistance gene was ligated into the appropriate restriction enzyme site (*sepA SunI*; *sepB HindII*; *sepC BstXI*) of the pAV2-10-sep derived vectors:-

-the use of the chloramphenicol resistant marker provided by the vector pACYC184 enhances the stability to each of the expression constructs i.e. -the antibiotic ampicilin to which the pAV2-10 is resistant too is cleaved in the media to an inactive form leading to possible plasmid free segregants arising. Conversely the antibiotic chloramphenicol is not cleaved heightening the level of plasmid stability under conditions of arabinose induction.

The tank of the many and the transfer of the

WO 01/16305 PCT/NZ00/00174

To validate the legitimacy of the fused genes to the arabinose expression vector, PCR generated products and the ligation junctions were verified by DNA sequencing.

Concurrent to this the *sepB* and *sepC* genes were placed as derived from pADAP downstream of *sepA*. Also *sepA*, *sepB* and *sepC* were placed as in pADAP downstream of orf3. This simulated wildtype conditions (i.e. the arrangement of the *sep* genes on pADAP) and hopefully get the production of the *sep* genes and the complex driven off the one upstream promoter. A method which Western analysis has shown to be successful —with moderate levels of *sepA*, *sepB* and *sepC* being detected.

The arabinose expression system is one of the tightest systems known with almost complete abolition of gene product under arabiniose free conditions Guzman *et al.* (1995), this abolition can be enhanced by providing glucose to the medium. In contrast providing arabinose at the concentration of 0.2% will switch the arabinose promoter on express any genes under its control e.g. *sepA* etc. Typically an overnight culture of the *E. coli* strain was set up the next day an 100 μ l of the culture was suspended in fresh media-supplemented with chloramphenicol (30 μ g/ml) the culture was grown until an OD of 400 at which time arabinose was added to the culture to a final concentration of 0.2% and the culture left shaking at 30 °C for 18 hours.

To date Western analysis has shown that each of the proteins is expressed and expressed to its correct predicted size:

20 SepA 262.7 kdal

5

10

15

SepB 156.6 kdal

SepC 107 kdal

SepC is expressed at high levels with minor levels of proteolytic cleavage. However both SepA and SepB though expressed are cleaved in high amounts by endogenous *E. coli* proteases. Alternative strains of *E. coli* are going to be assessed for loss of proteolytic activity against SepA and SepB

It has also been shown that placing all three of the *sep* genes under the control of a single arabinose promoter will result in the production of basil levels of the SepA, SepB, SepC toxin complex.

Each of the following Coleopteran species were mouth injected with 3-5 μl of an overnight suspension of induced bacteria (*E. coli* strain DHB101) containing either SepA, SepB and SepC or orf3, SepA, SepB and SepC.

Each larvae was then given a 3mm^3 piece of carrot coated with a 50% solution (dH₂0) of arabinose. Observations were noted each day and the larvae refed with a 3mm^3 piece of carrot coated with a 50% solution (dH₂0) of arabinose

Red headed cock chaffer

15 Tasmanian grass grub

10

20

Odontara

Grass grub (positive control)

Under these conditions it has been found that the arabinose expressed toxin complex SepA, SepB and SepC is active against grass grub but not any of the other species of scarabs tested (see above). It is therefore thought unlikely that the toxin complex will have activity to other insect orders.

WO 01/16305

10

PCT/NZ00/00174

SUMMARY

The bacteria Serratia entomophilia and S. proteamaculans cause amber disease in the grass grub, Costelytra zealandica (Coleoptera: Scarabaeidae), an important pasture pest in New Zealand. Larval disease symptoms include amber colouration, clearance of the gut and rapid cessation of feeding, before eventual death. The region containing pathogenic determinants of the disease has been cloned, and further defined by mutagenesis and deletion analysis to a 16.9 kb region. Sequence analysis of the minimal pathogenic encoding region showed significant protein homology, but little sequence homology to a group of newly described toxins from a member of the Enterobacteriaceae, Photorhabadus luminescens. This pathogenicity-encoding region from S. entomophilia plasmid pADAP is the subject of the invention. The proteins encoded by the genes (sepA, sepB, sepC) within the 16.9 kb region can be used for insect control whether as an inundative pesticide, within baits or expressed in other organisms such as plants or microbes.

Aspects of the present invention have been described by way of example only and it should be appreciated that modifications and additions may be made thereto without departing from the scope thereof as defined in the appended claims.

40

REFERENCES

Barloy F; Delecluse A; Nicolas L and Lecadet M M (1996)

Cloning and expression of the first anaerobic toxic gene from Clostridium bifermentans subsp. malaysia, encoding a new mosquitocidal protein with homologues to Bacillus thuringirnsis delta-endotoxins. J. Bact. 178: 3099-3105.

Blackburn M; Golubeva E; Bowen D and Ffrench-Constant R H (1998)

A novel insecticidal toxin from *Photorhabdus luminescens*, Toxin complex a (*Tca*), and Its Histopthological Effects on the Midgut of Manduca sexta. Applied and Environmental Microbiology 64: pp 3036-3041.

Bolivar F; Rodriguez R L; Greene P J; Betlach M C; Heyneker H L and Boyer H W (1977)

Construction and characterisation of new cloning vehicles II. A multipurpose cloning system. Gene 2: 95-113.

Bowen D J and Ensign J C (1998)

Purification and characterisation of a High-Molecular-Weight Insecticidal Protein Complex produced by the Entomopathogenic Bacterium *Photorhabdus luminescens* Applied and Environmental Microbiology 64: pp 3029-3035.

Bowen D; Rocheleau; Blackburn M; Andreev O; Golubeva E; Bharia R and Ffrench-Constant R H (1998)

Insecticidal Toxins from the Bacterium *Photorhabdus luminescens* Science 280: pp 2129-2132.

Casabadan M J and Cohen S N (1980)

Analysis of gene control signals by DNA fusion and cloning in *Escherichia coli*. J. Mol. Biol. 138: 179-207.

Chang A C Y and Cohen S N (1978)

Construction and characterisation of amplifiable multicopy DNA cloning vehicles derived from the p15A cryptic miniplasmid. J. Bact 134(3): 1141-1156.

Corbett (unpublished)

PCT/NZ00/00174

Ditta G; Stanfield S; Corbin D and Helinski D R (1980)

Broad host range cloning system for gram-negative bacteria: construction of a gene bank of *Rhizobium meliloti*. Proc. Natl. Acad. Sci. USA. 27: 7347-7351

Dower W J; Miller J F and Ragsdale C W (1988)

High efficacy transformation of *E.coli* by high voltage electroporation. Nucleic Acids Res. 16: 6127-6145.

Figurski D H and Helinski D R (1979)

Replication of an origin-containing derivative of plasmid RK2 dependent on a plasmid function provided in *trans*. Proc. Natl. Acad. Sci. USA. 76: 1648-1652.

Finnegan J and Sherrat D (1982) Plasmid ColE1 conjugal mobility: the nature of bom, a region required in cis for transfer. Mol. Gen. Genet. 185, 344-351.

Gierasch, L M (1989) Signal sequences. Biochem 28: 923-930

Glare T R; Corbett G E and Sadler A J (1993)

Association of a large plasmid with amber disease of the New Zealand grass grub, Costelytra zealandica, caused by Serratia entomophila and Serratia proteamaculans. Journal of Invertebrate Pathology 62, 165-170.

Glare T R; Hurst M R H and Grkovic S (1996)

Plasmid transfer among several members of the family Enterobacteriaceae increases the number of species capable of causing experimental amber disease in grass grub. FEMS Microbiology Letters 139: 117-120.

Grimont P A D; Jackson T A; Ageron E and Noonan M J (1988)

Serratia entomophila sp. nov. associated with amber disease in the New Zealand grass grub, Costelytra zealandica Int. J. System. Bacteriol, 38: 1-6.

Grkovic S; Glare T R; Jackson T A and Corbett G E (1995)

Genes essential for amber disease in grass grub are located on the large plasmid found in Serratia entomophila and Serratia proteamaculans. Applied and Environmental Microbiology 61, 2218-2223.

42

Gulig P A; Caldwell A L and Chiodo V A (1992)

Identification, genetic analysis and DNA sequence of a 7.8-kb virulence region of the Salmonella typhimurium virulence plasmid. Mol. Microbiol. 6: 1395-1411.

Hanahan D (1983)

Studies on transformation of Escherichia coli with plasmids. J. Mol. Biol. 166: 557.

Jackson T A; Huger A M and Glare T R (1993)

Pathology of amber disease in the New Zealand grass grub, Costelytra zealandica (Coleoptera: Scarabaeidae). J Invertebr. Pathol., 61: 123-130.

Jackson T A (1995)

Amber disease reduces trypsin activity in midgut of *Costelytra zealandica* larvae. J. Invent. Pathol. 65: 68-69.

Kleckner N; Bender J and Gottesman S (1991)

Uses of transposons with emphasis on Tn10. Methods Enzymol 204: 139-179.

Kyte J and Doolittle R F (1982) A simple method for displaying the hydropathic character of a protein. *J Mol Biol* 157: 105-132

Leininger E, Roberts M, Kenimer J G, Charles IG, Fairweather N, Novotny P, and Brennan M'J (1991) Pertactin, an Arg-Gly-Asp-containing *Bordetella pertussis* surface protein that promotes adherence to mammalian cells. *Proc Natl Acad Sci USA* 88: 345-349

Lorrow D and Jesse J (1990)

Max efficiency DH10BTM: A host for cloning methylated DNA.

Focus 12: 19.

Mendiola M V; Jubete Y and de la Cruz F (1992)

DNA sequence of IS91 and identification of the Transposase Gene. Journal of Bacteriology 174: 1345-1351.

Nunez-Valdez M E and Mahanty H K (1996)

The amb2 locus from Serratia entomophila confers anti-feeding effect on larvae of Costelytra zealandica (Coleoptera: Scarabaeidae). Gene 172: 75-79.

Pecenkova T; Benes V; Paces J; Vlcek C and Paces V (1996)

Bacteriophage B103: complete DNA sequence of its genome and relationship to other *Bacillus* phages. Gene 199 157-163.

Prere M F, Chandler M and Fayet O (1990) Transposition in *Shigella dysenteriae* isolation and analysis of IS911, a new member of the IS3 group of insertion sequences. *J Bacteriol* 172: 4090-4099.

Relman D A, Domenighini M, Tuomanen E, Rappuoli R and Falkow S (1989) Filamentous hemagglutinin of *Bordetella pertussis:* nucleotide sequence and crucial role in adherence. *Proc Natl Acad Sci USA* 86: 2637-2641.

Sambrook J; Fritsch E F and Maniatis T (1989)

Molecular cloning, 2nd edition, Cold Springs Harbour Laboratory Press, Cold Spring Harbour

Staskawicz B; Dahlbeck D; Keen N and Napoli C (1987)

Molecular characterization of cloned avirulence genes from Race 0 to Race 1 of Pseudomonas syringae pv slycinea. J. Bacteriol 169: 5789-5794.

Stucki G; Jackson T A and Noonan M J (1984)

Isolation and characterisation of Serratia strains pathogenic for larvae of the New Zealand grass grub Costelytra zealandica. NZ J Science 27: 255-260.

Trought T E T; Jackson T A and French R A (1982)

Incidence and transmission of a disease of grass grub (Costelytra zealandica) in Canterbury. NZ J. Exp. Agric. 10: 79-82.

Upadhyaya N M; Glare T R and Mahanty H K (1992)

Identification of a Serratia entomophila genetic locus encoding amber disease in New Zealand grass grub (Costelytra zealandica). J. Bacteriol 174: 1020-1028.

Valdivida R H and Falkow S (1997) Fluorescence-based isolation of bacterial genes expressed within host cells. Science 277 (5334), 2007-2011.

Wang Y D; Zhao S and Hill C H (1998)

Rhs elements comprise three subfamilies which diverged prior to acquisition by Escherichia coli J. Bacteriol. 180: 4102-10.

44

Welch R A (1991)

Pore-forming cytolysins of Gram-negative bacteria. Mol. Microbiol 5: 521-528.

Yanisch-Perron C; Vieira J and Messing J (1985)

Improved M13 phage cloning vectors and host strains: nucleotide sequence of M13mp18 and pUC19 vectors. Gene 33, 103-119.

Zimmer A and Schmieger H.

Lysis gene modules in the phage P22 gene pool Zimmer A; Institute for Genetics and Microbiology, University of Munich, Maria-Ward-Str. 1a, Muenchen D-80638, Germany X167137. Accession number (AF064539).

Guzman L-M., Belin, D., Carson, M.J., and Beckwith, J. (1995): Tight regulation, modulation, and high-level expression by vectors containing the arabinose P_{BAD} promoter. *J Bacteriol*. 177: 4121-4130.

Table 1 Bacterial strains, plasmids and bacteriophage used in the study

Bacteria	Description	Reference
Escherichia e	coli	
DH5α	F φ80d lacZρM15 ρ(lacZYA-argF)U169 recA1 endA1 supE44	Hanahan (1983)
DH10B	F mcrA ρ(mrr-hsdRMS-mcrBC)φ80d lacZpM15 placX74 endA1 recA1 deoRρ(ara, leu) 7697	Lorow and Jessee, (1990)
	araD139 galU galK nupG rpsL λ.	
DF1	γδ transposase(tnpA)	Gibco BRL
MC1061	sup ⁰ hsdR mcrB araD139 ρ(araA BC-leu)7679	Casadaban and Cohen,
MC4100	ρlacX74 galU galK rpsL thi araD139 ρ(lacZYA-argF)U169 rpsL150 St ^R relA1 flbB5301 deoC1 ptsF25	(1980) Silhavy <i>et al</i> . (1984)
	rbsR.	(1704)
XL1-BlueMR		Stratagene
Serratia ento	omophila	
A1MO2	Ap ^R , pADAP, pathogenic.	Grimont et al. (1988)
5.6	heat cured pADAP minus derivative of A1MO2	Glare et al. (1993)
5.6RC	Cm ^R recA pADAP minus strain	Grkovic et al. (1996)
5.6RK	Kn ^R recA pADAP minus strain	this study
Plasmids	· ·	
pACYC184	Cm ^R Tc ^R	Chang and Cohen, (1978)
pADAP	Amber disease associated plasmid	Glare et al. 1993)
pBR322	Ap ^R , Tc ^R	Bolivar et al. (1977)
pBM32	23-kb BamHI fragment from pMH32 cloned in pBR322	this study
pBM32-1-40	pBM32 containing mini-Tn10 insertions	this study
pDELTAI	Ap ^R , Sm ^R , Kn ^R , sucrose ^R	Gibco BRL
pLAFR3	Tc ^R pRK290 with λcos , lac Z α and multi- cloning site from pUC8.	Staskawicz et al. (1987)
pRK2013	IncP, Kn ^R Tra RK2 repRK2 repE1	Ditta et al. (1980)
pGLA20	10.6-kb <i>Hin</i> dIII pADAP fragment cloned in pLAFR3	Corbett (unpublished)
pACρ4	19-kb BamHI fragment from pBM32-4 cloned in pACYC184	this study
p ΑCρ8	17-kb BamHI fragment from pBM32-8 cloned in pACYC184	this study
pACp10	19.5-kb <i>Bam</i> HI fragment from pBM32-10 cloned in pACYC184	this study
ρΑСρ20	20-kb <i>Bam</i> HI fragment from pBM32-20 cloned in pACYC184	this study
pACρ23	21-kb BamHI fragment from pBM32-23 cloned in pACYC184	this study
рАСр24	21.2-kb BamHI fragment from pBM32-24 cloned in pACYC184	this study
pADK-10	pADAP::mini-Tn/0 insertion in 10.6-kb HindIII fragment, Kn ^R non-pathogenic	Grkovic <i>et al.</i> (1995)
pADK-13	pADAP::mini-Tn10 insertion in 10.6 - kb HindIII fragment, Kn ^R non-pathogenic	Grkovic et al.(1995)
pADK-35	pADAP::mini-Tn10 insertion in 10.6-kb HindIII	Grkovic et al. (1995)

рМН32	fragment, Kn ^R , pathogenic 23-kb <i>Bam</i> HI frgament of pADAP cloned into	this study
рМН41	pLAFR3 33-kb BamHI fragment of pADAP cloned into pLAFR3	this study
pBM32	23-kb BamHI fragment of pMH32 cloned into pBR322	this study
pUC19	Ap ^R , lacZα, multi-cloning site	Yannish-Perron, et al. (1985)
Bacteriophage		
λNK1316	mini-Tn10 derivative 103 donor λb522 c1857 Pam80 nin5	Kleckner et al. (1991)

Table 2 Position of genes and features of the predicted gene products encoded by sep genes

ORF	Putative ribosome-binding site*	Longest pote region	ntial coding	sep %GC (P. luminscens	
		Start at nucleotide	Stop at nt (ORF size bp)	homologue, %GC)	
sepA	ATGGGACCATCAACGTAATGAA TGAGG	2413	9547 (7131)	54 (tcbA, 43; tcdA, 44)	
sepB	CG <u>AGGAGA</u> CTGAGCATGCAA	9598	13885 (4287)	58 (tcaC, 51)	
sepC	ACAGGAGATCACATGAGC	14545	17467 (2922)	55 (tcoC, 54)	
ORFI	CATAGAGACTGTCGCTATGTTA	1287	1587 (300)	39	
ORF2	TTGGAGAATAACCGCCATGTT	1590	1863 (273)	39	
ORF3	GGG <u>GGAGA</u> AAAATGAAG	1860	2294 (435)	51	
ORF4	TGACTGGGAAGGAGGGGGGAC GGTGATGAGT	13908	14483 (576)	60	
ORF5	TAACGAGACTTTTTAGCAAAAT GGCACTTT	1761-1755, 1755-1773		?	
ORF6	GAGCATGGC-Mini-Tn10-8*	18934-18064		?	

^a Putative ribosome-binding sites are underlined, and potential start codons are in boldface; nt, nucleotides; ? degenerate or incomplete ORF. ^b ORF transcribed in opposing direction.

Table 3. Comparisons of GC content between the Sep and P. luminescen genes

Sep (%GC)	P. luminescen toxin (%GC)
верА (54%)	tcbA (43%) tcdA (44%)
sepB (58%)	tcaC (51%)
sepC (55%)	tccC (54%)

ORF6

(310)

1591

39/56 (94) 130-197 + "1"

39/58 (94) 224-318 + 2° 30/48 (76) 319-395 **+** -1° 4e⁻²⁸

S23782

E. coli

Table 4. Similarities of products of putative ORF's to protein sequences in the database

detected using BlastP Function of the homologous ORF Protein Degree of similarity Organism Blast score %identity/%similarity (a.a size) homoprotein Reference* logue (a.a (over) a.a residue – a.a size) residue 34/50 (1675) 41-1628* Photorhabdus TcbA insecticidal toxin complex იი SepA (2373)(2504)57/72 (751) 1630-2374* luminescens AF047457 protein 40/55 (2458)* P. luminescens TcdA insecticidal toxin complex 0.0 (2405)protein Ensign et al., (1997)TcaB 38/54 (764) 1625-2374* insecticidal toxin complex P. luminescens e-137 29/50 (281) 936-1198* AF046867 (1189)protein e-136 TccB 36/51 (859) 1575-2373* insecticidal toxin complex P. luminescens AF047028 (1565)31/51 (289) 930-1204* protein P. luminescens le s TcaA 36/56 (90) 94-183* insecticidal toxin complex (1095)18/39 (530) 435-928* protein AF046867 insecticidal toxin complex P. luminescens TccA 27/45 (186) 115-280* 5e ⁴ (965) protein AF047028 Cbm71 24/41 (199) 1057-1250* Mosquitocidal toxin Cbm71 Clostridium g2127309 bifermentans (613)49/63 (1276)1-1263* P. luminescens SepB TcaC insecticidal toxin complex (1428) (1485)64/78 (152) 1270-1421* AF046867 protein SpvB Salmonella virulence protein Salmonella 4e-62 40/52 (357) 9-365* (591) typhimurium S22664 TccC 53/66 (836) 3-782* insecticidal toxin complex P. luminescens 0.0 SepC (1043)AF047028 (938) protein 2e-12 SC2H4.02 23/34 (639) 68-677* Hypothetical wall associated Streptomyces coelicolor AL031514.1 (2183)protein 22/34 (430) 255-677* 2e-5 WapA Wall associated protein B. subtilis S32920 20/36 (613) 48-625* (2334)Precursor Y15898 21/34 (542) 181-684* hypothetical wall associated Coxiella burnetii 9e-5 Y15898 (334)protein Rhs core 21/35 (463) 237-677* Rhs core protein E. coli 3e⁴ AF044501 21/36 (285) 35-300* (1420)Bacillus subtilis 3e⁻²⁷ ORF3 BB103G 45/62 (142) 1-139* morphogenesis protein of CAA67646 (144)(263)bacteriophage B103 Phage P22, lysozyme (E LZBP22 46/61 (139) 1-143 Salmonella le-24 (146)gi 138699 3.2.1.17) le-6 ORF4 28/42 (188) 1-184* bacteriophage N15 protein E. coli Gp55 AF064539 (191)(181)7e⁻¹⁹ ORF5 75/79(68) 1-68 + Resolvase/invertase homologue S. typhimurium SprA AF029069 (236)AF020806

Percent identities and similarities were calculated in relation to the deduced gene products of the sequenced ORF. *indicates position of amino-acid similarity in relation to sequence generated in this study. • indicates position of amino-acid similarity in relation to data base protein sequence. * reading frame. * similarities were considered potentially significant if the BlastP score exceeded e⁻⁵.

IS91 transposase

Table 5 Positions of mini-Tn10 insertions

Mini-Tn10 insertion #	ORF	Position downstream of initiation codon (bp)
9/23	ORF3	120
24	ORF3	345
4	sepA	747
27	sepA	1037
40	sepA	1097
6	sepA	1727
38	sepA	2887
2	sepA	3197
5	sepA	3737
3	sepA	3697
19	sepA	3697
30	sepA	4467
37	sepA	4467
31	sepA	4627
12	sepB	182
22	sepB	172
11	sepB	362
10	sepB	2162
35	ORF4	557
13	sepC	2525
8		18937
ORF4/-35 ju	nction GG	G CGC <u>TGA TGA</u> ATC

THE CLAIMS DEFINING THE INVENTION ARE:

- A purified and isolated nucleic acid molecule comprising a nucleotide sequence of SEQ ID
 NO: 1 that encodes at least one of:
 - (i) an insecticidal protein complex, or
 - (ii) a functional fragment of said complex, or
 - (iii) a neutral mutation of said complex, or
 - (iv) a homolog of said complex,

each of which have at least 75% nucleic acid homology to SEQ ID NO: 1 and are capable of hybridising with said nucleic acid molecule under stringent hybridisation conditions.

- 2. A purified and isolated nucleic acid molecule as claimed in Claim 1 comprising the nucleotide sequence 1995-18937 of SEQ ID NO: 1.
- A purified and isolated nucleic acid molecule as claimed in Claim 1 comprising one or more of the nucleotide sequences 2411-9547, 9589-13883 or 14546-17467 of SEQ ID NO:
- 4. A purified and isolated nucleic acid molecule as claimed in Claim 3 comprising all of nucleotide sequences 2411-9547, 9598-13884 and 14546-17467 of SEQ ID NO: 1.
- 5. A purified and isolated nucleic acid molecule as claimed in Claim 1 comprising a sequence of SEQ ID NO: 1, operably linked to at least one further nucleotide sequence which encode an insecticidal protein.
- 6. A purified and isolated nucleic acid molecule as claimed in Claim 2 comprising nucleotides 1955-18937 of SEQ ID NO: 1, operably linked to at least one further nucleotide sequence which encode an insecticidal protein.

- 7. A purified and isolated nucleic acid molecule as claimed in Claim 3 comprising a sequence of SEQ ID NO: 1, or one or more of nucleotides 2411-9547, 9598-13884 or 14546-17467 of SEQ ID NO: 1, operably linked to at least one further nucleotide sequence which encode an insecticidal protein.
- 8. A purified and isolated nucleic acid molecule as claimed in any one of claims 4 through 6 wherein the said nucleotide sequence includes the nucleotide sequence which codes for at least one of the *Bacillus* delta endo toxins, vegatative insecticidal proteins (vips), cholesterol oxidases, *Clostridium bifermentens* mosquitocidal toxins and/or *Photorhabadus luminescens* toxins.
- 9. A purified and isolated nucleic acid molecule as claimed in claim 1 wherein nucleic acid molecule may comprise DNA, cDNA or RNA.
- 10. A purified and isolated nucleic acid molecule as claimed in claim 1 wherein the nucleic acid molecules said fragment, neutral mutation or homolog thereof capable of hybridising to said nucleic acid molecule, hybridise to the nucleotide sequence of SEQ ID NO: 1, or nucleotides 1955-18937, 2411-9547, 9598-13884 or 14546-17467 of SEQ ID NO: 1 if there is at least 75% or greater identity between the sequences.
- 11. A purified and isolated nucleic acid molecule as claimed in claim 1 wherein the nucleic acid molecule may be isolated from Serratia entomophila or Serratia proteamaculans strains of bacteria.
- 12. A recombinant expression vector(s) containing the nucleic acid molecule as claimed in Claim 1 and host transformed with the vector expressing a polypeptide.
- 13. A recombinant expression vector(s) as claimed in claim 11 wherein the vector is selectable from any suitable natural or artificial plasmid/vector.
- 14. A recombinant expression vector(s) as claimed in claim 13 wherein said suitable natural or

artificial plasmid/vector, including, pUC 19 (Yannish-Perron et al. 1995), pProEX HT (GibcoBRL, Gaithersburg, MD, USA), pBR322 (Bolivar et al. 1977), pACYC184 (Chang et al. 1978), pLAFR3 (Staskowicz et al. 1987).

- 15. A polypeptide resulting from the transformation or transfection of a host cell with a recombinant expression vector as claimed in any one of Claims 12 through 14.
- 16. A method of producing a polypeptide of claim 15 comprising the steps of:
 - (a) culturing a host cell which has been transformed or transfected with said vector as defined above to express the encoded polypeptide or peptide; and
 - (b) recovering the expressed polypeptide or peptide.
- 17. The use of a ligand that binds to a polypeptide of claim 15 to isolate and/or identify the polypeptide of claim 15.
- 18. An antibody or antibody binding fragment that binds to a polypeptide of claim 15.
- 19. Probes and primers comprising a fragment of the nucleic acid molecule as claimed in Claim 1 wherein said fragment is hybridisable under stringent conditions to a native insecticidal gene sequence.
- 20. Probes and primers comprising a fragment of the nucleic acid molecule as claimed in claim 19 wherein said probes and primers enable the structure and function of the gene to be determined and homologs of the gene to be obtained from bacteria other than Serratia sp.
- 21. A polypeptide as claimed in Claim 15 wherein the polypeptide has insecticidal activity encoded by the nucleic acid molecule of claim 1, or a functional fragment, neutral mutation or homolog thereof.
- 22. A polypeptide having insecticidal activity as claimed in claim 21 wherein the polypeptide

- PCT/NZ00/00174
- comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment, neutral mutation or homolog thereof.
- 23. A polypeptide having insecticidal activity as claimed in claim 21 wherein the polypeptide comprises amino acids 32-5118 of SEQ ID NO: 1.
- 24. A polypeptide having insecticidal activity as claimed in claim 21 wherein the polypeptide comprises at least one amino acid sequence of SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5 or SEQ ID NO: 6.
- 25. A polypeptide having insecticidal activity as claimed in claim 24 wherein the polypeptide preferably comprises amino acid sequence SEQ ID NO: 4; SEQ ID NO: 5 and SEQ ID NO: 6.
- 26. A polypeptide having insecticidal activity as claimed in claim 24 wherein the polypeptide preferably comprises all of SEQ ID NOs: 2-6.
- 27. A polypeptide having insecticidal activity as claimed in claim 21 wherein the polypeptide is obtained by expression of a DNA sequence coding therefore in a host cell or organism.
- 28. A polypeptide having insecticidal activity as claimed in claim 27 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1 linked to at least one further amino acid sequence encoding an insecticidal protein.
- 29. A polypeptide having insecticidal activity as claimed in claim 28 wherein the at least one further amino acid sequence includes the amino acid sequence which codes for *Bacillus* delta endo toxins, vegatative insecticidal proteins (vips), cholesterol oxidases, *Clostridium bifermentens* mosquitocidal toxins and/or *Photorhabadus luminescents* toxins.
- 30. A polypeptide having insecticidal activity as claimed in claim 28 wherein the polypeptides comprise at least 50%, preferably 60%, more preferably 70% and most preferably 90-95% or greater identity to SEQ ID NO: 1.

- 31. A polypeptide having insecticidal activity as claimed in claim 21 wherein the polypeptide is produced by expression of a vector comprising the nucleic acid of SEQ ID No:1 or a functional fragment, neutral mutation or homolog thereof, in a suitable host cell.
- 32. An insecticidal composition comprising at least the polypeptide as claimed in claim 21 and an agriculturally acceptable carrier.
- 33. An insecticidal composition as claimed in claim 32 wherein more than one polypeptide is included in the composition.
- 34. An insecticidal composition as claimed in claim 32 or 33 wherein the composition comprises additional pesticides, including compounds known to possess herbicidal, fungicidal, insecticidal or nematicidal activity.
- 35. An insecticidal composition as claimed in claim 34 wherein the composition comprises other known insecticidally active agents, including *Bacillus* delta endo toxins, vegatative insecticidal proteins (vips), cholesterol oxidases, *Clostridium bifermentens* mosquitocidal toxins and/or *Photorhabadus luminescents* toxins.
- 36. A method of combating pests, said method comprising applying to a locus, host and/or the pest, an effective amount of the polypeptide as claimed in Claim 21 that has functional insecticidal activity against said pest.
- 37. A method of inducing amber disease or like condition in insects comprising delivery to an insect an effective amount of the polypeptide as claimed in Claim 21 that has functional insecticidal activity against said insect.
- 38. A method of inducing amber disease or like condition in insects as claimed in claim 37 comprising delivery to an insect an effective amount of the polypeptide wherein the insect is selected from the order comprising Coleoptera.
- 39. A method of inducing amber disease or like condition in insects as claimed in Claim 38

comprising delivery to an insect an effective amount of the polypeptide wherein the insect includes *Costelytra zealandica* (Coleoptera: Scarabaeidae).

- 40. A method of delivering the insecticidal polypeptide to induce amber disease or like condition in insects including delivery of the insecticidal polypeptide as claimed in Claim 39 to the insect by any one of presenting the insecticidal polypeptide orally as a solid bait matrix, as a sprayable insecticide sprayed onto a substrate upon which the insect feeds, applied directly to the soil subsurface or as a drench or is expressed in an transgenic plant, bacterium, virus or fungus upon which the insect feeds.
- 41. A transgenic plant, bacterium virus or fungus, incorporating in its genome, a nucleic acid molecule as claimed in Claim 1 for providing the plant, bacterium virus or fungus with an ability to express an effective amount of an insecticidal polypeptide.

ATION PUBLISHED UNDER THE PATENT

PERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau

+64-7-578-4001

(43) International Publication Date 8 March 2001 (08.03.2001)

PCT

(10) International Publication Number WO 01/16305 A3

- C12N 15/31, (51) International Patent Classification?: 15/70, 15/82, C07K 14/24, C12Q 1/68, A01N 63/02. A01H 5/00
- (21) International Application Number: PCT/NZ00/00174
- (22) International Filing Date:

4 September 2000 (04.09.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 337610

2 September 1999 (02.09.1999)

- (71) Applicant (for all designated States except US): AGRE-SEARCH LIMITED [NZ/NZ]: 5th floor, Tower Block, Ruakura Research Centre, East Street, Hamilton 2001 (NZ).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): GLARE, Travis, Robert [AU/NZ]; 38 Whincorps Road, Halswell, Christehurch 8003 (NZ). HURST, Mark, Robin, Holmes [NZ/NZ]; 148 Hendersons Road, Hoon Hay, Christchurch 8002 (NZ). JACKSON, Trevor, Authory [NZ/NZ], 407 Halswell Road, Halswell, Christchurch 8003 (NZ).

- (74) Agent: WILSON, Kathryn, S.; all of Level 12. KPMG Center., 85 Alexandra Street, Private Bag 3140, Hamilton
- (81) Designated States (national): AE. AG. AL. AM. AT. AU. AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK. DM. DZ. EE, ES, FI, GB, GD, GE, GH, GM. HR. HU, ID, IL, IN, IS, JP, KE, KG. KP. KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM. TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG. CI, CM, GA, GN, GW, ML, MR, NE, SN, TD. TG).

Published:


- with international search report
- (88) Date of publication of the international search report: 10 January 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NUCLEOTIDE SEQUENCES ENCODING AN INSECTIDAL PROTEIN COMPLEX FROM SERRATIA

(57) Abstract: The present invention concerns novel nucleotide sequences encoding proteins from the Enterobacteriaceae, Serratia entomophila and Serratia proteamaculans, and the use of said nucleotide sequences and proteins for inherent insecticidal and potentially metazoacidal properties. The invention relates to an isolated nucleic acid molecule comprising a nucleotide sequence that encodes an insecticidal protein complex, or a functional fragment, neutral mutation, or homolog thereof capable of hybridising with the nucleic acid molecule under standard hybridisation conditions. The nucleotide sequences include a pathogenicity-encoding region cloned from bacteria Serratia entomophilia and S. proteamaculans. The region contain pathogenic determinants of a disease that affect the grass grub, Costelytra zealandica Coleoptera: Scarabaeldae, an important insect pasture pest in New Zealand. The proteins encoded by determined genes may be used for insect control whether as an inundative pesticide, within baits or expressed in other organisms such as plants or microbes.

WO 01/16305







FIGURE 3



IGURE 4

FIGURE 4 - continued

	1251 1255 1235 274 334	1334 1327 1320 295 435	1423 1435 1428 361 528	1510 1532 1525 384 637	1588 1603 1597 744	1620 1711 1707 441 783	1687 1815 1810 509 845	1796 1924 1919 606 955
	RIPSOLVCS(UPNISTATVVRIVER)	IVDERLING TOTALS VEHERAL SVDNDMILAVISDICITAS VEHERAL SVDNDMILAVISDICAT VEHERAL SVDNDMILAVIS VEHERAL SVDNDMILAVIS VEHERAL SVDNDMILAVIS VEHERAL SVDNDMILAVIS VEHERAL SVDNDMILAVIS VEHERAL SVDNDMILAVIS VEHERAL SVD	HIBANVSCRUSIFACIDEREPURATIERENDESEERINGTAGONNO NO	- NYKESTIBSDKAITÄLIBSSISKAN YVSSIGSOD FÄSYKSLAPALODIII AKTARASIENOMALODDYALDSLAKPDDLKOYIENADSKOTATOKSGPVELITAAISPAK DONNADAGETOCIDAGISSAN LOBIEVIGANESYKISVERITAAISPAK DONNADAGETOCIDAGISSAN LOBIEVIGANESYKISVERITAAISPAK RALERRINESPLEDINESPLEDILIDYTVKSSYLAMGSETPIGYALYTPEGTVLEDWFDKINYRIBSVFTSPDPPTLITTIKNFSKIADARETAG. 6RNITE	#TKSLSFTVATEDLYEDEFDVATETFTANDONNVVERYESFSTEVATURVENS-TEDN ALITHMENGREGOVIEFTRONDELL WATETOSCHANFANSPSTEVATETFTANDONNVYRI WATETOSCHANFANSPSTEVATETFTANDOLOR WATETOSCHANFANSPSTEVATETFTANDOLOR WATETOSCHANFANSPSTEVATETFTANDOLOR WATETOSCHANFANSPSTEVATETFTANDOLOR KRYSTOFFTETTOSCHANFANSPSTEVATETFTANDOLOR KRYSTOFFTETTOSCHANFANSPSTEVATETFTANDOLORIAN WATETOSCHANFANDOLORIANDOLOR	rianterrolvorantgida ilsmetgrutes ranterrolvorantgida ilsmetgregorgergergergergergergergergergerespaleranterrolbergergergergergerespersonscherger ranterrolpersonschipantschergergergergergergergergergergergergerge	-Albegendrangyvarion of the espanderana of the espanderange of the confidency of the confidence of the confidence of the espander of the espan	annreleedigande splosidedalagnerhaterskidillaargeberdalaraaraheraaranyoalailgedesterderaevirrederil annreleedismis-delosyoedangedenhykvastadilaargebankoerakaankaanaanaangesterderilaarakangesterderilaarakaktadilaaraangesterderilaara
1	epA cdA caB	Seph Seph Scala	Seph Toda Toba Tosa	Sepa Toda Toba Toba	SepA TodA TobA ToaB	SepA TcdA TcbA TcaB	SepA TcdA TcbA TcaB	10 TO

FIGURE 4 - continued






FIGURE 5



WO 01/16305

FIGURE 6



JAMES & WELLS (TGA)

PAGE 02

Atty Docket No. 24747-1104US

DECLARATION FOR PATENT APPLICATION

As a below-named inventor, I hereby declare that:

is attached hereto.

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NUCLEOTIDE SEQUENCES ENCODING AN INSECTICIDAL PROTEIN COMPLEX FROM SERRATIA

the specification of which

()

()	was filed by an author Application Serial No.	rized person on my behalf, on	as as
(X)		ication Serial No. PCT/NZ00/	00174 on
	04 September, 2000.		· ·
(X)	amended in a Prelimin	ary Amendment filed March	<u>1, 2002</u> .
		and understand the contents s amended by any amendmen	and the second s
• •	•	information which is material Title 37, Code of Federal Reg	
or §365(b) o and so identi east one cou dentified bel nternational	of any foreign application ified, or \$365(a) of any untry other than the Unitow any foreign applicate application on this inve	its under Title 35, United Stan(s) for patent or inventor's of PCT international application ited States of America, listed sion for patent or inventor's on the filed by us or our legal ore that of the application on	ertificate listed below that designated at below, and I have also ertificate or PCT representatives or
	,		Priority
	_		Claimed
<u>lumber</u> 337610	Country NEW ZEALAND	Day/Month/Year Filed	(Yes or No)
37610	NEW ZEALAND	02 September 1999	Yes
	m benefit under Title 35 pplication(s) listed beloy	, United States Code, §119(ev.	e) of any United States
Application S	Serial No.	<u>Filing Date</u>	

Atty Docket No. 24747-1104US

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.

Filing Date

<u>Status</u>

N/A

PCT Application No.

Status

Filing Date

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith and request that all correspondence and telephone calls in respect to this application be directed to Stephanie Seidman, HELLER EHRMAN WHITE AND McAULIFFE LLP, 4350 La Jolla Village Drive, 7th Floor, San Diego, California 92122-1246; 858-450-8400:

Attorney	Reg. No.
Stephanie Seidman	33,779 39,362
Paula K. Schoeneck	
Dale L. Rieger	43,045
Robert T. Ramos	37 915

and other members of the firm.

Address for correspondence:

Stephanie Seidman

HELLER EHRMAN WHITE AND MCAULIFFE LLP

4350 La Jolla Village Drive

7th Floor

San Diego, California 92122-1246

JAMES & WELLS (TGA)

Atty Docket No. 24747-1104US Travis Robert Glare Full name of inventor: Inventor's signature: Date: Halswell, New Zealand Residence: 38 Whincofos Road Post Office Address: Halswell, Christchurch, New Zealand Citizenship: Full name of inventor: Inventor's signature: Date: Hoon Hay, New Zealand Residence: 148 Hendersons Road Post Office Address: Hoon Hay, Christchurch, New Zealand New Zealand Citizenship: Trevor Anthony Full name of inventor: Inventor's signature: Date: Christchurch, New Zealand Residence: 407 Halswell Road Post Office Address: Christchurch, New Zealand New Zealand Citizenship:

10070489

DES PCTIPTO 17 SEP 2002

SEQUENCE LISTING

```
<110> Glare, Travis T
Hurst, Mark R H
      Jackson, Trevor A
<120> Insecticidal Nucleotide Sequences
<130> 24747-1104US
<140> US10/070,489
<141> 2002-03-01
<150> PCT/NZ00/00174
<151> 2000-09-04
<150> NZ 337610
<151> 1999-09-02
<160> 6
<170> FastSEQ for Windows Version 4.0
<210> 1
<211> 18937
<212> DNA
<213> Serratia entomophila
<220>
<221> CDS
<222> (2411)...(9547)
<223> SepA
<221> CDS
<222> (9598) ... (13884)
<223> SepB
<221> CDS
<222> (14546)...(17467)
<223> SepC
<221> CDS
<222> (1860)...(2294)
<223> ORF1
<221> CDS
<222> (13908) ... (14483)
<223> ORF2
<221> misc_feature
\langle 222 \rangle (195\overline{5}) \dots (18937)
<223> MINIMUM SEQUENCE REQUIRED FOR PATHOGENICITY AS
      DEFINED BY DELETION AND TRANSPOSON MUTAGENESIS
<400> 1
ggatccgagt gaaggaatca tcggccgctt tatacgtttc agggtgaata cggttggccg 60
caacgtggca atggatgttg tttgtgtcgg tatgaatcgc cgcaacgtac tggtgttctg 120
acatacccag tgccgataaa ctgtgacgaa cactatcaaa gatgtgttcc gtcgacctga 180
aagccaggat ttatttttac accaatggtt gggtgggctt cctttctgaa ctggtgcatc 240
atttagccgg catcatcaaa agatgcatgg aaatacaaat atcatattta cagacaccca 300
agttgatgac ctgctccgtg agttgaaatg ccgacggggg aaatcagcag ccttttcaac 360
teatggagea gggggaaate aateeteaat aaceegeatt ggatateetg ceagtgtgea 420
tttaaccttt ttagtgtgtt tccttaatat cccaatcgtt gaatcgctac atacggcaga 480
cattaqtatc tcacttatca tcaaaqtaat atcacaccga qaatgctaat ttcatgatat 540
gaaaacgttc cattaataaa ttttcagaaa cctaacacgg catttttatg ctgatcagtg 600
aattgattgt ttctgaaaaa attaattgca cctctgccac ttatcagata aaaacacccc 660
```

atgeggtaag tt ttaatgattt ta tacteaattt aa aaaaaaagta te gattattgee at tatageetta ge cegttageta ta tggattggte at ttttattett ge ggaaegace at aagggttate ge tggtgteaga ee gacaacaget te tggtgeettt gt agagagaaaa ta geegtgatt ge aaaaacattg te atcaggaega te atca	attaatgat tattgttggt attaataccc tetttttacc acatatgat attaatgtcg tetgaggt tattgcactct coggttatca actctggag actcttggcact teggtctat teggtctat teggtctat teggtctat teggtcttat teggtcttat teggtcttat teggtcttt teggtcttt teggtcttt teggtcttt teggtctctt teggtctcttt teggtctcttt teggtctcttt teggtctcttt teggtctcttt teggtctcttt teggtctctctt teggtctctctt teggtctctctt teggtctctctt teggtctctctt teggtctctctctct	ttactatag a tgaccatgt t tagaccatgt t tagaccatgt t aggaagatg a ttacatccat g ttatatgtga t tcaggggttcat tcaggggttcat tggggttcat tgggggttttttgttgt cgtgtttttatat cgtgaccgc a ataccaga t tatatgcaat ggt atc	tgaatgtta ttagatgag cctacttga cgggtgata taacactta tattttat tgttattgg cattattgt ataggaata gtatttttat ccgaattattttt tgttcata tcttttta ccgaattt tgttccaa tattcttat tgttccaa tattcttat tgttccaa tattcttat tgttccaa tattctat tgttccaa tattctat tgttccaa tattctat tgttccaa tattctat cggaaatcc cggaaatcc a tta atc	acatgggtga tggcacggat ggatgacctc aataataaaa ttgacttttt ataaaaccag tcattgattg taatcatact ctactgttgt tttgactggt attacgcaag ctcggtttga atacatatag gttatcatta tcatacttct ggcgtaccag ccgagacgat ttcggtggg aaa gag tto	taatttactt tcattattgt gacaggactt aaaacaaaag tttacttcta tttattgtg gtgtttaatc catgtcattt ttctattgtc tatatgcgc ataacttcat cattttcaga gaaatgacct tgagcaagat taatgttaat tcataaact tgagcaagat taatgttaat tgagcaagat tgagcaagat tgagcaagat tgagcaagat tgagcaagat tgagaaaaa cgagagaaaaa	780 840 900 960 1020 1080 1140 1260 1320 1380
ctg cgc tta c Leu Arg Leu F	cac gct tat His Ala Tyr 20	Arg Cys Al	c gct gac a Ala Asp 5	gtc tgg act Val Trp Thi	. Val Gly	1955
tat ggc cac a Tyr Gly His 1 35						2003
gaa gcc cag a Glu Ala Gln 7 50						2051
gtc agt cag o Val Ser Gln A 65						2099
ctg gtt tct t Leu Val Ser I						2147
acc ttg ttg a Thr Leu Leu I			n Asp Tyr		a Gly Asn	2195
gag ttt tta o Glu Phe Leu 7 115	ege tgg acc Arg Trp Thr	cgg gcc aa Arg Ala As 120	t ggg aag n Gly Lys	gtc ctt ccc Val Leu Pro 125	gga ctg Gly Leu	2243
att cgc cga c Ile Arg Arg A 130	ege gaa get Arg Glu Ala	gaa cgg gt Glu Arg Va 135	g ttg ttt l Leu Phe	gag aaa cto Glu Lys Leo 140	g ggt gca ı Gly Ala	2291
taa ccctttgcg *	ga cgtaccca	ca agatgaag	at aacacco	gegt actgage	eggt	2344
	tg agg caa	gac att atg	tat aat a Tyr Asn		att ctg	2404 2452
gag aaa gtg a Glu Lys Val <i>I</i>						2500

16	0	1	165		170		
gcg gtg ac Ala Val Th 175							
aaa atc ac Lys Ile Th 190							
agt cag gc Ser Gln Al							
att ctg gc Ile Leu Al							
ata cgg ca Ile Arg Gl 24	n Ala Ala	Gly Ser A				Phe Gly	
cgc gca ga Arg Ala As 255							
ccg gcg gc Pro Ala Al 270							
ccg gac ac Pro Asp Th							
gcg ctg gc Ala Leu Al							
agc ctg tc Ser Leu Se 32	r Asn Glu	Leu Leu I					
ctt gac ga Leu Asp As 335							
ggc ctg ac Gly Leu Th 350							
ctg gtg ca Leu Val Gl							
gcg cag ct Ala Gln Le							
tca ccg ga Ser Pro Gl 40	u Leu Tyr	Gln Ile I	ctg gcc Leu Ala 105	gaa gaa Glu Glu	att acg Ile Thr 410	aca gac Thr Asp	agt 3220 Ser
tac gaa gc Tyr Glu Al 415							
ctg tta tc	t tat gat	gca ctt g	gca aca	ttt tat	gat ctt	gat tac	gat 3316

Leu 430	Leu	Ser	Tyr	Asp	Ala 435	Leu	Ala	Thr	Phe	Tyr 440	Asp	Leu	Asp	Tyr	Asp 445	
gag Glu	cta Leu	act Thr	tcg Ser	tta Leu 450	ttg Leu	tca Ser	tta Leu	agg Arg	ctg Leu 455	gac Asp	ttt Phe	tca Ser	aat Asn	cca Pro 460	aac Asn	3364
					aat Asn											3412
					act Thr											3460
					aac Asn											3508
tat Tyr 510	ctt Leu	tat Tyr	aat Asn	ttc Phe	agc Ser 515	gtg Val	gtg Val	tca Ser	acg Thr	ata Ile 520	tca Ser	gag Glu	gat Asp	agt Ser	ttc Phe 525	3556
					ggt Gly											3604
					gly ggg											3652
					gat Asp											3700
					aça Thr											3748
					aaa Lys 595											3796
					gcg Ala											3844
aac Asn	ggt Gly	ctc Leu	acc Thr 625	att Ile	gac Asp	cat His	gcg Ala	gtc Val 630	ctg Leu	agt Ser	aaa Lys	atc Ile	ttc Phe 635	ctg Leu	gtc Val	3892
					cac His											3940
					atc Ile											3988
					ttc Phe 675											4036
					ccc Pro											4084

											aac Asn					4132
ggg Gly	ctt Leu	tcc Ser 720	acg Thr	ctc Leu	tgg Trp	cag Gln	ttg Leu 725	gcc Ala	agc Ser	ggt Gly	gac Asp	agc Ser 730	agc Ser	gct Ala	gly aaa	4180
											tac Tyr 745					4228
											ctg Leu					4276
											tcg Ser					4324
											tgg Trp					4372
											acg Thr					4420
											gct Ala 825					4468
											ctc Leu					4516
											gcc Ala					4564
											cca Pro					4612
											gcc Ala					4660
											ctg Leu 905					4708
ctg Leu 910	atc Ile	atc Ile	cgc Arg	agc Ser	acc Thr 915	ggc Gly	ctc Leu	agc Ser	acg Thr	cgc Arg 920	gag Glu	ctg Leu	acg Thr	ctg Leu	ctg Leu 925	4756
											cac His					4804
											cat His					4852
cgc Arg	agc Ser	ggc Gly 960	agc Ser	cat His	gcç Ala	Gly aaa	gag Glu 965	gtc Val	ctg Leu	acc Thr	gca Ala	ctt Leu 970	gag Glu	acc Thr	gga Gly	4900

gaa ctg to Glu Leu Se 975			. Ala Arg					4948
gat gtg ac Asp Val Th 990					Ala Gly			4996
aac agc gt Asn Ser Va	g ttc ac al Phe Th 10	r Ser Trp	gaa gag Glu Glu	gtg gac Val Asp 1015	cag gct Gln Ala	gag cag Glu Gln 102	Trp	5044
ctg gac at Leu Asp Me				Thr Pro				5092
ctg att go Leu Ile Al						Ala Pro		5140
tac agc ca Tyr Ser Gl 1055			Ser Gly					5188
agc agc ca Ser Ser Gl 1070					Glu Glu			5236
agc gcc ct Ser Ala Le		a Tyr Tyr					Val	5284
tcc ggg cg Ser Gly Ai				Leu Leu				5332
tca gcc aa Ser Ala Ly 13	ag gta aa /s Val Ly l20	a acc acc s Thr Thr	cgc att Arg Ile 1125	gcg gag Ala Glu	gcc atc Ala Ile 113	Ala Gly	ata Ile	5380
cgg ctg ta Arg Leu Ty 1135			Leu Asn					5428
gca gag gt Ala Glu Va 1150					Trp Asp			5476
aaa cgt ta Lys Arg Ty		r Trp Ala					Pro	5524
gaa aac ta Glu Asn Ty				Ile Gly				5572
gac acc ct Asp Thr Le	g ctg ca eu Leu Gl 200	g tct gtc n Ser Val	agc cag Ser Gln 1205	agc agt Ser Ser	atc aac Ile Asn 121	Arg Asp	acc Thr	5620
gtg gag ga Val Glu As 1215			Tyr Leu					5668
aat ctg aa Asn Leu As								5716

1230	1235	1240	1245
ggg act aca tgg tat Gly Thr Thr Trp Tyr 125	gtg ggt cgc agc atc Val Gly Arg Ser Ile 0 125	Thr Asp Gln Thr	aac tgg 5764 Asn Trp 1260
tac tgg cgc agc gcc Tyr Trp Arg Ser Ala 1265	aac cac agc aaa atc Asn His Ser Lys Ile 1270	caa gac tca atg Gln Asp Ser Met 1279	Met Pro
gcg aat gcc tgg acc Ala Asn Ala Trp Thr 1280	gga tgg aca aaa att Gly Trp Thr Lys Ile 1285	aac tgc gga atg Asn Cys Gly Met 1290	aat ccg 5860 Asn Pro
	tgc tcg gtg ttt ttc Cys Ser Val Phe Phe 1300		
	aat cag tct gct gat Asn Gln Ser Ala Asp 1315		
	agc tac acg ctg aaa Ser Tyr Thr Leu Lys 0 133	Leu Ser Phe Arg	
	tcc ccg gtg tcg ttc Ser Pro Val Ser Phe 1350		Asn Ile
	cag ggc atg cat gtg Gln Gly Met His Val 1365		
	gcg ttt tac tcc gtc Ala Phe Tyr Ser Val 1380		
	att tot gtg gat aat Ile Ser Val Asp Asn 1395		
	att ttt aag agc gtc Ile Phe Lys Ser Val 0 141	Ser His Glu Phe	
	att aat aat gtt ttt Ile Asn Asn Val Phe 1430		Ala Asn
	acg agt tta att gat Thr Ser Leu Ile Asp 1445		
	tct aaa act aca agt Ser Lys Thr Thr Ser 1460		
	acg cca gag ctt cat Thr Pro Glu Leu His 1475		
tgt ttt gtt agt act Cys Phe Val Ser Thr 149	gct ggc atc gcc act Ala Gly Ile Ala Thr 0 149	Gln Ser Thr Ile	gaa aaa 6484 Glu Lys 1500
ttc gtt cag gca ggg	ata gaa ttt gag gaa	att aat ttt tat	gca ggc 6532

Phe Val Gln Ala 150	-	Phe Glu Glu 1510	Ile Asn Phe	Tyr Ala 1515	Gly
cag gcc gcc ggc Gln Ala Ala Gly 1520	gga ttt gac Gly Phe Asp	gga ttt gtg Gly Phe Val 1525	gga gtg gat Gly Val Asp 153	Val Ser	aat 6580 Asn
tca aaa gta tac Ser Lys Val Tyr 1535		Lys Glu Ala			
tct tat tcc gtc Ser Tyr Ser Val 1550					
tca tca aat aaa Ser Ser Asn Lys			Ser Asp Lys		Thr
gct tta att agc Ala Leu Ile Ser 158	Gly Ser Thr				
ggc tct caa gat Gly Ser Gln Asp 1600				Ala Leu	
ata tat gaa tta Ile Tyr Glu Leu 1615		Ile Ile Leu			
act gaa att aaa Thr Glu Ile Lys 1630	tcc tgg cct Ser Trp Pro 1635	tcc gct gaa Ser Ala Glu	tgg tat aat Trp Tyr Asn 1640	gat aag Asp Lys	ctg 6916 Leu 1645
agt ctg caa tcc Ser Leu Gln Ser			Thr Lys Ser		Phe
acc gtt aat acc Thr Val Asn Thr 166	Ser Asp Ile				
acg ttc acc gct Thr Phe Thr Ala 1680	gtc gat cag Val Asp Gln	aat aac gtc Asn Asn Val 1685	gtg ctg gcc Val Leu Ala 169	Ala Arg	acg 7060 Thr
gcc ata tta acc Ala Ile Leu Thr 1695		Asn Ile Asn			
gca tta cgt aaa Ala Leu Arg Lys 1710					
ggt aac gat gtg Gly Asn Asp Val			Thr Leu Phe		Gln
ctg gtc gac cgg Leu Val Asp Arg		Gly Ile Asp			
1/4:	5	1750		1/33	

atg g Met A	gac Asp 1775	Phe	tcc Ser	gga Gly	gcc Ala	aat Asn 1780	Ala	ctc Leu	tat Tyr	ttc Phe	tgg Trp 1785	Glu	ctg Leu	ttc Phe	tat Tyr	7348
tac a Tyr 1 (1790	acg Thr	ccg Pro	atg Met	atg Met	gtg Val 1795	Phe	cag Gln	cgg Arg	ttg Leu	ttg Leu 1800	Gln	gaa Glu	cag Gln	cac His	ttc Phe 1805	7396
ccg (Pro (Trp					Trp					His	7444
gtg g Val V	gta Val	aac Asn	999 Gly 1825	Val	ctg Leu	cag Gln	aat Asn	tac Tyr 1830	Thr	tgg Trp	aat Asn	gtc Val	cgt Arg 1835	Pro	ctg Leu	7492
gag g Glu (Thr					Ser					Ile			7540
gat g Asp A		Ile					Pro					Val				7588
atg t Met S 1870						Leu					Āsp					7636
ctg (Leu l	ctc Leu	gag Glu	cgg Arg	gac Asp 1890	Thr	ctt Leu	aac Asn	gag Glu	gcc Ala 1899	Arg	atg Met	tgg Trp	tac Tyr	gtc Val 1900	Gln	7684
gcc o Ala I	ctg Leu	aac Asn	ctt Leu 1909	Leu	ggc Gly	gac Asp	gag Glu	ccc Pro 1910	Tyr	att Ile	tcc Ser	ttt Phe	gac Asp 1915	Āla	gac Asp	7732
tgg t Trp S			Leu					Ala					Thr			7780
gat t Asp :	tac Tyr 1935	Gln	gag Glu	gcc Ala	ctg Leu	ctg Leu 1940	Āla	gtg Val	cgc Arg	cgg Arg	ttg Leu 1945	Val	ccc Pro	gct Ala	ccc Pro	7828
gag a Glu 1 1950	aca Thr	cgg Arg	acg Thr	gcg Ala	aat Asn 1955	Ser	ctg Leu	acg Thr	gca Ala	ctg Leu 1960	Phe	ctc Leu	ccg Pro	cag Gln	cag Gln 1965	7876
aac (Asn (gag Glu	gtg Val	ctc Leu	aaa Lys 1970	Ğİy	tac Tyr	tgg Trp	caa Gln	acc Thr 1975	Leu	gca Ala	cag Gln	cgg Arg	ctc Leu 1980	His	7924
aac (Asn l	ctg Leu	cgc Arg	cac His 1985	Asn	ctc Leu	tcc Ser	att Ile	gac Asp 1990	ĞĨy	cag Gln	ccg Pro	ctt Leu	tcc Ser 1995	Leu	tcc Ser	7972
gtc (Val :	tac Tyr	gcc Ala 2000	Thr	ccg Pro	tcc Ser	gaa Glu	ccg Pro 2009	Ser	gcc Ala	ctg Leu	cag Gln	agt Ser 2010	Ala	gtc Val	gtc Val	8020
aac a Asn S	agc Ser 2015	Ala	cag Gln	ggt Gly	gct Ala	gca Ala 2020	Ala	ctg Leu	ccg Pro	gcc Ala	gcg Ala 2025	Val	atg Met	ccg Pro	ctt Leu	8068
tac Tyr 2030	Ser	ttc Phe	ccg Pro	gtc Val	atg Met 2039	Leu	gag Glu	aac Asn	gcc Ala	cgg Arg 2040	Gly	atg Met	gtg Val	agc Ser	ctg Leu 2045	8116

ctg acc ggg ttc ggc aac aca ctg ctc ggt att acc gag cgt cag gat 8 Leu Thr Gly Phe Gly Asn Thr Leu Leu Gly Ile Thr Glu Arg Gln Asp 2050 2055 2060	164
gcg gag gcg ctg gcc aaa ctg ctg cag acc cag ggc agt gaa ctg ata 8. Ala Glu Ala Leu Ala Lys Leu Gln Thr Gln Gly Ser Glu Leu Ile 2065 2070 2075	212
cgc cag ggc ctt cgc cag cag gat aac gtc ctc gag gaa atc gat gcg 8 Arg Gln Gly Leu Arg Gln Gln Asp Asn Val Leu Glu Glu Ile Asp Ala 2080 2085 2090	260
gat att gcc gcc ctg gag gag agc cgc cgc ggc gcg cag atg cgt ttt 8 Asp Ile Ala Ala Leu Glu Glu Ser Arg Arg Gly Ala Gln Met Arg Phe 2095 2100 2105	308
gaa cgt tac aaa gtg ttg tac gag gcg gac gtc aac acc ggc gaa aaa 8 Glu Arg Tyr Lys Val Leu Tyr Glu Ala Asp Val Asn Thr Gly Glu Lys 2110 2125	356
cag gcc atg gac ttg tac ctc agt tcg tcc gtg ctg tcg gca tca acc 8 Gln Ala Met Asp Leu Tyr Leu Ser Ser Val Leu Ser Ala Ser Thr 2130 2135 2140	404
gcc gcg ctc ttt ttg gcc gag gcc gcg gcc gat atg ctg ccc aat att 8 Ala Ala Leu Phe Leu Ala Glu Ala Ala Ala Asp Met Leu Pro Asn Ile 2145 2150 2155	452
tac ggg ctg gcc gtc ggg ggc tcc cgc tat ggg gca cta ttt aaa gcc 8 Tyr Gly Leu Ala Val Gly Gly Ser Arg Tyr Gly Ala Leu Phe Lys Ala 2160 2165 2170	500
acc gcc atc ggc atc cag gtg tcc tcc gat gcc acc cgc ata tca gcg 8 Thr Ala Ile Gly Ile Gln Val Ser Ser Asp Ala Thr Arg Ile Ser Ala 2175 2180 2185	548
gac aaa atc agc cag tcg gaa gtg tac cgc cgt cgc cgg gag gag tgg 8 Asp Lys Ile Ser Gln Ser Glu Val Tyr Arg Arg Arg Arg Glu Glu Trp 2190 2195 2200 2205	596
gaa atc cag cgt gat agt gcg cag tct gac gtg gcg cag att gat gcc 8 Glu Ile Gln Arg Asp Ser Ala Gln Ser Asp Val Ala Gln Ile Asp Ala 2210 2215 2220	644
cag ctg gcg gcc atg gca gtg cgc cgg gaa ggg gct gag ctg cag aaa 8 Gln Leu Ala Ala Met Ala Val Arg Arg Glu Gly Ala Glu Leu Gln Lys 2225 2230 2235	692
act tac ctt gag acc cag cag acc cag gca cag gcg cag ttg gca ttc 8 Thr Tyr Leu Glu Thr Gln Gln Thr Gln Ala Gln Ala Gln Leu Ala Phe 2240 2245 2250	740
ctg cag agt aag ttc aac aat acg gct ctg tac agc tgg ctg cgg ggc 8 Leu Gln Ser Lys Phe Asn Asn Thr Ala Leu Tyr Ser Trp Leu Arg Gly 2255 2260 2265	788
agg ttg tcc gcc att tat tac cag ttc tat gac ctg gca gta tcc cgc 8 Arg Leu Ser Ala Ile Tyr Tyr Gln Phe Tyr Asp Leu Ala Val Ser Arg 2270 2285	836
tgc ctg atg gcg caa cag gcc tgg cag tgg gat aaa ttc gag act agg 8 Cys Leu Met Ala Gln Gln Ala Trp Gln Trp Asp Lys Phe Glu Thr Arg 2290 2295 2300	884
tcg ttt atc cag ccg ggg gcc tgg atg ggg gca aat gcc ggt ctg ctg 8	

\	2305	2310	2315	
gcc ggg gaa Ala Gly Glu 2320	acc ctg atg ctg aat Thr Leu Met Leu Asn) 2325	Leu Ala Gln Met G	ag cag gcc tgg lu Gln Ala Trp 330	8980
ctg acg ggg Leu Thr Gly 2335	gat gag cgg gca ata Asp Glu Arg Ala Ile 2340	gag gtg acg cgg a Glu Val Thr Arg T 2345	cg gtc tgc ctg hr Val Cys Leu	9028
tcg gag gtc Ser Glu Val 2350	tat acc agc ctc gcg Tyr Thr Ser Leu Ala 2355	gag gat gcg gca t Glu Asp Ala Ala P 2360	tc tct ctg gcc he Ser Leu Ala 2365	9076
gac aag gtg Asp Lys Val	gtg gaa ctg gtc agt Val Glu Leu Val Ser 2370	aac ggt tcg ggc a Asn Gly Ser Gly S 2375	gt gcg ggt acg er Ala Gly Thr 2380	9124
aaa agc aac Lys Ser Asn	gga tta cag atg gat Gly Leu Gln Met Asp 2385	caa cag caa ctc g Gln Gln Gln Leu G 2390	ag gcc acc ctg lu Ala Thr Leu 2395	9172
aaa ctg gct Lys Leu Ala 2400	gac ctc ggt atc ggc Asp Leu Gly Ile Gly 0 2405	Asn Asp Tyr Pro V	tc tcc ctt ggc al Ser Leu Gly 410	9220
acc atg agg Thr Met Arg 2415	cgc atc aaa caa ata Arg Ile Lys Gln Ile 2420	agc gtc acg ctc c Ser Val Thr Leu P 2425	cg gcg ctg gtc ro Ala Leu Val	9268
ggc ccc tat Gly Pro Tyr 2430	cag gac gtc cgt gcg Gln Asp Val Arg Ala 2435	gtt ctc agc tac g Val Leu Ser Tyr G 2440	gc gga agt atg ly Gly Ser Met 2445	9316
gtc atg ccc Val Met Pro	cgg ggt tgc agc gcg Arg Gly Cys Ser Ala 2450	ctg gcg gtc tca c Leu Ala Val Ser H 2455	ac gga atg aac is Gly Met Asn 2460	9364
gac agc ggc Asp Ser Gly	caa ttc caa ctg gat Gln Phe Gln Leu Asp 2465	ttc aat gac ccg c Phe Asn Asp Pro A 2470	gt tac ctg ccg rg Tyr Leu Pro 2475	9412
ttt gaa gga Phe Glu Gly 2480	ctt cca gtt gat gac Leu Pro Val Asp Asp 0 248	Thr Gly Thr Leu T	ca ctg agc ttc Thr Leu Ser Phe 1490	9460
ccg gat gct Pro Asp Ala 2495	gac ggc aaa caa cag Asp Gly Lys Gln Gln 2500	gcg atg ctc ctc a Ala Met Leu Leu S 2505	Ser Leu Ser Asp	9508
atc atc ctg Ile Ile Leu 2510	cat atc cgt tac acc His Ile Arg Tyr Thr 2515	att atc agc tga t Ile Ile Ser * 2520	ag gtatcaacat *	9557
agcgcaggcc (cccgaacgag ggcctgcgaq	g gagactgagc atg c Met	caa aat cat caa Gln Asn His Gln 2525	9612
gac atg gcc Asp Met Ala	att act gcc ccc acg Ile Thr Ala Pro Thr 2530	ttg cct tcc ggg c Leu Pro Ser Gly G 2535	ggc ggt gcg gtc Sly Gly Ala Val 2540	9660 [°]
acc ggg ctc Thr Gly Leu	aag ggt gat atc gcg Lys Gly Asp Ile Ala 2545	gcg gca ggg ccg g Ala Ala Gly Pro A 2550	gat ggt gcg gcg Asp Gly Ala Ala 2555	9708
acc ctg agt	att ccc ttg ccg gtt	agc ccc ggt cgg g	ggt tac gcc ccc	9756

Thr	Leu	Ser 2560		Pro	Leu	Pro	Val 2565		Pro	Gly	Arg	Gly 2570		Ala	Pro	
		Āla			tat Tyr		Ser					Gly				9804
att Ile 259	Gly	tgg Trp	ggt Gly	atc Ile	ggc Gly 259!	Gly	g¢t Ala	gct Ala	gtc Val	cag Gln 2600	Arg	cgt Arg	acg Thr	cgc Arg	aac Asn 2605	9852
					gat Asp)					Phe					Ğİy	9900
				Pro	gca Ala				Āla					Āla		9948
			Ser		ctg Leu			Asn					Phe			9996
		Tyr			cgt Arg		Glu					Arg				10044
	Leu				gag Glu 2675	Thr					Trp					10092
					Ala					Asn						10140
				Āla	cca Pro				Ala					Glu		10188
			Leu		ggc Gly			Met					Arg			10236
		Asp			gac Asp		Ala					His				10284
	Āla				ccg Pro 2755	Val					ĠĪу					10332
					gcg Ala)					Pro					Trp	10380
				Val	ttt Phe				Glu					Leu		10428
			Ala		caa Gln			Gly					Leu			10476
		Cys			gly ggg		Glu					Leu				10524

cgc ctg tgc cgt Arg Leu Cys Arg 2830	cag gtt ttg Gln Val Leu 2835	atg ttc cat Met Phe His	tac cta ggt Tyr Leu Gly 2840	gtt ctg Val Leu	gcg 10572 Ala 2845
ggg agt tcg gga Gly Ser Ser Gly			Leu Ile Ser		Leu
ctg gac tac agg Leu Asp Tyr Arg 2865	Glu Ser Pro	tca ctc agt Ser Leu Ser 2870	ctg ctc gag Leu Leu Glu	aac gtg Asn Val 2875	cac 10668 His
cag gtg gct tat Gln Val Ala Tyr 2880				Pro Ala	
gca ttg ggg tgg Ala Leu Gly Trp 2895		Thr Pro Pro			
acg cgt gac gat Thr Arg Asp Asp 2910					
gta gac ctt aac Val Asp Leu Asn	ggc gaa ggt Gly Glu Gly 2930	gtg gtg ggt Val Val Gly 293	Ile Leu Tyr	cag gac Gln Asp 2940	Ser
ggt gcc tgg tgg Gly Ala Trp Trp 2945	Tyr Arg Glu				
gat gct gtg acc Asp Ala Val Thr 2960				Met Pro	
ttg cat aac agc Leu His Asn Ser 2975	ggc atc ctg Gly Ile Leu 298	Ala Asp Leu	aat ggg gat Asn Gly Asp 2985	ggt cgg Gly Arg	ctg 11004 Leu
gag tgg gtc gtt Glu Trp Val Val 2990	acc gcc ccc Thr Ala Pro 2995	ggt gtg gcg Gly Val Ala	ggg atg tat Gly Met Tyr 3000	gat cgc Asp Arg	acc 11052 Thr 3005
ccc ggc cgc gac Pro Gly Arg Asp	tgg ttg cat Trp Leu His 3010	ttc acc ccc Phe Thr Pro 301	Leu Ser Ala	ttg ccc Leu Pro 3020	Val
gaa tat gcg cat Glu Tyr Ala His 3025	Pro Lys Ala				
tta acg gac atg Leu Thr Asp Met 3040				Leu Tyr	
ggc aaa aac gat Gly Lys Asn Asp 3055	ggt tgg aat Gly Trp Asn 306	Lys Gly Glu	acc gtg cag Thr Val Gln 3065	caa acg Gln Thr	gaa 11244 Glu
aga ctc act ctg Arg Leu Thr Leu 3070					
ttc agt gat atg Phe Ser Asp Met			His Leu Thr		Arg

gct aat gga gta Ala Asn Gly Val 310	Arg Tyr Tr	g cca aac cto Pro Asn Lei 3110	ggg cac ggt Gly His Gly	cgt ttc gg Arg Phe Gl 3115	t 11388 Y
cag ccg gtg aat Gln Pro Val Asn 3120	att ccc gg	t ttt agc cac Phe Ser Glr 3125	tca gtg act Ser Val Thr 313	Thr Phe As	c 11436 n
cct gac cag ata Pro Asp Gln Ile 3135		a Asp Thr Asp			
ctg att tat gcg Leu Ile Tyr Ala 3150				Asn Gln Se	
ggt aat tat ttc Gly Asn Tyr Phe	gcc gag ccc Ala Glu Pro 3170	g cat acg cto His Thr Let 317	Leu Leu Pro	aaa ggt gt Lys Gly Va 3180	g 11580 .1
cgc tat gat cgc Arg Tyr Asp Arg 318	Thr Cys Se				
ggg gtg cct agc Gly Val Pro Ser 3200	ctg tta ctg Leu Leu Le	g acg gtc ccc n Thr Val Pro 3205	cat gtc gcg His Val Ala 321	Pro His Hi	c 11676 s
tgg gtg tgc cat Trp Val Cys His 3215		a Asp Lys Pro			
aac aac aat atg Asn Asn Asn Met 3230	ggg gcc cg Gly Ala Ar 3235	g cat gca cto g His Ala Leu	g cac tat cgc His Tyr Arg 3240	Ser Ser Va	g 11772 .1 45
cag ttc tgg ctg Gln Phe Trp Leu	gat gag aa Asp Glu Ly 3250	a gcc gag gca s Ala Glu Ala 325	ı Leu Ala Ala	ggc agt to Gly Ser Se 3260	c 11820 cr
cct gcc tgc tac Pro Ala Cys Tyr 326	Leu Pro Ph				
gtg cag gat gag Val Gln Asp Glu 3280				Val Leu Ty	
cgc cac ggc gtc Arg His Gly Val 3295	tgg gac gg Trp Asp Gl	/ Gln Glu Arg	gag ttt cgg Glu Phe Arg 3305	ggg ttt gg Gly Phe Gl	t 11964 Y
ttt gtt gag atc Phe Val Glu Ile 3310				Gly Thr Al	
acg gaa ctg agt Thr Glu Leu Ser			Asn Trp Tyr		
gta ccg gca gta Val Pro Ala Val 334				Gln Asn As	
	-	3350		3355	

3360	3365	3370	
gag gat gag cag aca Glu Asp Glu Gln Thr 3375	tat act ccg gac ga Tyr Thr Pro Asp As 3380	c agc aag aca ttc tgg p Ser Lys Thr Phe Trp 3385	; ttg 12204) Leu
Gln Arg Ala Leu Lys	ggc atc ctg ctg cg Gly Ile Leu Leu Ar 3395	c agt gag tta tac ggt g Ser Glu Leu Tyr Gly 3400	gcc 12252 Ala 3405
gat ggc agc agc cag Asp Gly Ser Ser Gln 3410	Ala Asp Ile Pro Ty	c agc gtc act gag tct r Ser Val Thr Glu Ser 15 342	: Arg
ccg cag gta cgg cta Pro Gln Val Arg Leu 3425	gtt gaa gcg aat gg Val Glu Ala Asn Gl 3430	a gac tac ccg gtg gtc y Asp Tyr Pro Val Val 3435	g tgg 12348 L Trp
ccg atg ggc gcg gaa Pro Met Gly Ala Glu 3440	agc cgt acg tca gt Ser Arg Thr Ser Va 3445	t tat gaa cgg tac cac l Tyr Glu Arg Tyr His 3450	c aat 12396 s Asn
gat cct caa tgc caa Asp Pro Gln Cys Gln 3455	cag cag gcg gta ct Gln Gln Ala Val Le 3460	c ctc agt gat gaa tao u Leu Ser Asp Glu Tyi 3465	ggt 12444 Gly
ttc cca ctg cgt cag Phe Pro Leu Arg Gln 3470	gtc agt gtc aat ta Val Ser Val Asn Ty 3475	t cca cga cgc cct ccg r Pro Arg Arg Pro Pro 3480	g tcg 12492 o Ser 3485
gcg gac aat cca tat Ala Asp \Asn Pro Tyr 3490	Pro Ala Ser Leu Pr	g gcg acg ctg ttc gcc o Ala Thr Leu Phe Ala 95	a Asn
agt tat gac gag cag Ser Tyr Asp Glu Gln 3505	cag cag ata tta cg Gln Gln Ile Leu Ar 3510	c ctg ggg ttg caa cag g Leu Gly Leu Gln Gli 3515	g agc 12588 n Ser
agt gca cat cac ctt Ser Ala His His Leu 3520	gtt tca ctg tct ga Val Ser Leu Ser Gl 3525	ng ggg cat tgg ttg ttg nu Gly His Trp Leu Lei 3530	g ggg 12636 u Gly
ttg gcg gag gcg tcg Leu Ala Glu Ala Ser 3535	cgg gac gat gta tt Arg Asp Asp Val Ph 3540	c acg tac tet geg gad ne Thr Tyr Ser Ala Asj 3545	c aac 12684 p Asn
gtg ccg gaa ggg ggt Val Pro Glu Gly Gly 3550	Leu Thr Leu Glu Hi	c ctg ttg gcg ccc ga s Leu Leu Ala Pro Gl 3560	a agc 12732 u Ser 3565
ctg gtc tcg gat agt Leu Val Ser Asp Ser 3570	Gln Val Gly Thr Le	g gcg ggt cag cag ca eu Ala Gly Gln Gln Gl: 375 35	n Val
tgg tat ctg gat tca Trp Tyr Leu Asp Ser 3585	caa gac gtt gcc ac Gln Asp Val Ala Th 3590	cc gtc gct gct ccg cc nr Val Ala Ala Pro Pr 3595	a ctc 12828 o Leu
ccc ccc aag gta gct Pro Pro Lys Val Ala 3600	ttt atc gaa acg go Phe Ile Glu Thr Al 3605	cc gtg ctg gat gag gg La Val Leu Asp Glu Gl 3610	t atg 12876 y Met
gtc agt tca ctg gct Val Ser Ser Leu Ala 3615	gcc tac att gtg ga Ala Tyr Ile Val As 3620	at gaa cat ctc gag ca sp Glu His Leu Glu Gl 3625	a gcc 12924 n Ala
ggt tac cgg caa tcc	gga tac ctt ttc co	ct cga ggc agg gaa gc	a gaa 12972

Gly Tyr 3630	Arg Gln	Ser Gly 3635		Phe	Pro	Arg 3640		Arg	Glu	Ala	Glu 3645	
cag gca Gln Ala	ttg tgg Leu Trp	acc cag Thr Gln 3650	tgt cag Cys Gln	gga Gly	tat Tyr 3655	Val	acc Thr	tat Tyr	gcc Ala	ggc 3660	Ala	13020
gag cat Glu His	ttc tgg Phe Trp 366	cta ccg Leu Pro 5	cta tcc Leu Ser	ttt Phe 3670	Arg	gac Asp	agt Ser	atg Met	ttg Leu 3675	Thr	ggc Gly	13068
cca gtt Pro Val	acc gtg Thr Val 3680	acg cgt Thr Arg	gac gcg Asp Ala 368	Tyr	gac Asp	tgc Cys	gtc Val	atc Ile 3690	Thr	cag Gln	tgg Trp	13116
cag gat Gln Asp 3695	Ala Ala	ggg att Gly Ile	gtc acc Val Thr 3700	aca Thr	gcc Ala	gac Asp	tat Tyr 3705	Asp	tgg Trp	cgc Arg	ttc Phe	13164
ctg acg Leu Thr 3710	ccc gtc Pro Val	cgg gtg Arg Val 371	Thr Asp	ccc Pro	aat Asn	gat Asp 3720	Asn	ctg Leu	cag Gln	tcc Ser	gtc Val 3725	13212
act ctg Thr Leu	gat gct Asp Ala	ctg ggc Leu Gly 3730	cgg gtg Arg Val	acc Thr	acc Thr 373	Leu	cga Arg	ttc Phe	tgg Trp	ggc Gly 3740	Thr	13260
gag aat Glu Asn	ggt att Gly Ile 374	gcc acc Ala Thr 5	ggt tac Gly Tyr	agt Ser 375	Asp	gcc Ala	acg Thr	ttg Leu	tcc Ser 375	Val	ccg Pro	13308
gac ggc Asp Gly	gca gca Ala Ala 3760	gcc gct Ala Ala	ctg gcg Leu Ala 376	Leu	acg Thr	gcg Ala	ccc Pro	cta Leu 3770	Pro	gta Val	gca Ala	13356
cag tgt Gln Cys 3779	Leu Val	tat gtc Tyr Val	acg gad Thr Asp 3780	agt Ser	tgg Trp	gga Gly	gat Asp 3785	Asp	gac Asp	aat Asn	gag Glu	13404
aaa atg Lys Met 3790	ccc ccg Pro Pro	cac gtg His Val 379	Val Val	g ctg . Leu	gct Ala	acc Thr 3800	Asp	cgc Arg	tat Tyr	gac Asp	agt Ser 3805	13452
gat acc Asp Thr	gga cag Gly Gln	cag gtc Gln Val 3810	cgc caa Arg Glr	ı cag ı Gln	gtg Val 381	Thr	ttc Phe	agt Ser	gac Asp	ggt Gly 3820	Phe	13500
		caa tcg Gln Ser 5			Gln					Ala		13548
caa cga Gln Arg	gga cgc Gly Arg 3840	gac ggc Asp Gly	aaa cto Lys Let 384	ı Val	acg Thr	gcc Ala	agt Ser	gac Asp 385	Gly	ttg Leu	ccg Pro	13596
	Val Ala	acg aat Thr Asn						${ t Gly}$				13644
tat gac Tyr Asp 3870	aat aaa Asn Lys	ggt ctg Gly Leu 387	Pro Va	cgg L Arg	gtt Val	tat Tyr 3880	Gln	ccg Pro	tat Tyr	ttt Phe	ctg Leu 3885	13692
gac agt Asp Ser	tgg caa Trp Glr	tat gtc Tyr Val 3890	agt gat Ser Asp	gac Asp	agt Ser 389	Ala	cgc Arg	cag Gln	gac Asp	ctg Leu 390	Tyr	13740

gcc gac acg cac ttt Ala Asp Thr His Phe 3905	tac gat ccg acg Tyr Asp Pro Thr 391	Ala Arg Glu Trp	cag gtt att Gln Val Ile 3915	13788									
acg gca aaa ggt gaa Thr Ala Lys Gly Glo 3920	a cgg cga cag gtg n Arg Arg Gln Val 3925	ctg tat acc ccg Leu Tyr Thr Pro 3930	Trp Phe Val	13836									
gtc agt gaa gac gag Val Ser Glu Asp Glu 3935	g aat gat acc gtt 1 Asn Asp Thr Val 3940	ggg cta aac gac Gly Leu Asn Asp 3945	gca tcc tga Ala Ser *	13884									
ctgggaagga gggggggacg gtg atg agt ccg tcg ccc ctg aca ggc gct gcc 1 Met Ser Pro Ser Pro Leu Thr Gly Ala Ala 3950 3955													
ctg atg gag aca aag Leu Met Glu Thr Lys 3960	g atg aaa ata cac s Met Lys Ile His 3965	tat cag gtt gcg Tyr Gln Val Ala 3970	gcg gtt gtg Ala Val Val	13985									
ctg aca ggt gtt ato Leu Thr Gly Val Met 3975	g gtt tgg ggg ctt Val Trp Gly Leu 3980	tcc cat tgg cgt Ser His Trp Arg 3985	tac acc gtc Tyr Thr Val 3990	14033									
ggt tac cac gcg gca Gly Tyr His Ala Ala 399	a Asp Thr Gln Trp	caa caa cgc cag Gln Gln Arg Gln 4000	gcc gaa cag Ala Glu Gln 4005	14081									
gaa agg gcc gat gcg Glu Arg Ala Asp Ala 4010	g ttg gcc ctc ctg a Leu Ala Leu Leu 401	Ala Ala Glu Thr	cgg gaa aga Arg Glu Arg 4020	14129									
aag tgg gag cag caa Lys Trp Glu Gln Gli 4025	a cga cag act gac n Arg Gln Thr Asp 4030	atg aac aag gtg Met Asn Lys Val 4035	Ala Ile His	14177									
gct gaa gaa gaa cto Ala Glu Glu Glu Leo 4040				14225									
cgc act ggt cag cgc Arg Thr Gly Gln Arg 4055	c ctg cag cac acc g Leu Gln His Thr 4060	gtt acc acc ctc Val Thr Thr Leu 4065	cag cgg caa Gln Arg Gln 4070	14273									
ctt gcc agt cgt gaa Leu Ala Ser Arg Glu 40'	ı Thr Arg Arg Leu	tcc gca gct acc Ser Ala Ala Thr 4080	gct atc ggt Ala Ile Gly 4085	14321									
aca gac gac ctc gg: Thr Asp Asp Leu Gly 4090	a ggc caa ccc ggc y Gly Gln Pro Gly 409	Val Leu Phe Ala	gaa ctg ttc Glu Leu Phe 4100	14369									
cgc cgc gct gac cag Arg Arg Ala Asp Gli 4105	g aga gcg gga gag n Arg Ala Gly Glu 4110	ctg gca gcg tat Leu Ala Ala Tyr 4115	Ala Asp Arg	14417									
acc aga gtg aaa tgg Thr Arg Val Lys Trj 4120	g cag gcc tgc ggg o Gln Ala Cys Gly 4125	cgc gcc tat cag Arg Ala Tyr Gln 4130	gcg gct acg Ala Ala Thr	14465									
cac gaa gca gaa aa His Glu Ala Glu Ly: 4135		ccgttaagga aaagtg	acgg	14513									
tgttttcgcg attaata	tta acaggagatc ac	atg agc aca tcc Met Ser Thr Ser 4140		14566									

agc Ser	acc Thr	ccg Pro	tcg Ser 4150	Val	gcg Ala	gtg Val	ctc Leu	gac Asp 4155	Asn	cgc Arg	ggc Gly	ctg Leu	ttg Leu 4160	Va⊥	cgg Arg	14614
gag Glu	ctg Leu	cag Gln 4165	Tyr	tac Tyr	cgc Arg	cat His	ccg Pro 4170	Asp	aca Thr	ccg Pro	gag Glu	gag Glu 4175	Thr	gac Asp	gag Glu	14662
cgt Arg	atc Ile 4180	Thr	tgc Cys	cat His	cag Gln	cac His 4185	Asp	gag Glu	cgc Arg	ggc Gly	agc Ser 4190	Leu	tca Ser	caa Gln	agc Ser	14710
gcc Ala 419	gac Asp	ccg Pro	cgg Arg	tta Leu	cac His 4200	Ala	gcc Ala	ggt Gly	ctg Leu	aca Thr 4205	Asn	ttc Phe	acg Thr	tac Tyr	ctg Leu 4210	14758
aat Asn	agc Ser	ctg Leu	acc Thr	999 Gly 4215	Thr	gta Val	ctg Leu	cag Gln	agc Ser 4220	Val	agc Ser	gcc Ala	gat Asp	gcc Ala 4225	GIY	14806
acg Thr	tcg Ser	ctg Leu	gaa Glu 4230	Leu	agc Ser	gat Asp	gcc Ala	gcc Ala 4235	Gly	cgg Arg	gcg Ala	ttt Phe	ctg Leu 4240	Ala	gtc Val	14854
acc Thr	с Gly 999	gct Ala 4245	Gly	acg Thr	gaa Glu	gac Asp	gcg Ala 4250	Val	acc Thr	cgc Arg	acc Thr	tgg Trp 425!	Gln	tat Tyr	gaa Glu	14902
gac -Asp	gat Asp 4260	Thr	ctg Leu	ccg Pro	ggc Gly	cgc Arg 426	Pro	ctg Leu	agc Ser	atç Ile	acc Thr 4270	Glu	cag Gln	gtt Val	acc Thr	14950
ggt Gly 427	gaa Glu 5	gcc Ala	gcc Ala	caa Gln	att Ile 4280	Thr	gaa Glu	cgc Arg	ttc Phe	gtg Val 428!	Tyr	gct Ala	ggc Gly	aat Asn	acg Thr 4290	14998
gat Asp	gcc Ala	gag Glu	aag Lys	att Ile 429	Leu	aat Asn	ctg Leu	gct Ala	ggc Gly 430	Gln	tgt Cys	gtc Val	agt Ser	cat His 430	Tyr	15046
gat Asp	acc Thr	gcc Ala	gga Gly 431	Leu	gtg Val	cag Gln	acg Thr	gac Asp 431	Ser	atc Ile	gcc Ala	ctg Leu	agc Ser 432	GГУ	gtg Val	15094
ccg Pro	ctc Leu	gcc Ala 432	Val	acg Thr	cgg Arg	cag Gln	ttg Leu 433	Leu	ccc Pro	gac Asp	gcg Ala	gcg Ala 433	_Gly	gcc Ala	aac Asn	15142
tgg Trp	atg Met 434	Gly	gag Glu	gat Asp	gcc Ala	tcg Ser 434	Ala	tgg Trp	aat Asn	gac Asp	ctg Leu 435	Leu	gat Asp	ggg ggg	gag Glu	15190
acg Thr 435	ttc Phe 5	ttc Phe	acc Thr	cag Gln	acc Thr 436	His	gct Ala	gat Asp	gcg Ala	acc Thr 436	Gly	gcc Ala	gtc Val	ctg Leu	agc Ser 4370	15238
atc Ile	acc Thr	gat Asp	gca Ala	aaa Lys 437	Gly	aat Asn	ctg Leu	cag Gln	cgt Arg 438	Val	gca Ala	tat Tyr	gat Asp	gtg Val 438	Ala	15286
gly aaa	ctg Leu	cta Leu	tcg Ser 439	Gly	agt Ser	tgg Trp	ttg Leu	acg Thr 439	Leu	aag Lys	gac Asp	ggc Gly	acg Thr 440	Glu	cag Gln	15334
gtc Val	atc Ile	gtg Val	gcc Ala	tcc Ser	ctg Leu	acg Thr	tac Tyr	tcg Ser	gcc Ala	gcc Ala	gly ggg	aaa Lys	aag Lys	ttg Leu	cgt Arg	15382

4405	4410	4415
------	------	------

gaa Glu	gaa Glu 4420	His	ggc	aac Asn	ggc Gly	gtg Val 4425	Val	acc Thr	tcg Ser	tat Tyr	att Ile 4430	Tyr	gag Glu	ccg Pro	gaa Glu	15430
aca Thr 4435	Gln	cgc Arg	ctg Leu	acg Thr	999 Gly 4440	att Ile)	aaa Lys	acg Thr	gaa Glu	cgt Arg 4445	Pro	tct Ser	ggg Gly	cac His	gtt Val 4450	15478
gcc Ala	gga Gly	gca Ala	aaa Lys	gtg Val 4455	Leu	cag Gln	gac Asp	ctg Leu	cgc Arg 4460	Tyr	acg Thr	tat Tyr	gac Asp	ccg Pro 4465	val	15526
ggc Gly	aac Asn	gta Val	ctc Leu 4470	Ser	gtc Val	aat Asn	aac Asn	gat Asp 4475	Ala	gaa Glu	gag Glu	acc Thr	cgc Arg 4480	Phe	tgg Trp	15574
cgt Arg	aac Asn	cag Gln 448!	Lys	gtg Val	gta Val	ccg Pro	gag Glu 4490	Asn	acg Thr	tac Tyr	atc Ile	tac Tyr 4499	Asp	agc Ser	ctg Leu	15622
tac Tyr	cag Gln 4500	Leu	gtc Val	agc Ser	gcc Ala	aca Thr 4505	Gly	cgt Arg	gag Glu	atg Met	gcc Ala 4510	Asn	gcc Ala	ggc Gly	cag Gln	15670
cag Gln 451	Gly	aac Asn	gac Asp	tta Leu	cca Pro 4520	tcc Ser	gct Ala	aca Thr	gcc Ala	ccc Pro 452!	Leu	cct Pro	aca Thr	gac Asp	agc Ser 4530	15718
tct Ser	gcc Ala	tac Tyr	acc Thr	aat Asn 453	Tyr	acg Thr	cgc Arg	acc Thr	tac Tyr 454	Arg	tat Tyr	gac Asp	cgt Arg	ggt Gly 454	GLY	15766
aac Asn	ctg Leu	acg Thr	cag Gln 455	Met	cgc Arg	cac His	agt Ser	gcc Ala 455	Pro	gcc Ala	acg Thr	aac Asn	aat Asn 456	Asn	tat Tyr	15814
acg Thr	aca Thr	gac Asp 456	Ile	acg Thr	gtt Val	agt Ser	gac Asp 457	Arg	agc Ser	aat Asn	agg Arg	gcg Ala 457	Val	ctg Leu	agc Ser	15862
acg Thr	ttg Leu 458	Ala	gaa Glu	gtg Val	ccg Pro	tca Ser 458	Asp	gtt Val	gat Asp	atg Met	ctg Leu 459	Phe	agt Ser	gca Ala	gga Gly	15910
ggt Gly 459	His	cag Gln	aag Lys	cac His	ctg Leu 460	Gln	ccg Pro	ggg ggg	caa Gln	gca Ala 460	Leu	gtg Val	tgg Trp	acg Thr	cca Pro 4610	15958
cgt Arg	gga Gly	gaa Glu	ctg Leu	caa Gln 461	Lys	gtg Val	aca Thr	ccg Pro	gtg Val 462	Val	cgt Arg	gat Asp	Gl y 999	999 Gly 462	Ala	16006
gac Asp	gac Asp	ago Ser	gaa Glu 463	Ser	tat Tyr	cgg Arg	tat Tyr	gat Asp 463	Ala	ggc Gly	agt Ser	cag Gln	cgt Arg 464	Ile	atc Ile	16054
aaa Lys	acc Thr	ggc Gly 464	Thr	cgg Arg	caa Gln	act Thr	ggc Gly 465	Asn	aac Asn	gtt Val	cag Gln	aca Thr 465	Gln	cgg Arg	gta Val	16102
gtg Val	tac Tyr 466	Leu	g ccg Pro	gly ggg	ctg Leu	gag Glu 466	Leu	cgt Arg	ato Ille	atg Met	gca Ala 467	Asn	ggc Gly	gtg Val	acg Thr	16150
gaa	aaa	gaa	ago	ctg	cag	gtt	att	acg	gtg	ggc	gag	gct	999	cgg	gca	16198

Glu Lys 4675	Glu Ser	Leu Gln 4680		Thr V	al Gly 4685	Glu A	la Gly	Arg .	Ala 4690	
caa gtg Gln Val	cgc gta Arg Val	ttg cac Leu His 4695	tgg gag Trp Glu	Ile G	gc aag ly Lys 700	ccg g Pro A	gat gac Asp Asp	ctc Leu 4705	gat Asp	16246
gag gac Glu Asp	tcg gtg Ser Val 471	cgt tac Arg Tyr 0	agt tac Ser Tyr	gat a Asp A 4715	ac ctg sn Leu	gtg g Val G	ggc agc Sly Ser 472	Ser	cag Gln	16294
ctg gag Leu Glu	ctg gac Leu Asp 4725	aga gag Arg Glu	ggt tac Gly Tyr 473	Leu I	itc agt le Ser	GIU G	gag gag Blu Glu 1735	ttc Phe	tac Tyr	16342
ccg tat Pro Tyr 4740	Gly Gly	acg gct Thr Ala	gtt ctg Val Leu 4745	acg g Thr A	gcg cga Ala Arg	agt 9 Ser 0 4750	gag gtt Glu Val	gag Glu		16390
gac tac Asp Tyr 4755	aaa act Lys Thr	atc cga Ile Arg 476	Tyr Ser	ggc a Gly I	aag gag Lys Glu 4765	Arg A	gac gcg Asp Ala	acg Thr	ggg Gly 4770	16438
ctg gat Leu Asp	tat tac Tyr Tyr	ggt tat Gly Tyr 4775	cgg tat Arg Tyr	Tyr G	cag cca Sln Pro 1780	tgg g Trp <i>I</i>	gca ggg Ala Gly	cgc Arg 4785	Trp	16486
ctc tcc Leu Ser	acg gac Thr Asp 479	ccg gca Pro Ala 0	ggc acg Gly Thr	gtg g Val A 4795	gac ggg Asp Gly	ctg a	aac ctg Asn Leu 480	Pne	cgc Arg	16534
atg gtg Met Val	cgg aat Arg Asn 4805	aat ccc Asn Pro	gtc acg Val Thr 481	Leu I	ttt gac Phe Asp	Ser I	aac ggg Asn Gly 4815	cgg Arg	atc Ile	16582
agt act Ser Thr 4820	Gly Gln	gag gcc Glu Ala	aga cga Arg Arg 4825	tta q J Leu V	gtg ggg Val Gly	gaa Glu 4830	gca ttt Ala Phe	gtt Val	cat His	16630
ccg tta Pro Leu 4835	cac ato His Met	cct gtt Pro Val 484	Phe Glu	a aga a n Arg I	att tct Ile Ser 484	Val	gag aga Glu Arg	aag J Lys	att Ile 4850	16678
tca atg Ser Met	agc gta Ser Val	agg gaa Arg Glu 4855	gct ggd Ala Gly	z Ile :	tat act Tyr Thr 4860	att Ile	tca gcg Ser Ala	g ctg Leu 486!	GIY	16726
gaa ggt Glu Gly	gca gca Ala Ala 487	a gca aaa a Ala Lys 70	ggc cat Gly His	aat a s Asn 1 4875	att cta Ile Leu	gag Glu	aaa acc Lys Thi 488	: тте	aaa Lys	16774
ccc ggt Pro Gly	tcc ctc Ser Let 4885	g aag gct 1 Lys Ala	atc tata Ile Ty: 48:	r Gly I	gat aaa Asp Lys	Ala	gag tca Glu Se: 4895	a att r Ile	ctt Leu	16822
gga ctg Gly Leu 490	Ala Lys	a cgt ago s Arg Sei	ggt cto Gly Lev 4905	gtt (u Val	ggc cga Gly Arg	gta Val 4910	GIA GT	g tgg n Trp	gat Asp	16870
gca tca Ala Ser 4915	. ggt gta . Gly Val	a cgt gga l Arg Gly 492	/ Ile Ty	t gcg r Ala	cac aac His Asn 492	Arg	ccg gg Pro Gl	t ggt y Gly	gag Glu 4930	16918
gat ttg Asp Leu	gtt ta Val Ty:	t cct gto r Pro Val 4935	agc ct l Ser Le	u Gln	aat act Asn Thr 4940	tct Ser	gcc aa Ala As	t gaa n Glu 494	lie	16966

gtt aa Val As	at g sn A	la	tgg Trp 4950	Ile	aaa Lys	ttt Phe	aaa Lys	atc Ile 4955	Ile	acg Thr	ccc Pro	tac Tyr	acc Thr 4960	GTA	gat Asp	17014
tat ga Tyr A	sp M	itg Iet 1965	His	gat Asp	att Ile	att Ile	aaa Lys 4970	Phe	tct Ser	gat Asp	Gly 999	aaa Lys 4975	GIY	cat His	gtg Val	17062
cct ac Pro Ti 4	ca c hr <i>P</i> 980	gcg Ala	gaa Glu	agt Ser	agt Ser	gag Glu 4985	Glu	aga Arg	gga Gly	gta Val	aaa Lys 4990	Asp	cta Leu	att Ile	aat Asn	17110
aaa g Lys G 4995	gt s ly V	gtt 7al	gcg Ala	gag Glu	gtc Val 5000	Asp	cct Pro	tcc Ser	aga Arg	ccc Pro 5005	Phe	gag Glu	tat Tyr	aca Thr	gcg Ala 5010	17158
atg a Met A	at g sn V	gtt /al	att Ile	cgc Arg 501	His	gga Gly	cca Pro	cag Gln	gtg Val 5020	Asn	ttt Phe	gtt Val	ccc Pro	tat Tyr 5025	Met	17206
tgg g Trp G	aa d lu F	cat His	gag Glu 5030	His	gat Asp	aaa Lys	gtc Val	gtt Val 5039	Asn	gat Asp	aat Asn	ggt Gly	tat Tyr 504	ьeu	gly aaa	17254
gtg g Val V	al A	gct Ala 5045	Ser	ccg Pro	ggg ggg	ccg Pro	ttc Phe 5050	Pro	gta Val	gcg Ala	atg Met	gta Val 505	His	cag Gln	gly aaa	17302
gaa t Glu T 5	gg 3	act Thr	gtt Val	ttt Phe	gac Asp	aac Asn 506	Ser	gaa Glu	gaa Glu	ctg Leu	ttt Phe 507	Asn	ttc Phe	tat Tyr	aaa Lys	17350
tct a Ser T 5075	ica a hr i	aat Asn	aca Thr	cct Pro	ctt Leu 508	Pro	gaa Glu	cac His	tgg Trp	tcc Ser 508!	Gln	gat Asp	ttt Phe	atg Met	gac Asp 5090	17398
aga g Arg G	gly i	aaa Lys	gga Gly	ata Ile 509	Val	gca Ala	act Thr	cct Pro	cgg Arg 510	His	gct Ala	gaa Glu	ctt Leu	ctt Leu 510	Asp	17446
aaa c Lys A	ga (Arg)	cga Arg	gtc Val 511	Met	tac Tyr	taa *	tcg	taac	gat	ttcc [.]	tgcc	tt a	ccca	aagt.	a	17497
tatgtt atgtt catgg atcgg atcgg atggt taggt taggt taccg agaat taccg	cette cege getgete getgete gete cette gete geteete geteete geteete geteete	oggeottgattgoctactgttgo	ctca tca tca tca tca tca tca tca tca tca	tcta accg atcg accac caaaacaacat caacat cagggc accgc ggccc gggccc gggccc	aa gette gataa gatteete agagteete	tcta gctaat gcgtcaat catggat catggat acaacaat accgtttt catgat cataat cataat cataat cataa	acgataggataggaaaggataggaaaggtcaggtcaggt	gt gc ga gatt ggct a gggc gg	atttcaattgcaaggccttattggcaaggcctcactggcaaggccttattggcaaggtcgcattgcaggccaggcctagcaggccagagagcagagcagagccagagagcag	ttag ttgta gcat gcagat gggggat gagt gagt	caat aag gat aa aag gag aag aag gag aag a	aatggaagactaagggggggagagagtgaggtgaggtga	gca gagttaaccaacgtttttgccggtgcttatt	ctttcc ggatecateggatecateggatactateggatetttggatecatateggatettggatettggatetttggategatettggategate	atacege actatt gategt gategt getet ggtete ggtete gtacege ttacege ttacege ttacege atggee atggee atggee atggee atggee atggee atggee ggteaget gteaageteaageteaageteaageteaageteaageteaageteaageteaageteaageteaageteaageteaagete	17617 17677 17737 17797

gtggagcgcg caaaaaatgc cggcctcgat gccctgccgg cgtgcccagc ggagcatggc 18937

```
<210> 2
<211> 144
<212> PRT
<213> Serratia entomophila
<223> ORF1 amino acid sequence encoding an insecticidal protein when
     linked with at least SEQ ID NO: 1
Met Lys Ile Ser Ser Arg Gly Ile Ala Leu Ile Lys Glu Phe Glu Gly
                                    10
Leu Arg Leu His Ala Tyr Arg Cys Ala Ala Asp Val Trp Thr Val Gly
                                25
Tyr Gly His Thr Ala Gly Val Thr Lys Gly Asp Ile Ile Thr Val Asp
        35
                            40
Glu Ala Gln Thr Met Leu Thr Asn Asp Ile Thr Val Phe Glu Arg Ala
                                             60
                        55
Val Ser Gln Ala Val Ala Val Pro Leu Asn Gln Ser Gln Tyr Asp Ala
                                        75
                    70
Leu Val Ser Leu Val Phe Asn Ile Gly Gln Gly Asn Phe Lys Arg Ser
                                    90
                                                         95
                85
Thr Leu Leu Lys Lys Leu Asn Lys Gln Asp Tyr Val Gly Ala Gly Asn
                                105
            100
Glu Phe Leu Arg Trp Thr Arg Ala Asn Gly Lys Val Leu Pro Gly Leu
                                                 125
                            120
        115
Ile Arg Arg Arg Glu Ala Glu Arg Val Leu Phe Glu Lys Leu Gly Ala
                        135
    130
<210> 3
<211> 191
<212> PRT
<213> Serratia entomophila
<223> ORF2 amino acid sequence encoding an insecticidal protein when
      linked with at least SEQ ID NO: 1
Met Ser Pro Ser Pro Leu Thr Gly Ala Ala Leu Met Glu Thr Lys Met
                                     10
 1
Lys Ile His Tyr Gln Val Ala Ala Val Val Leu Thr Gly Val Met Val
                                 25
Trp Gly Leu Ser His Trp Arg Tyr Thr Val Gly Tyr His Ala Ala Asp
                                                 45
                             40
        35
Thr Gln Trp Gln Gln Arg Gln Ala Glu Gln Glu Arg Ala Asp Ala Leu
                                             60
                        55
Ala Leu Leu Ala Ala Glu Thr Arg Glu Arg Lys Trp Glu Gln Gln Arg
                                         75
                     70
Gln Thr Asp Met Asn Lys Val Ala Ile His Ala Glu Glu Glu Leu Ala
                85
                                     90
Ala Ala Arg Asp Ala Ala Ala Asp Ala Gln Arg Thr Gly Gln Arg Leu
                                                     110
                                 105
            100
Gln His Thr Val Thr Thr Leu Gln Arg Gln Leu Ala Ser Arg Glu Thr
                                                 125
                             120
Arg Arg Leu Ser Ala Ala Thr Ala Ile Gly Thr Asp Asp Leu Gly Gly
                                             140
                         135
Gln Pro Gly Val Leu Phe Ala Glu Leu Phe Arg Arg Ala Asp Gln Arg
                                         155
                     150
Ala Gly Glu Leu Ala Ala Tyr Ala Asp Arg Thr Arg Val Lys Trp Gln
                                                         175
                                     170
                 165
Ala Cys Gly Arg Ala Tyr Gln Ala Ala Thr His Glu Ala Glu Lys
```

180

```
<211> 2376
<212> PRT
<213> Serratia entomophila
<220>
<223> SepA amino acid sequence encoding an insecticidal protein when
     linked with at least SEQ ID NO: 1
Met Arg Gln Asp Ile Met Tyr Asn Ile Asp Asp Ile Leu Glu Lys Val
                                    1.0
Asn Ala Pro Arg Ala Arg Leu Ser Glu Glu Asn Asp Thr Ala Val Thr
                                2.5
            20
Leu Thr Asp Leu Phe Ser Arg Ser Phe Pro Glu Val Lys Lys Ile Thr
                                                45
                           40
Gly Asp Ser Leu Ser Trp Gly Glu Val Cys Tyr Leu Tyr Ser Gln Ala
                       55
                                            60
Gln His Glu Gln Lys Glu Asn Arg Leu Thr Glu Ser Arg Ile Leu Ala
                                        75
                    70 .
Arg Ala Asn Pro Leu Leu Val Asn Ala Val Arg Leu Gly Ile Arg Gln
                                    90
               85
Ala Ala Gly Ser Arg Ser Tyr Asp Asp Trp Phe Gly Ser Arg Ala Asp
                                105
                                                    11Ô
            100
Arg Phe Ala Arg Pro Gly Ser Val Ala Ser Met Phe Ser Pro Ala Ala
                                                125
                           120
        115
Tyr Leu Thr Glu Leu Tyr Arg Glu Ala Lys Asp Leu His Pro Asp Thr
                        135
Ser Leu Phe Arg Leu Asp Ile Arg Arg Pro Asp Leu Ala Ala Leu Ala
                   150
                                        155
Leu Ser Gln Asn Asn Met Asp Asp Glu Leu Ser Thr Leu Ser Leu Ser
                                    170
                                                         175
                165
Asn Glu Leu Leu Tyr Arg Gly Ile Gly Ala Ala Glu Gly Leu Asp Asp
                                185
                                                     190
            180
Asp Ser Val Arg Glu Leu Leu Ala Gly Tyr Arg Leu Thr Gly Leu Thr
                                                 205
        195
                            200
Pro Tyr His Trp Ala Tyr Glu Ala Ala Arg Gln Ala Ile Leu Val Gln
                        215
                                            220
  210
Asp Pro Thr Leu Met Gly Phe Ser Arg Asn Pro Asp Val Ala Gln Leu
                                        235
                                                             240
225
                    230
Met Asp Pro Ala Ser Met Leu Ala Ile Glu Ala Asp Ile Ser Pro Glu
                                                         255
                                    250
                245
Leu Tyr Gln Ile Leu Ala Glu Glu Ile Thr Thr Asp Ser Tyr Glu Ala
                                                     270
                                265
            260
Leu Trp Ser Lys Asn Phe Gly Asp Met Pro Pro Ser Ser Leu Leu Ser
                            280
                                                 285
        275
Tyr Asp Ala Leu Ala Thr Phe Tyr Asp Leu Asp Tyr Asp Glu Leu Thr
                                             300
                        295
Ser Leu Leu Ser Leu Arg Leu Asp Phe Ser Asn Pro Asn Asn Glu Tyr
                                                             320
                    310
                                         315
Tyr Ile Asn Ser Gln Leu Ser Val Val Thr Leu Asn Glu Ser Thr Gly
                                                         335
                325
                                     330
Leu Ile Thr Ile His His Tyr Leu Arg Thr Leu Gly Gly Asp Ser Gln
                                                     350
            340
                                345
Gln Ile Asn Pro Glu Leu Ile Pro Tyr Gly Asp Gly Thr Tyr Leu Tyr
                                                 365
                            360
Asn Phe Ser Val Val Ser Thr Ile Ser Glu Asp Ser Phe Lys Leu Gly
                        375
                                             380
Ser Leu Gly Ser Asn Ser Ser Asn Leu Tyr Ser Gly Asp Tyr Gln Leu
                                         395
                    390
Gln Lys Gly Val Arg Tyr Ser Ile Pro Val Glu Ile Asp Glu Gly Lys
                                                         415
                                    410
                405
Leu Asn Asp Gly Ile Thr Ile Gly Leu Ser Arg Lys Gly Gly Tyr
                                                     430
                                425
            420
Tyr Ser Thr Val Asn Phe Thr Leu Ile Glu Tyr Asp Pro Ala Ile Phe
```

<210> 4

```
Ile Leu Lys Leu Asn Lys Val Ile Arg Leu Tyr Lys Ala Thr Gly Met
                       455
Thr Thr Ala Glu Ile Tyr Gln Ile Thr Asn Ile Leu Asn Asn Gly Leu
                  470
                                        475
Thr Ile Asp His Ala Val Leu Ser Lys Ile Phe Leu Val Arg Tyr Leu
                                                       495
                                   490
               485
Met Arg His Tyr Gln Leu Asp Val Ala Arg Ser Leu Ile Leu Cys Asn
                               505
           500
Gly Thr Ile Ser Asp Gln Ala Phe Ser Gly Glu Thr Gly Leu Phe Thr
                                                525
                            520
Thr Leu Phe Asn Thr Pro Pro Leu Asn Gly Gln Leu Phe Ser Ala Asp
                       535
                                            540
Asp Thr Pro Leu Asp Leu Arg Ser Glu Ala Pro Glu Asp Ala Phe Arg
                   55Q
                                        555
Leu Ser Val Leu Lys Arg Ala Phe Asn Ile Ser Ala Ser Gly Leu Ser
               565
                                    570
Thr Leu Trp Gln Leu Ala Ser Gly Asp Ser Ser Ala Gly Phe Ser Cys
                                585
            580
Ser Ala Asp Asn Ile Ala Ala Leu Tyr Arg Val Lys Leu Leu Ala Asp
                            600
                                               605
       595
Ile His Asp Leu Ser Ala Gly Glu Leu Ser Met Leu Leu Ser Val Ser
                       615
                                           620
Pro Phe Ser Gly Val Ala Ala Gly Ser Leu Ser Asp Asn Glu Leu Thr
                                        635
625
                   630
Gin Phe Leu Tyr Gln Thr Thr Thr Trp Leu Thr Glu Gln Gly Trp Thr
                                   650
                645
Val Ser Asp Val Phe Leu Met Leu Thr Thr Gln Tyr Gly Thr Leu Leu
                                665
           660
Thr Pro Asp Ile Glu Asn Leu Leu Ala Ser Leu Arg Asn Gly Leu Ser
                                                685
                           680
       675
Gly Arg Glu Leu Phe Pro Glu Thr Leu Pro Gly Asp Gly Ala Pro Phe
                       695
   690
Ile Ala Ala Ala Met Gln Leu Asp Ala Thr Asp Thr Ala Lys Ala Met
                                        715
                    710
Leu Thr Trp Ala Asp Gln Leu Lys Pro Glu Gly Leu Thr Leu Thr Glu
                725
                                    730
                                                        735
Phe Ile Leu Leu Val Met Asn Ala Ala Pro Asn Asp Glu Gln Ala Gly
            740
                                745
Gln Met Ala Gly Phe Cys Gln Ala Leu Trp Gln Leu Ala Leu Ile Ile
        755
                            760
Arg Ser Thr Gly Leu Ser Thr Arg Glu Leu Thr Leu Leu Val Ser Gln
                        775
                                            780
Pro Gly Arg Phe Arg Thr Gly Trp His His Leu Pro His Asp Leu Pro
                                        795
                    790
Ala Leu Arg Asp Ile Thr Arg Phe His Ala Val Val Asn Arg Ser Gly
               805
                                    810
                                                        815
Ser His Ala Gly Glu Val Leu Thr Ala Leu Glu Thr Gly Glu Leu Ser
                                825
                                                    830
Ser Ala Leu Leu Ala Arg Ala Leu Ser Gln Asn Glu Gln Asp Val Thr
                            840
                                                845
Gly Ala Leu Ala Gln Val Arg Gly Ala Gly Glu Gln Asp Asn Ser Val
                        855
                                            860
Phe Thr Ser Trp Glu Glu Val Asp Gln Ala Glu Gln Trp Leu Asp Met
                    870
                                        875
Ser Glu Thr Leu Ser Ile Thr Pro Ser Gly Leu Ala Ser Leu Ile Ala
                                    890
                885
Leu Lys Tyr Ile Asn Val Ser Asp Asp Ser Ala Pro Leu Tyr Ser Gln
            900
                                905
                                                    910
Trp Gln Val Val Ser Gly Leu Leu Gln Ala Gly Leu Lys Ser Ser Gln
                                                925
        915
                            920
Ser Ser Ala Leu His Asp Tyr Leu Glu Glu Gly Thr Ser Ser Ala Leu
                        935
                                            940
    930
Cys Ala Tyr Tyr Leu Arg Asn Leu Ala Pro Asn Met Val Ser Gly Arg
                   950
                                      955
Asp Asp Leu Phe Gly Tyr Leu Leu Leu Asp Asn Gln Val Ser Ala Lys
                                    970
                965
Val Lys Thr Thr Arg Ile Ala Glu Ala Ile Ala Gly Ile Arg Leu Tyr
```

```
990
                             985
           980
Ile Asn Arg Ala Leu Asn Gly Ile Glu Leu Ser Ala Met Ala Glu Val
995 1000 1005
Arg Gly Arg Gln Phe Phe Thr Asp Trp Asp Thr Phe Asn Lys Arg Tyr
                                         1020
                    1015
   1010
Ser Thr Trp Ala Gly Val Ser Glu Leu Val Tyr Tyr Pro Glu Asn Tyr
                                     1035
                  1030
Leu Asp Pro Thr Val Arg Ile Gly Gln Thr Gly Met Met Asp Thr Leu
                                                     1055
                                 1050
              1045
Leu Gln Ser Val Ser Gln Ser Ser Ile Asn Arg Asp Thr Val Glu Asp
                                               1070
                              1065
           1060
Ala Phe Lys Thr Tyr Leu Thr Thr Phe Glu Gln Ile Ala Asn Leu Asn
                                             1085
                         1080
     1075
Thr Val Ser Gly Tyr His Asp Asn Ala Ser Met Thr Gln Gly Thr Thr
                               1100
                   1095
  1090
Trp Tyr Val Gly Arg Ser Ile Thr Asp Gln Thr Asn Trp Tyr Trp Arg
                                  11,15
                 1110
1105
Ser Ala Asn His Ser Lys Ile Gln Asp Ser Met Met Pro Ala Asn Ala
                                  1130
               1125
Trp Thr Gly Trp Thr Lys Ile Asn Cys Gly Met Asn Pro Trp Ser Asp
                                                 1150
                             1145
           1140
Leu Val Cys Ser Val Phe Phe Asn Ser Arg Leu Tyr Val Val Trp Val
                                            1165
       1155
                        1160
Glu Glu Asn Gln Ser Ala Asp Thr Glu Ala Glu Ser Thr Thr Thr Thr
                     1175
                                        1180
  1170
Gln Gln Ser Tyr Thr Leu Lys Leu Ser Phe Arg Arg Tyr Asp Gly Thr
                                    1195
                   1190
Trp Ser Ser Pro Val Ser Phe Asp Ile Thr Gly Asn Ile Ala Phe Pro
Glu Thr Gln Gly Met His Val Thr Cys Asn Pro Leu Thr Glu Gln Leu
1220 1225 1230
Tyr Cys Ala Phe Tyr Ser Val Thr Ser Lys Pro Asp Phe Asp Asn Ala
                1240
                                              1245
       1235
Gln Leu Ile Ser Val Asp Asn Asp Met Thr Leu Asn Val Ile Ser Asp
                                         1260
                      1255
Ile Gly Ile Phe Lys Ser Val Ser His Glu Phe Asn Thr Ser Thr Glu
                 1270
                                      1275
Lys Phe Ile Asn Asn Val Phe Ser Asp Pro Ser Ala Asn Tyr Phe Val
                                                     1295
                                  1290
              1285
Ser Ala Thr Ser Leu Ile Asp Asp Val Ile His Ser Asp Phe Ser Leu
                                                  1310
            1300
                              1305
Leu Asn Ser Lys Thr Thr Ser Thr Val Phe Thr Asn Glu Asp Ser Ser
                                             1325
                         1320
        1315
Leu Leu Thr Pro Glu Leu His Ile Thr Ala Asn Val Ser Cys Phe Val
                                          1340
                      1335
Ser Thr Ala Gly Ile Ala Thr Gln Ser Thr Ile Glu Lys Phe Val Gln
                                      1355
                 1350
Ala Gly Ile Glu Phe Glu Glu Ile Asn Phe Tyr Ala Gly Gln Ala Ala
                                  1370
                                                      1375
               1365
Gly Gly Phe Asp Gly Phe Val Gly Val Asp Val Ser Asn Ser Lys Val
                                              1390
            1380
                               1385
Tyr Gln Val Gly Lys Glu Ala Val Gly Val Thr Val Lys Ser Tyr Ser
                                              1405
                           1400
        1395
Val Thr Gly Val Ser Gly Ser Val Glu Leu Phe Ile Asp Ser Ser Asn
                                          1420
                       1415
  1410
Lys Tyr Phe Ser Gly Ile Leu Ser Asp Lys Met Ile Thr Ala Leu Ile
                                      1435
                   1430
 Ser Gly Ser Thr Ser Lys Val Asn Tyr Val Ser Ser Ile Gly Ser Gln
                                                      1455
                1445
                                  1450
Asp Phe Trp Ser Val Lys Ser Leu Met Pro Ala Leu Gln Ile Tyr Glu
                                                  1470
            1460
                               1465
 Leu Ile Asp Asp Ile Ile Leu Thr Ser Gly Val Asn Gly Thr Glu Ile
1475 1480 1485
 Lys Ser Trp Pro Ser Ala Glu Trp Tyr Asn Asp Lys Leu Ser Leu Gln
                                         1500
                       1495
 Ser Gly Asn Asn Leu Phe Asn Thr Lys Ser Leu Ser Phe Thr Val Asn
                                       1515
```

```
Thr Ser Asp Ile Val Glu Asp Glu Phe Asp Val Thr Phe Thr Phe Thr
                                 1530
              1525
Ala Val Asp Gln Asn Asn Val Val Leu Ala Ala Arg Thr Ala Ile Leu
                                                 1550
                              1545
           1540
Thr Val Ile Arg Asn Ile Asn Asn Asp Thr Ser Val Ile Ala Leu Arg
                                             1565
                         1560
       1555
Lys Asn Thr Arg Gly Ala Gln Tyr Ile Arg Phe Thr Ala Gly Asn Asp
               1575
  1570
Val Ala Leu Ile Arg Leu Asn Thr Leu Phe Ala Arg Gln Leu Val Asp
                 1590
                                     1595
Arg Ala Asn Thr Gly Ile Asp Thr Ile Leu Ser Met Glu Thr Gln Arg
                                                     1615
                                 1610
               1605
Leu Thr Glu Pro Ala Leu Glu Glu Gly Ser Asp Val Phe Met Asp Phe
                                                 1630
                              1625
           1620
Ser Gly Ala Asn Ala Leu Tyr Phe Trp Glu Leu Phe Tyr Tyr Thr Pro
                                            1645
                        1640
       1635
Met Met Val Phe Gln Arg Leu Leu Gln Glu Gln His Phe Pro Glu Ala
                                          1660
                    1655
   1650
Thr Arg Trp Leu Gln Tyr Val Trp Asn Pro Ala Gly His Val Val Asn
                                     1675
                                                         1680
             1670
Gly Val Leu Gln Asn Tyr Thr Trp Asn Val Arg Pro Leu Glu Glu Asp
                                1690
                                                   1695
              1685
Thr Gly Trp Asn Asp Ser Pro Leu Asp Ser Ile Asp Pro Asp Ala Ile
                          1705
                                       1710
          1700
Ala Gln Tyr Asp Pro Met His Tyr Lys Val Ala Thr Phe Met Ser Tyr
                          1720
                                             1725
      1715
Leu Asp Leu Leu Ile Ala Arg Gly Asp Ala Ala Tyr Arg Leu Leu Glu
                                      1740
                     1735
    1730
Arg Asp Thr Leu Asn Glu Ala Arg Met Trp Tyr Val Gln Ala Leu Asn 1745 1750 1755 176
                  1750
Leu Leu Gly Asp Glu Pro Tyr Ile Ser Phe Asp Ala Asp Trp Ser Ala
                                                     1775
                                  1770
              1765
Leu Thr Leu Gly Asp Ala Ala Ser Glu Val Thr Arg Arg Asp Tyr Gln
                                                  1790
                              1785
           1780
Glu Ala Leu Leu Ala Val Arg Arg Leu Val Pro Ala Pro Glu Thr Arg
                          1800
                                             1805
Thr Ala Asn Ser Leu Thr Ala Leu Phe Leu Pro Gln Gln Asn Glu Val
                                       1820
  1810
                       1815
Leu Lys Gly Tyr Trp Gln Thr Leu Ala Gln Arg Leu His Asn Leu Arg
                                                         1840
                            1835
                  1830
His Asn Leu Ser Ile Asp Gly Gln Pro Leu Ser Leu Ser Val Tyr Ala
                                  1850
               1845
Thr Pro Ser Glu Pro Ser Ala Leu Gln Ser Ala Val Val Asn Ser Ala
                              1865
                                                  1870
Gln Gly Ala Ala Ala Leu Pro Ala Ala Val Met Pro Leu Tyr Ser Phe
                                              1885
                           1880
       1875
Pro Val Met Leu Glu Asn Ala Arg Gly Met Val Ser Leu Leu Thr Gly
                                          1900
                       1895
Phe Gly Asn Thr Leu Leu Gly Ile Thr Glu Arg Gln Asp Ala Glu Ala
                                      1915
                   1910
Leu Ala Lys Leu Leu Gln Thr Gln Gly Ser Glu Leu Ile Arg Gln Gly
                                  1930
                                                      1935
               1925
Leu Arg Gln Gln Asp Asn Val Leu Glu Glu Ile Asp Ala Asp Ile Ala
                              1945
                                                 1950
            1940
Ala Leu Glu Glu Ser Arg Arg Gly Ala Gln Met Arg Phe Glu Arg Tyr
                                              1965
                           1960
       1955
Lys Val Leu Tyr Glu Ala Asp Val Asn Thr Gly Glu Lys Gln Ala Met
                       1975
                                          1980
    1970
Asp Leu Tyr Leu Ser Ser Ser Val Leu Ser Ala Ser Thr Ala Ala Leu
                                                          2000
                                      1995
                   1990
Phe Leu Ala Glu Ala Ala Ala Asp Met Leu Pro Asn Ile Tyr Gly Leu
                                  2010
                                                      2015
               2005
Ala Val Gly Gly Ser Arg Tyr Gly Ala Leu Phe Lys Ala Thr Ala Ile
                               2025
                                                  2030
            2020
Gly Ile Gln Val Ser Ser Asp Ala Thr Arg Ile Ser Ala Asp Lys Ile
                          2040
                                              2045
        2035
 Ser Gln Ser Glu Val Tyr Arg Arg Arg Arg Glu Glu Trp Glu Ile Gln
```

```
Arg Asp Ser Ala Gln Ser Asp Val Ala Gln Ile Asp Ala Gln Leu Ala
                                       2075
                   2070
Ala Met Ala Val Arg Arg Glu Gly Ala Glu Leu Gln Lys Thr Tyr Leu
                                                       2095
                                   2090
               2085
Glu Thr Gln Gln Thr Gln Ala Gln Ala Gln Leu Ala Phe Leu Gln Ser
                                                 2110
                               2105
           2100
Lys Phe Asn Asn Thr Ala Leu Tyr Ser Trp Leu Arg Gly Arg Leu Ser
                                               2125
                        2120
       2115 ·
Ala Ile Tyr Tyr Gln Phe Tyr Asp Leu Ala Val Ser Arg Cys Leu Met
                                         2140
                        2135
    2130
Ala Gln Gln Ala Trp Gln Trp Asp Lys Phe Glu Thr Arg Ser Phe Ile
                                      2155
                   2150
Gln Pro Gly Ala Trp Met Gly Ala Asn Ala Gly Leu Leu Ala Gly Glu
                           2170
                2165
Thr Leu Met Leu Asn Leu Ala Gln Met Glu Gln Ala Trp Leu Thr Gly
                                                   2190
                               2185
            2180
Asp Glu Arg Ala Ile Glu Val Thr Arg Thr Val Cys Leu Ser Glu Val
                            2200
        2195
Tyr Thr Ser Leu Ala Glu Asp Ala Ala Phe Ser Leu Ala Asp Lys Val
                                           2220
                       2215
Val Glu Leu Val Ser Asn Gly Ser Gly Ser Ala Gly Thr Lys Ser Asn
                                      2235
                                                           2240
                    2230
Gly Leu Gln Met Asp Gln Gln Gln Leu Glu Ala Thr Leu Lys Leu Ala
                                   2250
                                                       2255
                2245
Asp Leu Gly Ile Gly Asn Asp Tyr Pro Val Ser Leu Gly Thr Met Arg
                                                   2270
                              2265
            2260
Arg Ile Lys Gln Ile Ser Val Thr Leu Pro Ala Leu Val Gly Pro Tyr
                                               2285
                          2280
        2275
Gln Asp Val Arg Ala Val Leu Ser Tyr Gly Gly Ser Met Val Met Pro
               2295
                                           2300
    2290
Arg Gly Cys Ser Ala Leu Ala Val Ser His Gly Met Asn Asp Ser Gly
                                                           2320
                                        2315
                 2310
2305
Gln Phe Gln Leu Asp Phe Asn Asp Pro Arg Tyr Leu Pro Phe Glu Gly
                                                      2335
               2325
                                    2330
Leu Pro Val Asp Asp Thr Gly Thr Leu Thr Leu Ser Phe Pro Asp Ala
                               2345
                                                 2350
            2340
 Asp Gly Lys Gln Gln Ala Met Leu Leu Ser Leu Ser Asp Ile Ile Leu
                                                2365
                           2360
        2355
 His Ile Arg Tyr Thr Ile Ile Ser
    2370
                        2375
 <210> 5
<211> 1428
 <212> PRT
 <213> Serratia entomophila
 <220>
 <223> SepB amino acid sequence encoding an insecticidal protein when
       linked with at least SEQ ID NO: 1
 <400>5
 Met Gln Asn His Gln Asp Met Ala Ile Thr Ala Pro Thr Leu Pro Ser
                                    1.0
 Gly Gly Gly Ala Val Thr Gly Leu Lys Gly Asp Ile Ala Ala Ala Gly
            20
                                25
 Pro Asp Gly Ala Ala Thr Leu Ser Ile Pro Leu Pro Val Ser Pro Gly
                                                45
                            40
        35
 Arg Gly Tyr Ala Pro Thr Gly Ala Leu Asn Tyr His Ser Arg Ser Gly
                                           60
                        55
 Asn Gly Pro Phe Gly Ile Gly Trp Gly Ile Gly Gly Ala Ala Val Gln
                                        75
                    70
 Arg Arg Thr Arg Asn Gly Ala Pro Thr Tyr Asp Asp Thr Asp Glu Phe
                                    90
                 85
 Thr Gly Pro Asp Gly Glu Val Leu Val Pro Ala Leu Thr Ala Ala Gly
             100
```

```
Thr Gln Glu Ala Arg Gln Ala Thr Ser Leu Leu Gly Ile Asn Pro Gly
                            120
Gly Ser Phe Asn Val Gln Val Tyr Arg Ser Arg Thr Glu Gly Ser Leu
                                            140
                        135
Ser Arg Leu Glu Arg Trp Leu Pro Ala Asp Glu Thr Glu Thr Glu Phe
                                        155
                    150
Trp Val Leu Tyr Thr Pro Asp Gly Gln Val Ala Leu Leu Gly Arg Asn
                                                        175
                                    170
               165
Ala Gln Ala Arg Ile Ser Asn Pro Thr Ala Pro Thr Gln Thr Ala Val
                                185
                                                    190
           180
Trp Leu Met Glu Ser Ser Val Ser Leu Thr Gly Glu Gln Met Tyr Tyr
                                                205
                           200
       195
Gln Tyr Arg Ala Glu Asp Asp Asp Gly Cys Asp Glu Ala Glu Arg Asp
                                            220
                        215
   210
Ala His Pro Gln Ala Gly Ala Gln Arg Tyr Pro Val Ala Val Trp Tyr
                                       235
                   230
Gly Asn Arg Gln Ala Ala Arg Thr Leu Pro Ala Leu Val Ser Thr Pro
                                    250
                245
Ser Met Asp Ser Trp Leu Phe Ile Leu Val Phe Asp Tyr Gly Glu Arg
                                                    270
                                265
            260
Ser Ser Val Leu Ser Glu Ala Pro Ala Trp Gln Thr Pro Gly Ser Gly
                            280
                                                285
        275
Glu Trp Leu Cys Arg Gln Asp Cys Phe Ser Gly Tyr Glu Phe Gly Phe
                       295
                                            300
Asn Leu Arg Thr Arg Arg Leu Cys Arg Gln Val Leu Met Phe His Tyr
                    310
                                        315
Leu Gly Val Leu Ala Gly Ser Ser Gly Ala Asn Asp Ala Pro Ala Leu
                                                        335
                325
                                    330
Ile Ser Arg Leu Leu Leu Asp Tyr Arg Glu Ser Pro Ser Leu Ser Leu
                                                    350
                                345
Leu Glu Asn Val His Gln Val Ala Tyr Glu Ser Asp Gly Thr Ser Cys
                                                365
                            360
Ala Leu Pro Ala Leu Ala Leu Gly Trp Gln Thr Phe Thr Pro Pro Thr
                                            380
                        375
Leu Ser Ala Trp Gln Thr Arg Asp Asp Met Gly Lys Leu Ser Leu Leu
                                        395
                    390
Gln Pro Tyr Gln Leu Val Asp Leu Asn Gly Glu Gly Val Val Gly Ile
                                  410
                405
Leu Tyr Gln Asp Ser Gly Ala Trp Trp Tyr Arg Glu Pro Val Arg Gln
                                425
            420
Ser Gly Asp Asp Pro Asp Ala Val Thr Trp Gly Ala Ala Ala Leu
                                                445
                            440
        435
Pro Thr Met Pro Ala Leu His Asn Ser Gly Ile Leu Ala Asp Leu Asn
                                            460
                        455
Gly Asp Gly Arg Leu Glu Trp Val Val Thr Ala Pro Gly Val Ala Gly
                                        475
                    470
Met Tyr Asp Arg Thr Pro Gly Arg Asp Trp Leu His Phe Thr Pro Leu
                                    490
                485
Ser Ala Leu Pro Val Glu Tyr Ala His Pro Lys Ala Val Leu Ala Asp
                                505
            500
Ile Leu Gly Ala Gly Leu Thr Asp Met Val Leu Ile Gly Pro Arg Ser
                                                 525
                            520
        515
Val Arg Leu Tyr Ser Gly Lys Asn Asp Gly Trp Asn Lys Gly Glu Thr
                        535
    530
Val Gln Gln Thr Glu Arg Leu Thr Leu Pro Val Pro Gly Val Asp Pro
                                         555
                    550
Arg Thr Leu Val Ala Phe Ser Asp Met Ala Gly Ser Gly Gln Gln His
                                    570
                                                         575
                565
Leu Thr Glu Val Arg Ala Asn Gly Val Arg Tyr Trp Pro Asn Leu Gly
                                                     590
                                585
            580
His Gly Arg Phe Gly Gln Pro Val Asn Ile Pro Gly Phe Ser Gln Ser
                                                 605
        595
                             600
Val Thr Thr Phe Asn Pro Asp Gln Ile Leu Leu Ala Asp Thr Asp Gly
                        615
                                             620
Ser Gly Thr Thr Asp Leu Ile Tyr Ala Met Ser Asp Arg Leu Val Ile
                     630
                                         635
Tyr Phe Asn Gln Ser Gly Asn Tyr Phe Ala Glu Pro His Thr Leu Leu
```

```
655
               645
                                   650
Leu Pro Lys Gly Val Arg Tyr Asp Arg Thr Cys Ser Leu Gln Val Ala
                                                   670
                              665
           660
Asp Ile Gln Gly Leu Gly Val Pro Ser Leu Leu Leu Thr Val Pro His
                                               685
                           680
Val Ala Pro His His Trp Val Cys His Leu Ser Ala Asp Lys Pro Trp
                                           700
                       695
Leu Leu Asn Gly Met Asn Asn Asn Met Gly Ala Arg His Ala Leu His
                  710
                                       715
Tyr Arg Ser Ser Val Gln Phe Trp Leu Asp Glu Lys Ala Glu Ala Leu
                                   730
               725
Ala Ala Gly Ser Ser Pro Ala Cys Tyr Leu Pro Phe Thr Leu His Thr
                                                   750
                               745
Leu Trp Arg Ser Val Val Gln Asp Glu Ile Thr Gly Asn Arg Leu Val
                                               765
                           760
Ser Asp Val Leu Tyr Arg His Gly Val Trp Asp Gly Gln Glu Arg Glu
                                           780
                       775
Phe Arg Gly Phe Gly Phe Val Glu Ile Arg Asp Thr Asp Thr Leu Ala
                                       795
                    790
Ser Gln Gly Thr Ala Thr Glu Leu Ser Met Pro Ser Val Ser Arg Asn
                                                       815
                805
                                   810
Trp Tyr Ala Thr Gly Val Pro Ala Val Asp Glu Arg Leu Pro Glu Thr
                                                   830
            820
                               825
Tyr Trp Gln Asn Asp Ala Ala Ala Phe Ala Asp Phe Ala Thr Arg Phe
                                               845
                           840
Thr Val Gly Ser Gly Glu Asp Glu Gln Thr Tyr Thr Pro Asp Asp Ser
                                          860
                       855
Lys Thr Phe Trp Leu Gln Arg Ala Leu Lys Gly Ile Leu Leu Arg Ser
                                       875
                   870
Glu Leu Tyr Gly Ala Asp Gly Ser Ser Gln Ala Asp Ile Pro Tyr Ser
                                   890
                                                       895
               885
Val Thr Glu Ser Arg Pro Gln Val Arg Leu Val Glu Ala Asn Gly Asp
                               905
            900
Tyr Pro Val Val Trp Pro Met Gly Ala Glu Ser Arg Thr Ser Val Tyr
                           920
                                                925
        915
Glu Arg Tyr His Asn Asp Pro Gln Cys Gln Gln Gln Ala Val Leu Leu
                        935
                                            940
Ser Asp Glu Tyr Gly Phe Pro Leu Arg Gln Val Ser Val Asn Tyr Pro
                                       955
                   950
Arg Arg Pro Pro Ser Ala Asp Asn Pro Tyr Pro Ala Ser Leu Pro Ala
                                    970
               965
Thr Leu Phe Ala Asn Ser Tyr Asp Glu Gln Gln Gln Ile Leu Arg Leu
                                985
                                                    990
            980
Gly Leu Gln Gln Ser Ser Ala His His Leu Val Ser Leu Ser Glu Gly
                                                1005
                           1000
       995
His Trp Leu Leu Gly Leu Ala Glu Ala Ser Arg Asp Asp Val Phe Thr
                                           1020
                       1015
  1010
Tyr Ser Ala Asp Asn Val Pro Glu Gly Gly Leu Thr Leu Glu His Leu
                                                            1040
                                        1035
                    1030
1025
Leu Ala Pro Glu Ser Leu Val Ser Asp Ser Gln Val Gly Thr Leu Ala
                                                       1055
                                   1050
                1045
Gly Gln Gln Gln Val Trp Tyr Leu Asp Ser Gln Asp Val Ala Thr Val
                                                    1070
                                1065
            1060
Ala Ala Pro Pro Leu Pro Pro Lys Val Ala Phe Ile Glu Thr Ala Val
                           1080
                                                1085
      1075
Leu Asp Glu Gly Met Val Ser Ser Leu Ala Ala Tyr Ile Val Asp Glu
                        1095
                                            1100
    1090
His Leu Glu Gln Ala Gly Tyr Arg Gln Ser Gly Tyr Leu Phe Pro Arg
                                                            1120
                   1110
                                       1115
Gly Arg Glu Ala Glu Gln Ala Leu Trp Thr Gln Cys Gln Gly Tyr Val
1125 1130 1135
                1125
                                    1130
Thr Tyr Ala Gly Ala Glu His Phe Trp Leu Pro Leu Ser Phe Arg Asp
                                                    1150
           1140
                                1145
 Ser Met Leu Thr Gly Pro Val Thr Val Thr Arg Asp Ala Tyr Asp Cys
                            1160
                                                1165
 Val Ile Thr Gln Trp Gln Asp Ala Ala Gly Ile Val Thr Thr Ala Asp
                        1175
```

```
Tyr Asp Trp Arg Phe Leu Thr Pro Val Arg Val Thr Asp Pro Asn Asp
                                     1195
                  1190
Asn Leu Gln Ser Val Thr Leu Asp Ala Leu Gly Arg Val Thr Thr Leu
                               1210
              1205
Arg Phe Trp Gly Thr Glu Asn Gly Ile Ala Thr Gly Tyr Ser Asp Ala
                            1225
          1220
Thr Leu Ser Val Pro Asp Gly Ala Ala Ala Ala Leu Ala Leu Thr Ala
                     1240
       1235
Pro Leu Pro Val Ala Gln Cys Leu Val Tyr Val Thr Asp Ser Trp Gly
                      1255
                                        1260
Asp Asp Asp Asn Glu Lys Met Pro Pro His Val Val Val Leu Ala Thr
                                    1275
                                                       1280
       1270
1265
Asp Arg Tyr Asp Ser Asp Thr Gly Gln Gln Val Arg Gln Gln Val Thr
                                 1290
                                                    1295
              1285
Phe Ser Asp Gly Phe Gly Arg Glu Leu Gln Ser Ala Thr Arg Gln Ala
                            1305
                                                1310
          1300
Glu Gly Asn Ala Trp Gln Arg Gly Arg Asp Gly Lys Leu Val Thr Ala
                          1320
                                            1325
       1315
Ser Asp Gly Leu Pro Val Thr Val Ala Thr Asn Phe Arg Trp Ala Val
                   1335
                                        1340
  1330
Thr Gly Arg Ala Glu Tyr Asp Asn Lys Gly Leu Pro Val Arg Val Tyr
1345
1350
1355
1350
1355
1350
1370
1375
                                                      1360
            1365
Arg Gln Asp Leu Tyr Ala Asp Thr His Phe Tyr Asp Pro Thr Ala Arg
                                              1390
                             1385
           1380
Glu Trp Gln Val Ile Thr Ala Lys Gly Glu Arg Arg Gln Val Leu Tyr
                                   1405
                         1400
Thr Pro Trp Phe Val Val Ser Glu Asp Glu Asn Asp Thr Val Gly Leu
                                         1420
   1410
                      1415
Asn Asp Ala Ser
1425
```

```
<210> 6
<211> 973
<212> PRT
<213> Serratia entomophila
```

<220>
<223> SepC amino acid sequence encoding an insecticidal protein when linked with at least SEQ ID NO: 1

<400> 6 Met Ser Thr Ser Leu Phe Ser Ser Thr Pro Ser Val Ala Val Leu Asp Asn Arg Gly Leu Leu Val Arg Glu Leu Gln Tyr Tyr Arg His Pro Asp 3.0 2.0 Thr Pro Glu Glu Thr Asp Glu Arg Ile Thr Cys His Gln His Asp Glu Arg Gly Ser Leu Ser Gln Ser Ala Asp Pro Arg Leu His Ala Ala Gly Leu Thr Asn Phe Thr Tyr Leu Asn Ser Leu Thr Gly Thr Val Leu Gln Ser Val Ser Ala Asp Ala Gly Thr Ser Leu Glu Leu Ser Asp Ala Ala Gly Arg Ala Phe Leu Ala Val Thr Gly Ala Gly Thr Glu Asp Ala Val Thr Arg Thr Trp Gln Tyr Glu Asp Asp Thr Leu Pro Gly Arg Pro Leu Ser Ile Thr Glu Gln Val Thr Gly Glu Ala Ala Gln Ile Thr Glu Arg Phe Val Tyr Ala Gly Asn Thr Asp Ala Glu Lys Ile Leu Asn Leu Ala Gly Gln Cys Val Ser His Tyr Asp Thr Ala Gly Leu Val Gln Thr Asp

```
Ser Ile Ala Leu Ser Gly Val Pro Leu Ala Val Thr Arg Gln Leu Leu
            180
                                185
Pro Asp Ala Ala Gly Ala Asn Trp Met Gly Glu Asp Ala Ser Ala Trp
                            200
        195
Asn Asp Leu Leu Asp Gly Glu Thr Phe Phe Thr Gln Thr His Ala Asp
                        215
   210
Ala Thr Gly Ala Val Leu Ser Ile Thr Asp Ala Lys Gly Asn Leu Gln
                  230
                                       235
Arg Val Ala Tyr Asp Val Ala Gly Leu Leu Ser Gly Ser Trp Leu Thr
                245
                                    250
                                                        255
Leu Lys Asp Gly Thr Glu Gln Val Ile Val Ala Ser Leu Thr Tyr Ser
                                                    270
                                265
            260
Ala Ala Gly Lys Lys Leu Arg Glu Glu His Gly Asn Gly Val Val Thr
                                                285
        275
                            280
Ser Tyr Ile Tyr Glu Pro Glu Thr Gln Arg Leu Thr Gly Ile Lys Thr
                        295
                                            300
Glu Arg Pro Ser Gly His Val Ala Gly Ala Lys Val Leu Gln Asp Leu
                                        315
                    310
Arg Tyr Thr Tyr Asp Pro Val Gly Asn Val Leu Ser Val Asn Asn Asp
                                   330
                                                         335
                325
Ala Glu Glu Thr Arg Phe Trp Arg Asn Gln Lys Val Val Pro Glu Asn
                                345
                                                     350
Thr Tyr Ile Tyr Asp Ser Leu Tyr Gln Leu Val Ser Ala Thr Gly Arg
                            360
                                                365
Glu Met Ala Asn Ala Gly Gln Gln Gly Asn Asp Leu Pro Ser Ala Thr
                        375
                                            380
Ala Pro Leu Pro Thr Asp Ser Ser Ala Tyr Thr Asn Tyr Thr Arg Thr
                    390
                                        395
Tyr Arg Tyr Asp Arg Gly Gly Asn Leu Thr Gln Met Arg His Ser Ala
                                   410
                                                         415
                405
Pro Ala Thr Asn Asn Asn Tyr Thr Thr Asp Ile Thr Val Ser Asp Arg
                                                     430
            420
                                425
Ser Asn Arg Ala Val Leu Ser Thr Leu Ala Glu Val Pro Ser Asp Val
                                                445
        435
                            440
Asp Met Leu Phe Ser Ala Gly Gly His Gln Lys His Leu Gln Pro Gly
                        455
                                            460
Gln Ala Leu Val Trp Thr Pro Arg Gly Glu Leu Gln Lys Val Thr Pro
                    470
                                        475
Val Val Arg Asp Gly Gly Ala Asp Asp Ser Glu Ser Tyr Arg Tyr Asp
                                    490
                                                         495
                485
Ala Gly Ser Gln Arg Ile Ile Lys Thr Gly Thr Arg Gln Thr Gly Asn
                                505
                                                     510
            500
Asn Val Gln Thr Gln Arg Val Val Tyr Leu Pro Gly Leu Glu Leu Arg
                                                 525
                            520
        515
Ile Met Ala Asn Gly Val Thr Glu Lys Glu Ser Leu Gln Val Ile Thr
                                            540
                        535
    530
Val Gly Glu Ala Gly Arg Ala Gln Val Arg Val Leu His Trp Glu Ile
                                        555
                    550
Gly Lys Pro Asp Asp Leu Asp Glu Asp Ser Val Arg Tyr Ser Tyr Asp
                                    570
                565
Asn Leu Val Gly Ser Ser Gln Leu Glu Leu Asp Arg Glu Gly Tyr Leu
                                                     590
                                585
            580
Ile Ser Glu Glu Glu Phe Tyr Pro Tyr Gly Gly Thr Ala Val Leu Thr
                            600
        595
Ala Arg Ser Glu Val Glu Ala Asp Tyr Lys Thr Ile Arg Tyr Ser Gly
  610
                        615
Lys Glu Arg Asp Ala Thr Gly Leu Asp Tyr Tyr Gly Tyr Arg Tyr Tyr
                    630
                                        635
Gln Pro Trp Ala Gly Arg Trp Leu Ser Thr Asp Pro Ala Gly Thr Val
                                     650
                                                         655
                645
Asp Gly Leu Asn Leu Phe Arg Met Val Arg Asn Asn Pro Val Thr Leu
                                665
                                                     670
Phe Asp Ser Asn Gly Arg Ile Ser Thr Gly Gln Glu Ala Arg Arg Leu
                             680
                                                 685
Val Gly Glu Ala Phe Val His Pro Leu His Met Pro Val Phe Glu Arg
                        695
                                             700
Ile Ser Val Glu Arg Lys Ile Ser Met Ser Val Arg Glu Ala Gly Ile
```

```
715
705
                   710
Tyr Thr Ile Ser Ala Leu Gly Glu Gly Ala Ala Ala Lys Gly His Asn
                                    730
                                                        735
               725
Ile Leu Glu Lys Thr Ile Lys Pro Gly Ser Leu Lys Ala Ile Tyr Gly
                                                   750
                               745
           740
Asp Lys Ala Glu Ser Ile Leu Gly Leu Ala Lys Arg Ser Gly Leu Val
755 760 765
Gly Arg Val Gly Gln Trp Asp Ala Ser Gly Val Arg Gly Ile Tyr Ala
                                         780
                       775
His Asn Arg Pro Gly Gly Glu Asp Leu Val Tyr Pro Val Ser Leu Gln 785 790 795 800
                    790
Asn Thr Ser Ala Asn Glu Ile Val Asn Ala Trp Ile Lys Phe Lys Ile
                                   810
               805
Ile Thr Pro Tyr Thr Gly Asp Tyr Asp Met His Asp Ile Ile Lys Phe 820 825 830
                            825
            820
Ser Asp Gly Lys Gly His Val Pro Thr Ala Glu Ser Ser Glu Glu Arg
                                                845
                           840
       835
Gly Val Lys Asp Leu Ile Asn Lys Gly Val Ala Glu Val Asp Pro Ser
                                            860
                        855
Arg Pro Phe Glu Tyr Thr Ala Met Asn Val Ile Arg His Gly Pro Gln
                                       .875
                   870
Val Asn Phe Val Pro Tyr Met Trp Glu His Glu His Asp Lys Val Val
                                   890
               885
Asn Asp Asn Gly Tyr Leu Gly Val Val Ala Ser Pro Gly Pro Phe Pro
                                905
           900
Val Ala Met Val His Gln Gly Glu Trp Thr Val Phe Asp Asn Ser Glu
                                              925
                           920
        915
Glu Leu Phe Asn Phe Tyr Lys Ser Thr Asn Thr Pro Leu Pro Glu His
                       935
                                            940
Trp Ser Gln Asp Phe Met Asp Arg Gly Lys Gly Ile Val Ala Thr Pro
         , 950
                                     955
945
Arg His Ala Glu Leu Leu Asp Lys Arg Arg Val Met Tyr
                                    970
                965
```

303

1070489

Rec'd PCT/PTO 01 MAR 2002

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: Glare, Hurst,

Glare, Travis T Hurst, Mark R H Jackson, Trevor A

(ii) TITLE OF INVENTION: Insecticidal nucleotide sequences

(iii) NUMBER OF SEQUENCES: 6

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: A J Park & Son

(B) STREET: Huddart Parker Building, Post Office Square

(C) CITY: Wellington

(D) COUNTRY: New Zealand

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18937 nucleotides (A) LENGTH: 5118 amino acids

(B) TYPE: nucleotide

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(C) STRANDEDNESS:

(D) TOPOLOGY: Linear

(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: DNA

(ii) MOLECULE TYPE: PROTEIN

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

ggatccgagt gaaggaatca tcggccgctt tatacgtttc agggtgaata cggttggccg 60 caacgtggca atggatgttg tttgtgtcgg tatgaatcgc cgcaacgtac tggtgttctg 120 acatacccaq tqccqataaa ctqtqacqaa cactatcaaa gatqtqttcc gtcqacctga 180 aagccaggat ttatttttac accaatggtt gggtgggctt cctttctgaa ctggtgcatc 240 atttagcdgg catcatcaaa agatgcatgg aaatacaaat atcatattta cagacaccca 300 agttgatgac ctgctccgtg agttgaaatg ccgacggggg aaatcagcag ccttttcaac 360 tcatggagca gggggaaatc aatcctcaat aacccgcatt ggatatcctg ccagtgtgca 420 tttaaccttt ttagtgtgtt teettaatat eecaategtt gaategetae ataeggeaga 480 cattagtatc tcacttatca tcaaagtaat atcacaccga gaatgctaat ttcatgatat 540 qaaaacgttc cattaataaa ttttcaqaaa cctaacacgg catttttatg ctgatcagtg 600 aattgattgt ttotgaaaaa attaattgoa oototgooac ttatoagata aaaacaccoo 660 atgcggtaag tittttattt titattaatg attitattaa tgattitatt aatgatitta 720 ttaatgattt tattaatgat tttactatag atgaatgtta acatgggtga taatttactt 780 tactcaattt aattgttggt atgaccatgt tttagatgag tggcacggat tcattattgt 840 aaaaaaagta totaaaacct ttagcagcaa tootacttga ggatgacctc gacaggactt 900 gattattgcc attttttacg aaggaagatg acgggtgata aataataaaa aaaacaaaag 960 tatageetta ggtategeeg attacateea gtaacaetta ttgaettttt tttaetteta 1020

ccgtt	agct	a ta	aata	tgat	att	taaa	tct	gtat	tttt	at a	ataaa	acca	g tt	tatg	atgc	1080
tggat	tggt	c at	taaa	igteg	tta	tatg	tga	tcgt	tato	tg t	catt	gatt	g gt	gttt	aatc	1140
tttta	ttct	t cc	agto	gaggt	ttc	aggg	ıgga	atgt	attg	igg (taato	atac	et ca	atgto	attt	1200
gttgc	tttg	ja tg	jttaa	atta	acc	tgtt	cat	tcat	tatg	gtt (ctact	gttg	jt ti	tctat	tgtc	1260
cggaa	cgac	c at	agag	gactg	tes	gctat	gtt	aata	aggaa	ita 1	tttga	actgo	jt ta	atato	gegee	1320
aaggg	gttat	c go	etgca	actct	cts	99999	gat	ggta	attça	atc a	attad	gcaa	ag a	taact	tcat	1380
tggtg	gtcag	ga co	gggtg	gttat	tg(tttt	tgt	gtct	tttt	ta	ctcg	gtttg	ja c	atttt	caga	1440
gacaa	acago	et to	ccgt	tatca	a act	ttcta	atat	ccc	gaato	gat	atac	atata	ag g	aaatg	gacct	1500
tggtg	geett	t gt	ttac	cage	g cc	gtgad	ggt	gaag	gcttl	ttt ·	gtta	tcati	ta t	gagca	aagat	1560
agaga	agaaa	aa ta	atct	tggag	g aa	taaco	egee	atg	ttcca	aaa	tcat	actt	ct t	aatgi	ttaat	1620
gccg	tgati	tt g	cttg	gctai	t tg	ccgt	caga	tta	ttcci	tgt	ggcg	tatc	aa t	cata	aaatg	1680
aaaa	acati	tg t	cgtc	tctt	t ta	ttgc	ttt	ctc	atta	tta	cg gc	gtgc	gg c	gctg	tctcc	1740
atca	ggac	ga t	gacg	gggg	a gt	atta	ctat	gcg	gatt	ggt	ccga	gacg	at c	atta	acctt	1800
tege	tttt	cc t	gtct	gttt	a ta	tacg	caat	ggc	gaaa	tcc	ttcg	gtgg	a a	ıgaga	aaaa	1859
atg Met 1	aag Lys	ata Ile	agt Ser	tcc Ser 5	cga Arg	ggt Gly	atc Ile	gca Ala	tta Leu 10	atc Ile	aaa Lys	gag Glu	ttc Phe	gaa Glu 15	ggt Gly	1907
ctig Leu	c gc Arg	tta Leu	cac His 20	gct Ala	tat Tyr	cgc Arg	tgc Cys	gcc Ala 25	gct Ala	gac Asp	gtc Val	tgg Trp	act Thr 30	gtc Val	ggt Gly	1955
tat Tyr	gly ggc	cac His 35	acg Thr	gca Ala	ggg ggg	gtt Val	aca Thr 40	aag Lys	ggt Gly	gac Asp	atc Ile	atc Ile 45	acg Thr	gtc Val	gat Asp	2003
gaa Glu	gcc Ala 50	cag Gln	acg Thr	atg Met	ctg Leu	aca Thr 55	Asn	gat Asp	att Ile	acc Thr	gta Val 60	ttt Phe	gaa Glu	cgg Arg	gcg Ala	2051
											_		_	gat Asp		2099
														cgc Arg 95		2147 ~
acc Thr	ttg Leu	ttg Leu	aaa Lys 100	aaa Lys	ctc Leu	aac Asn	aaa Lys	cag Gln 105	Asp	tat Tyr	gtc Val	ggc	gcc Ala 110	ggg ggg	aac Asn	2195
gag	ttt	tta	cgc	tgg	acc	cgg	gcc	aat	9 99	aag	gtc	ctt	ccc	gga	ctg	2243

															-/ ··		
G	lu	Phe	Leu 115	Arg	Trp	Thr _. I		Ala . 120	Asn (Gly :	Lys V		Leu I 125	Pro (Gly 1	Leu	
						gct (Phe (2291
t	aa	ccci	tttg	cga (gtac	ccac	a ag	atga	agat	aac	accg	cgt :	actg	agcg	gt		2344
1	45																
g	gcç	gcaa	caa (tgaal	taaat	gac	tgtg	tacg	ged	tgtc	ctt	caca	acgg	at g	ggac	catca	2404
а	cgt	aa				aa g Sln A					I na						2452
G						cca Pro 165											2500
_	_		_	_		gat Asp			_								2548
ī	aa .ys	atc Ile	act	ggc Gly 195	Asp	agc Ser	ctg Leu	tca Ser	tgg Trp 200	gga Gly	gag Glu	gtc Val	tgc Cys	tat Tyr 205	ctg Leu	tac Tyr	2596
				Gln		gaa Glu											2644
			. Ala			aat Asn											2692
	ata Ile 240	Arc	g Cag	g gca	gcc Ala	ggc Gly 245	agt Ser	cgc Arg	agc Ser	tat Tyr	gat Asp 250	gac Asp	tgg Trp	ttt Phe	ggc Gly	tcc Ser 255	2740
	cgc	gca Ala	a gad a Asj	c cgt p Arg	tto Phe 260	gcc Ala	cgc Arg	ccc Pro	ggc	tcg Ser 265	Val	gcc Ala	tcc Ser	atg Met	ttc Phe 270	tca Şer	2788
	ccg Pro	gcg Ala	g gcg a Ala	g tat a Tyr 27!	r Lei	acc Thr	gag Glu	ctg Leu	tac Tyr 280	Arg	gag Glu	gcg Ala	aag Lys	gac Asp 285	Leu	cat His	2836
	cce Pro	g gad o Asi	c ac p Th 29	r Se	g cto r Le	g ttc ı Phe	cgg	ctg Leu 295	а Авр	ato Ile	cgg Arg	cgt Arg	ccc Pro 300	gac Asp	ctg Leu	gcg Ala	2884
	gc <u>c</u> Ala	g cte a Le 30	u Al	c ct a Le	t ago u Se:	c cag	aat Asn 310	Asr	ato n Met	gac : Asp	gac Asp	gag Glu 315	Leu	tcc Ser	acc Thr	ctg Leu	2932
	age	c ct	g to	c aa	t ga	g cta	ctg	, tat	c cgc	ggt	ato	999	gca	gcg	g gaa	ggg	2980

Ser 320	Leu	Ser	Asn	Glu	Leu 325	Leu	Tyr	Arg	Gly	11e 330	Gly	Ala	Ala	Glu	Gly 335	
	gac Asp	_	-	_	_			_		-			_	-		3028
	ctg Leu						_				_			_		3076
_	gtg Val	_	_	_	_	_					_		_	_		3124
_	cag Gln 385		_	•		_		_	_	_		-	_	_		3172
	ecg Pro		_		_		_	_	_	-		_		_	_	3220
	gaa Glu	-			_	_				_	_					3268
_	tta Leu			_	_		-						-		_	3316
	cta Leu		_		_				_	-						3364
	gaa Glu 465					_			-	•	_	Thr	_			3412
							_				Arg			_	gga Gly 495	3460
_		_	_		Asn					Pro			_		aca Thr	3508
				Phe	-	_			Thr					Ser	ttc Phe	3556
			Ser					Sex					ser		gat Asp	3604
tat Tyr	cag Glr 545	Leu	caa Glr	a aaa a Lys	ggg Gly	gtt Val 550	Arg	tat j Tyr	ago Sei	att	e Pro	Val	gaa Glu	ata Ile	gat Asp	3652

(gaa Glu 560	gga Gly	aag Lys	tta Leu	aat Asn	gat Asp 565	G 1y 3 33	atc Ile	aca Thr	ata Ile	gga Gly 570	ttg Leu	agt Ser	agg Arg	aaa Lys	999 Gly 575	3700
											ctg Leu						3748
											atc Ile						3796
											atc Ile						3844
									-	_	agt Ser		_		-	_	3892
	_		_	_				_		_	gtg Val 650	_			_		3940
											ttc Phe						3988
	_			_	Leu					_	ctg Leu				_	ttt Phe	4036
				Asp					Leu		tct Ser			Pro			4084
			Arg					Lys			ttt Phe		Ile			tcg Ser	4132
		Leu					Gln					qaA				ggg Gly 735	4180
		_	_		_	aA r			_	_	Lev		-	-		ctc Leu	4228
					Hi:					Gly					Let	g ctg 1 Leu	4276
	t co	gto	tce L Se:	r Pro	t tto Phe	e Sei	Gly	g gtg / Val	l Ala	e gco a Ala	ggo a Gly	tc Sei	g ctg Let 780	ı Sei	gat Asj	t aat p Asn	4324
	ga	g cts	ac	g ca	g ttl	t ctq	g tad	c cag	g ac	e ac	e acc	e tg	g cto	c ace	g ga	g cag	4372

Glu	Leu 785	Thr	Gln	Phe	Leu	Tyr 790	Gln	Thr	Thr	Thr	Trp 795	Leu	Thr	Glu	Gln	
	tgg Trp	_	-	_	_			_	_	_	-	-	_			4420
	ctg Leu'				-											4468
	ctg Leu	Ser		-		_		_								4516
_	ccc Pro			_	_				-	-			-	_	-	4564
	gcg Ala 865															4612
	acg Thr															4660
	gçg Ala															4708
_	atc Ile	Ile	_	Ser					_	_		_				4756
	agc Ser		Pro										Leu			4804
_	_	Pro				_	Ile	_				Ala	_		aac Asn	4852
cgc Arg 960	ş Şer	ggc Gly	ago Ser	cat His	gcc Ala 965	Gly	gag Glu	gtc Val	ctg Leu	acc Thr 970	Ala	ctt Leu	gag Glu	acc Thr	gga Gly 975	4900
ga: Gl:	a Cto u Lei	tcg Ser	tca Ser	gcc Ala 980	Let	g ctg 1 Leu	gco Ala	cgg Arg	gco Ala 989	l Lei	tca Ser	cag Glr	aat Asn	gag Glu 990	g cag u Gln	4948
				Ala					Arg					Glr	g gac 1 Asp	4996
			Phe					ı Glı					a Glu		g tgg n Trp	5044

					•
-	Ser Glu Thr	_	acg cca tcc gg Thr Pro Ser Gl 1035		5092
_	- •		tcc gat gac ag Ser Asp Asp Se 1050		5140
		Val Ser Gly	ctg ctg cag go Leu Leu Gln Al 065		5188
Ser Ser Gln			tat ctg gag ga Tyr Leu Glu Gl		5236
	Cys Ala Tyr		aat ctg gca co Asn Leu Ala Pi 110		5284
	Asp Asp Leu			at aat cag gtg sp Asn Gln Val	5332
				te gee gge ata le Ala Gly Ile 1135	5380
	·	Ala Leu Asn		tc agc gcc atg eu Ser Ala Met 1150	5428
		_		at acg ttc aac sp Thr Phe Asn 1165	5476
	Ser Thr Trp			tt tac tat ccg al Tyr Tyr Pro 80	5524
_	Leu Asp Pro			cc ggc atg atg hr Gly Met Met	5572
				ac cgc gat acc sn Arg Asp Thr 1215	5620
		Thr Tyr Leu		ag cag att gcc lu Gln Ile Ala 1230	5668
_			-	gc atg acg cag er Met Thr Gln 1245	571 6
ggg act ac	a tgg tat gtg	ggt cgc agc	atc aca gat o	ag act aac tgg	5764

Gly		Thr 250	Trp	Tyr	Val		Arg 255	Ser	lle	Thr		Gln ' 260	Thr	Asn '	Trp	
Tyr					Asn			aaa Lys		Gln						5812
	Asn			Thr				aaa Lys	Ile					Asn		5860
			Leu					ttt Phe 1					Leu			5908
		Val					Ser	gct Ala 1320				Ala				5956
	Thr	_	_	_	_	Tyr		ctg Leu		Leu		Phe	Arg	Arg		6004
Asp					Ser			tcg Ser		qaA						6052
	Phe			Thr				cat His	Val					Leu		6100
			Tyr					tcc Ser					Pro			6148
_		Ala	_	Leu			Val	gat Asp 1400				Thr		naA		6196
	Ser		Ile			Phe		agc Ser			His					6244
		Glu					Asn	gtt Val		Ser						6292
Туз						ser		att Ile			Val			Ser		6340
tto Phe	c tca e Ser	cto Lei	ctt Lev	aat 1 Asi 1460	ı Sei	aaa Lys	act Thi	aca Thr	agt Ser 1469	Thr	gtt Val	ttt Phe	act Thi	aat Asn 1470	gaa Glu	6388
				ı Lei					ı His					n Val	tcg Ser	6436

								•							
tgt tt Cys Ph	_	_		_	Gly		_			Ser			_		6484
ttc gt Phe Va 150	l (Gln			Ile					Ile						6532
cag go Gln Al 1520	_		Gly		_		-	Val			-	_	Ser		6580
tca aa Ser Ly		Tyr					Glu					Thr			6628
tct ta Ser Ty	r Ser	_			_	Ser			_		Leu			-	6676
tca to Ser Se		Lys			Ser			_		qaA					6724
gct to Ala Lo	u Ile	_		Ser				_	Asn			_			6772
ggc to Gly So 1600			Phe					Ser					Leu		6820
	at gaa yr Glu	Leu					Ile					Val			6868
_	aa att lu Ile		Ser			Ser	-	_			Asn	_	Lys	_	6916
_	tg caa eu Glr 1650	ı Ser			Asn		Phe			Lys		Leu	-		6964
Thr V	tt aat al Ası 65			Asp		Val			Glu						7012
	tc acc				Gln					Leu					7060
	ta tt			Ile			ılle		Asn					Ile	7108
gca t	tà cg	t aaa	a aat	acg	cgt	ggo	gcg	g cag	tat	att	cgt	: tto	e act	gcg	7156

Ala	Leu		Lys 715	Asn	Thr	Arg		Ala 720	Gln '	Tyr	Ile		Phe 725	Thr .	Ala	
ggt Gly	Asn					lle					Leu					7204
ctg Leu 1					Asn					Thr						7252
	Gln			Thr	-		gcc Ala	_	Glu	-			-	Val		7300
_	_		ser		-		gcc Ala	Leu					Leu		tat Tyr	7348
	_	Pro	_	_			cag Gln		_	_	-	Glu	_			7396
_	Glu	_		_		Leu	cag Gln 1815			-	naA					7444
Val					Leu		aat Asn			Trp						7492
	Glu			Gly			gac		Pro					Asp		7540
			Ala		Tyr		ccc Pro	Met					Ala			7588
		Туг		qaA			att Ile		Arg			Ala		Tyr		7636
		_	Arg	-			aac Asn 1895	Glu					Tyr	_	_	7684
gcc Ala	ctg Lev 1905	Asn	ctt Lev	ctg Lev	ggc Gly	gac Asp 1910	gag Glu	cco Pro	tat Tyr	att Ile	tcc Ser 1915	Phe	gac Asp	gcc Ala	gac Asp	7732
	Ser					Gly	gac Asp				: Glu					7780
					a Lei					Arg					ccc: Pro	7828

gag a Glu 1		Arg					Leu					Leu				7876
aac q Asn (Glu					Tyr				_	Ala	_				7924
naA	_	-			Leu					Gln						.7972
gtc Val 2000	Tyr			Pro					Ala					Val		8020
aac Asn			Gln					Leu					Met			8068
	_	Phe	_	_	_	_	Glu		_			atg Met			-	8116
	Thr					Thr					Thr	gag Glu 2060				8164
Ala		Ala			Lys					Gln					ata Ile	8212
cgc Arg 2080	Gln	ggc Gly	ctt Leu	Arg	cag Gln 2085	cag Gln	gat Asp	aac Asn	Val	ctc Leu 2090	Glu	gaa Glu	atc Ile	gat Asp	gcg Ala 2095	8260
					Glu					Gly					ttt Phe	8308
				Val					Asp			Thr		glu Glu	aaa Lys	8356
			Asp					Ser					Ala		acc Thr	8404
Ala	gcg Ala 2149	a Let	ttt 1 Phe	ttg Lev	gco Ala	gaç Glu 2150	ı Ala	geg Ala	g gcc A Ala	gat Asp	ate Met 2155	Leu	Pro	c aat o Asi	att 1 Ile	8452
tac Tyr 216	Gl	g cto y Lei	g gco	c gto a Val	999 1 Gly 2169	/ Gl	tco Sei	c ego	tat g Tyi	gg9 Gly 2170	y Ala	a cta a Lei	a tti	t aaa e Ly	a gcc s Ala 2175	8500
acc	gc	c at	c gg	c at	cag	gt	g tc	= tc	c gat	gc	c ac	e ego	at	a tc	a gcg	8548

Thr Ala II	le Gly Ile (2180	Gln Val Ser	Ser Asp Ala 2185	a Thr Arg Ile S	Ser Ala 190
_		Ser Glu Val		c cgc cgg gag g g Arg Arg Glu (2205	- -
_	ln Arg Asp			g gcg cag att o l Ala Gln Ile . 2220	
				g gct gag ctg y Ala Glu Leu 2235	-
	eu Glu Thr			g gcg cag ttg n Ala Gln Leu 0	-
	-		-	c agc tgg ctg r Ser Trp Leu 2	
		Tyr Tyr Gln		c ctg gca gta p Leu Ala Val 2285	
Cys Leu M			Gln Trp As	t aaa ttc gag p Lys Phe Glu 2300	
				a aat gcc ggt a Asn Ala Gly 2315	
	Slu Thr Leu			ng atg gag cag n Met Glu Gln 0	
				eg egg acg gte nr Arg Thr Val	
				eg gca ttc tct la Ala Phe Ser 2365	
Asp Lys			Asn Gly Se	eg ggc agt gcg er Gly Ser Ala 2380	
				aa ctc gag gcc ln Leu Glu Ala 2395	
				ac ccg gtc tcc yr Pro Val Ser 10	

acc atg agg Thr Met Arg	-			al Thr Leu		-
ggc ccc tat Gly Pro Tyr						
gtc atg ccc Val Met Pro 2450		Сув Ser A		la Val Ser	-	
gac agc ggc Asp Ser Gly 2465			•			-
Phe Glu Gly 2480	Leu Pro	Val Asp 1 485	Asp Thr G	ly Thr Leu 2490	aca ctg ago Thr Leu Ser	Phe 2495
				et Leu Leu	agt ctg ago Ser Leu Ser 2510	Asp
Ile Ile Leu	His Ile 2515	Arg Tyr	Thr Ile I 2520	le Ser	tag gtatcaa	
agcgcaggcc	cccgaacga	ig ggcctg	cgag gaga		caa aat cat Gln Asn His	
Asp Met Ala 2530	lle Thr	Ala Pro	Thr Leu F	Pro Ser Gly 2540	ggc ggt gcg	a Val 2545
			Ala Ala A		gat ggt gcg Asp Gly Ala 256	a Ala O
Thr Leu Ser	lle Pro 2565	Leu Pro	Val Ser I 2570	Pro Gly Arg	ggt tac ge Gly Tyr Al 2575	a Pro
Thr Gly Ala 258	Leu Asn	Tyr His 2	Ser Arg 8	Ser Gly Asn	ggc ccc tt Gly Pro Ph 2590	e Gly
att ggc tgg Ile Gly Try 2595	g ggt atc p Gly Ile	Gly Gly	gct gct g	gtc cag cgt Val Gln Arg 2605	cgt acg cg Arg Thr Ar	c aac 9852 g Asn
2595		2600		2001		
gga gca cc	o Thr Tyr	gat gat	_	gaa ttc acc	e ggt ccg ga	* .

Glu Val Leu	Val Pro Ala Le 2630		Ala Gly Thr 635	Gln Glu Ala Arg 2640	
Gln Ala Thr		_		agc ttc aac gtt Ser Phe Asn Val 2655	9996
			Ser Leu Ser	cgc ctt gag cgt Arg Leu Glu Arg 2670	10044
		hr Glu Thr		gtg tta tat acc Val Leu Tyr Thr	10092
				cag gct cgc atc Gln Ala Arg Ile 2705	10140
-	-	hr Gln Thr		ctg atg gag tcc Leu Met Glu Ser 2720	10188
Ser Val Ser				tac cgt gcg gaa Tyr Arg Ala Glu 2735	10236
-	Gly Cys Asp G		Arg Asp Ala	cac ccg cag gcc His Pro Gln Ala 2750	10284
	Arg Tyr Pro V			aac cgt cag gcg Asn Arg Gln Ala	10332
				atg gat agc tgg Met Asp Ser Trp 2785	10380
		sp Tyr Gly		tcg gtg ctg tct Ser Val Leu Ser 2000	10428
				tgg ctg tgt cgt Trp Leu Cys Arg 2815	10476
	s Phe Ser Gly			c ctg cgg act cgc n Leu Arg Thr Arg 2830	10524
	s Arg Gln Val	-		a ggt gtt ctg gcg 1 Gly Val Leu Ala 5	10572
				t tct cgc ctg ttg e Ser Arg Leu Leu 2865	10620

ctg Leu	-		Arg	_				Leu					Asn	_		10668
cag Gln		Ala					Gly					Leu				10716
gca Ala	Leu					Phe					Leu		_			10764
Thr		_	_	_	Gly	-	-	_	_	Leu		,	tat Tyr	_		10812
	Asp			Gly	_				Gly		_		cag Gln	Asp	-	10860
	-		Trp		_	-	_	Val	-				gat Asp 2	_	_	10908
-	_	Val		~ ~			Āla		_	_	_	Thr	atg Met 2975		_	10956
_	His		_			Leu		_			Gly	_	ggt Gly		_	11004
Glu					Ala					Gly			gat Asp			11052
	Gly	_	_	Trp	-				Pro	_		_	ttg Leu	Pro	-	11100
-			His			-		Leu	_	_		-	Gly aaa	_	Gly	11148
		_	_				Gly	_	Arg	-	_	Arg	ctc Leu 3055			11196
			Asp			Asn		Gly			Val	_	Gln		gaa Glu	11244
-		Thr	_	_	Val	-	Gly	-	_	Pro		Thr		_	gcg Ala	11292
ttc	aģt	gat	atg	gct	ggc	agt	gga	cag	cag	cat	ttg	acg	g gag	gtg	gegt	11340

•				
Phe Ser Asp Met 3090	Ala Gly Ser C 3095	Gly Gln Gln H 31		Val Arg 3105
gct aat gga gta Ala Asn Gly Val 3		_	ly His Gly Arg	
cag ccg gtg aat Gln Pro Val Asn 3125				
cct gac cag ata Pro Asp Gln Ile 3140	Leu Leu Ala			
ctg att tat gcg Leu Ile Tyr Ala 3155				
ggt aat tat ttc Gly Asn Tyr Phe 3170		His Thr Leu I		
cgc tat gat cgc Arg Tyr,Asp Arg			Ala Asp Ile Gln	
ggg gtg cct agc Gly Val Pro Ser 3205				
	Leu Ser Ala		tgg ttg ttg aat Trp Leu Leu Asn 3230	
			cac tat cgc agt His Tyr Arg Ser 3245	
		Ala Glu Ala	ctg gcg gca ggc Leu Ala Ala Gly 260	
Pro Ala Cys Tyr	Leu Pro Phe		acc ctg tgg cgt Thr Leu Trp Arg	
gtg cag gat gag Val Gln Asp Glu 3285	lle Thr Gly	aac cgt ctg Asn Arg Leu 3290	gtc agc gac gtg Val Ser Asp Val 3295	Leu Tyr
	Trp Asp Gly		gag ttt cgg ggg Glu Phe Arg Gly 3310	
		Asp Thr Leu	gca agc cag ggt Ala Ser Gln Gly 3325	

acg ga Thr Gl 3330			Met					Arg A					Thr C		12060
gta co Val Pi		Val					Pro (Gln i			12108
gcc gc Ala A						Ala '					Val •				12156
gag g	at Ygaç sp Glu 3380	Gln	aca Thr	tat Tyr	Thr	ccg Pro 385	gac (Asp	gac (Asp	agc Ser	Lys	aca Thr 390	ttc Phe	tgg Trp	ttg Leu	12204
cag c Gln A 33	ga gco rg Ala 95	c ctg a Leu	aaa Lys	Gly	atc Ile 400	ctg Leu	ctg Leu .	cgc Arg	Ser	gag Glu 405	tta Leu	tac Tyr	ggt Gly	gcc Ala	12252
gat g Asp G 3410	gc age	c agc r Ser	Gln	gcc Ala 3415	gat A sp	atc Ile	cct Pro	Tyr	agc Ser 420	gtc Val	act Thr	gag Glu	Ser	ege Arg 425	12300
	ag gt: ln Va						Asn					Val			12348
ccg a	itg gg Met Gl	c gcg y Ala 3445	Glu	agc Ser	cgt Arg	Thr	tca Ser 450	gtt Val	tat Tyr	gaa Glu	Arg	tac Tyr 3455	cac His	aat Asn	12396
gat o	cct ca Pro Gl 346	n Cys	caa Gln	cag Gln	Gln	gcg Ala 3465	gta Val	ctc Leu	ctc Leu	Ser	gat Asp 3470	gaa Glu	tac Tyr	ggt Gly	12444
Phe l	cca ct Pro Le 475	g cgt	cag g Gln	Val	agt Ser 3480	gtc Val	aat Asn	tat Tyr	Pro	cga Arg 3485	Arg	cct Pro	ccg Pro	tcg Ser	12492
gcg g Ala i 3490	gac aa Asp As	it cca	a tat	ccg Pro 3495	Ala	tcc Ser	tta Leu	Pro	gcg Ala 3500	Thr	ctg Leu	ttc Phe	Ala	aac Asn 3505	12540
agt Ser	tat ga Tyr As	ac ga sp Gl	g cag u Glr 3510	ı Gln	cag Gln	ata Ile	Leu	cgc Arg 3515	ctg Leu	Gly	ttg Leu	Gln	cag Gln 3520	agc Ser	12588
agt Ser	gca ca Ala H:	at ca is Hi 352	s Lev	t gtt ı Val	tca Ser	ctg Leu	ser 3530	Glu	ggg Gly	cat His	tgg Trp	Leu 3535	Leu	ggg	12636
ttg Leu	gcg ga Ala G 35	lu Al	g teg a Şei	g cgg r Arg	gac J Asp	gat Asp 3545	Val	ttc Phe	acg Thr	tac Tyn	tct Ser 3550	Ala	gac Asp	aac Asn	12684
gtg	ccg g	aa gg	g gg	t cto	ace	g ctg	gaa	cac	cto	y tto	g gcg	gee	gaa	agc	12732

Val Pro Glu Gly Gly Leu Thr Leu Glu His Leu Leu Ala Pro Glu Ser 3555 3560 3565	
ctg gtc tcg gat agt cag gtc ggt acg ctg gcg ggt cag cag caa gtc Leu Val Ser Asp Ser Gln Val Gly Thr Leu Ala Gly Gln Gln Gln Val 3570 3575 3580 3585	12780
tgg tat ctg gat tca caa gac gtt gcc acc gtc gct ccg cca ctc Trp Tyr Leu Asp Ser Gln Asp Val Ala Thr Val Ala Ala Pro Pro Leu 3590 3595 3600	12828
ccc ccc aag gta gct ttt atc gaa acg gcc gtg ctg gat gag ggt atg Pro Pro Lys Val Ala Phe Ile Glu Thr Ala Val Leu Asp Glu Gly Met 3605 3610 3615	12876
gtc agt tca ctg gct gcc tac att gtg gat gaa cat ctc gag caa gcc Val Ser Ser Leu Ala Ala Tyr Ile Val Asp Glu His Leu Glu Gln Ala 3620 3625 3630	12924
ggt tac cgg caa tcc gga tac ctt ttc cct cga ggc agg gaa gca gaa Gly Tyr Arg Gln Ser Gly Tyr Leu Phe Pro Arg Gly Arg Glu Ala Glu 3635 3640 3645	12972
cag gca ttg tgg acc cag tgt cag gga tat gtt acc tat gcc ggc gca Gln Ala Leu Trp Thr Gln Cys Gln Gly Tyr Val Thr Tyr Ala Gly Ala 3650 3655 3660 3665	13020
gag cat ttc tgg cta ccg cta tcc ttt cgg gac agt atg ttg acc ggc Glu His Phe Trp Leu Pro Leu Ser Phe Arg Asp Ser Met Leu Thr Gly 3670 3675 3680	13068
cca gtt acc gtg acg cgt gac gcg tac gac tgc gtc atc acg cag tgg Pro Val Thr Val Thr Arg Asp Ala Tyr Asp Cys Val Ile Thr Gln Trp 3685 3690 3695	13116
cag gat gcc gca ggg att gtc acc aca gcc gac tat gac tgg cgc ttc Gln Asp Ala Ala Gly Ile Val Thr Thr Ala Asp Tyr Asp Trp Arg Pho 3700 3705 3710	13164
ctg acg ccc gtc cgg gtg acg gac ccc aat gat aat ctg cag tcc gtc Leu Thr Pro Val Arg Val Thr Asp Pro Asn Asp Asn Leu Gln Ser Va 3715 3720 3725	13212
act ctg gat gct ctg ggc cgg gtg acc acc ctg cga ttc tgg ggc acc Thr Leu Asp Ala Leu Gly Arg Val Thr Thr Leu Arg Phe Trp Gly Th 3730 3740 374	r
gag aat ggt att gcc acc ggt tac agt gat gcc acg ttg tcc gtt cc Glu Asn Gly Ile Ala Thr Gly Tyr Ser Asp Ala Thr Leu Ser Val Pr 3750 3755 3760	g 13308 o
gac ggc gca gca gcc gct ctg gcg ttg acg gcg ccc cta cca gta gc Asp Gly Ala Ala Ala Leu Ala Leu Thr Ala Pro Leu Pro Val Al 3765 3770 3775	a 13356 .a
cag tgt ctg gtg tat gtc acg gac agt tgg gga gat gac gac aat ga Gln Cys Leu Val Tyr Val Thr Asp Ser Trp Gly Asp Asp Asn G 3780 3785 3790	ng 13404 Lu

·	
aaa atg ccc ccg cac gtg gtc gtg ctg gct acc gat cgc tat gac agt Lys Met Pro Pro His Val Val Val Leu Ala Thr Asp Arg Tyr Asp Ser 3795 3800 3805	13452
gat acc gga cag cag gtc cgc caa cag gtg aca ttc agt gac ggt ttt Asp Thr Gly Gln Gln Val Arg Gln Gln Val Thr Phe Ser Asp Gly Phe 3810 3815 3820 3825	13500
ggg cgt gag ttg caa tcg gca acc cgg cag gcc gag ggc aac gcc tgg Gly Arg Glu Leu Gln Ser Ala Thr Arg Gln Ala Glu Gly Asn Ala Trp 3830 3840	13548
caa cga gga cgc gac ggc aaa ctg gtg acg gcc agt gac gga ttg ccg Gln Arg Gly Arg Asp Gly Lys Leu Val Thr Ala Ser Asp Gly Leu Pro 3845 3850 3855	13596
gtc act gta gca acg aat ttc cgc tgg gcg gtc acc ggg agg gcg gag Val Thr Val Ala Thr Asn Phe Arg Trp Ala Val Thr Gly Arg Ala Glu 3860 3865 3870	13644
tat gac aat aaa ggt ctg cct gtt cgg gtt tat cag ccg tat ttt ctg Tyr Asp Asn Lys Gly Leu Pro Val Arg Val Tyr Gln Pro Tyr Phe Leu 3875 3880 3885	13692
gac agt tgg caa tat gtc agt gat gac agt gcc cgc cag gac ctg tat Asp Ser Trp Gln Tyr Val Ser Asp Asp Ser Ala Arg Gln Asp Leu Tyr 3890 3895 3900 3905	13740
gcc gac acg cac ttt tac gat ccg acg gca cgg gaa tgg cag gtt att Ala Asp Thr His Phe Tyr Asp Pro Thr Ala Arg Glu Trp Gln Val Ile 3910 3915 3920	13788
acg gca aaa ggt gaa cgg cga cag gtg ctg tat acc ccg tgg ttt gtg Thr Ala Lys Gly Glu Arg Arg Gln Val Leu Tyr Thr Pro Trp Phe Val 3925 3930 3935	13836
gtc agt gaa gac gag aat gat acc gtt ggg cta aac gac gca tcc tga Val Ser Glu Asp Glu Asn Asp Thr Val Gly Leu Asn Asp Ala Ser 3940 3945 3950	13884
ctgggaagga gggggggacg gtg atg agt ccg tcg ccc ctg aca ggc gct gcc Met Ser Pro Ser Pro Leu Thr Gly Ala Ala 3955 3960	c 13937 a
ctg atg gag aca aag atg aaa ata cac tat cag gtt gcg gcg gtt gtg Leu Met Glu Thr Lys Met Lys Ile His Tyr Gln Val Ala Ala Val Val 3965 3970 3975	13985
ctg aca ggt gtt atg gtt tgg ggg ctt tcc cat tgg cgt tac acc gtc Leu Thr Gly Val Met Val Trp Gly Leu Ser His Trp Arg Tyr Thr Val 3980 3985 3990 3995	14033
ggt tac cac gcg gca gat act caa tgg caa caa cgc cag gcc gaa cag Gly Tyr His Ala Ala Asp Thr Gln Trp Gln Gln Arg Gln Ala Glu Gln 4000 4005 4010	14081
gaa agg gcc gat gcg ttg gcc ctc ctg gca gca gaa acc cgg gaa aga	14129

		•	
Glu Arg Ala Asp Al 4015	a Leu Ala Leu Leu 4020	Ala Ala Glu Thr Arg Glu 4025	Arg
aag tgg gag cag ca Lys Trp Glu Gln Gl 4030	a cga cag act gac n Arg Gln Thr Asp 4035	atg aac aag gtg gct ata Met Asn Lys Val Ala Ile 4040	cat 14177 His
gct gaa gaa gaa ct Ala Glu Glu Glu Le 4045	g gct gct gcg cgt u Ala Ala Ala Arg 4050	gac gct gcc gct gat gct Asp Ala Ala Ala Asp Ala 4055	cag 14225 Gln
cgc act ggt cag cg Arg Thr Gly Gln Ar 4060	c ctg cag cac acc g Leu Gln His Thr 4065	gtt acc acc ctc cag cgg Val Thr Thr Leu Gln Arg 4070	caa 14273 Gln 4075
	u Thr Arg Arg Leu	tcc gca gct acc gct atc Ser Ala Ala Thr Ala Ile 1085 4090	
		gtt ttg ttt gcc gaa ctg Val Leu Phe Ala Glu Leu 4105	
		ctg gca gcg tat gct gac Leu Ala Ala Tyr Ala Asp 4120	
acc aga gtg aaa tg Thr Arg Val Lys Tr 4125	gg cag gcc tgc ggg rp Gln Ala Cys Gly 4130	cgc gcc tat cag gcg gct Arg Ala Tyr Gln Ala Ala 4135	acg 14465 Thr
cac gaa gca gaa aa His Glu Ala Glu Ly 4140		ccgttaagga aaagtgacgg	14513
tgttttcgcg attaata	atta acaggagate ac	atg agc aca tcc ttg ttc Met Ser Thr Ser Leu Phe 4150	
		aac cgc ggc ctg ttg gtg Asn Arg Gly Leu Leu Val 4165	
gag ctg cag tac ta Glu Leu Gln Tyr Ty 4170	ac ege cat eeg gat yr Arg His Pro Asp 4175	aca ccg gag gag acg gac Thr Pro Glu Glu Thr Asp 4180	gag 14662 Glu
cgt atc acc tgc ca Arg Ile Thr Cys Hi 4185	at cag cac gat gag is Gln His Asp Glu 4190	cgc ggc agc ttg tca caa Arg Gly Ser Leu Ser Gln 4195	agc 14710 Ser 4200
	eu His Ala Ala Gly	ctg aca aat ttc acg tac Leu Thr Asn Phe Thr Tyr 4210 4215	Leu
aat agc ctg acc gg Asn Ser Leu Thr G 4220	gg aca gta ctg cag ly Thr Val Leu Gln 4225	agc gtc agc gcc gat gcc Ser Val Ser Ala Asp Ala 4230	ggt 14806 Gly

	Ser					gat Asp . 4					Ala					14854
Thr					Glu	gac Asp 255				Arg						14902
	Asp			Pro		cgc Arg			Ser					Val		14950
			Ala			acg Thr		Arg					Gly			14998
		Glu				aat Asn	Leu					Val				15046
gat Asp	Thr	gcc Ala 4315	gga Gly	ctg Leu	gtg Val	cag Gln	acg Thr 1320	gac Asp	agc Ser	atc Ile	Ala	ctg Leu 1325	agc Ser	ggc Gly	gtg V al	15094
Pro					Arg	cag Gln 4335				qaA						15142
	Met			qaA		tcg Ser			Asn					Gly		15190
			Thr		Thr	cac His		Asp							Ser	15238
atc Ile	acc Thr	gat Asp	gca Ala 4380	Lys	ggt Gly	aat Asn	Leu	cag Gln 4385	cgt Arg	gtg Val	gca Ala	Tyr	gat Asp 4390	Val	gct Ala	15286
G1 y 999	ctg Lev	cta Leu 4395	Ser	ggc Gly	agt Ser	Trp	ttg Leu 4400	Thr	ctg Leu	aag Lys	qaA	ggc Gly 4405	Thi	gag Glu	g cag ı Gln	15334
		val					Tyr					Lys			g cgt 1 Ar g	15382
gaa Glu 442	ı Glu	a cạc ı Hi	ggo Gly	aac Asr	ggc Gly 4430	val	gta Val	acc Thr	tcg Ser	tat Tyr 4435	: Ile	tac Tyr	gag Glu	g ccc	g gaa Glu 4440	15430
aca Thi	a cag	g cg	c ctq g Lei	g acq u Thi 4449	c Gly	g att / Ile	aaa Lys	a acg	gaa Glu 4450	ı Arç	g Pro	tct Ser	gg	g cae y Hi: 445!	c gtt s Val	15478
gco	gg:	a gc	a aa	a gt	g cte	g caç	g gad	c cts	g cg	e ta	t acc	g tat	ga.	c cc	g gta	15526

Ala Gly A	la Lys Val 4460	_	Leu Arg T 4465	yr Thr Tyr <i>I</i> 44	Asp Pro Val	
	al Leu Ser			aa gag acc d lu Glu Thr <i>l</i> 4485		15574
				ac atc tac o yr Ile Tyr <i>I</i> 4500		15622
	eu Val Ser		Arg Glu M	itg gcc aat o Met Ala Asn 1 515		15670
				cc ctt cct a		15718
_		Tyr Thr Arg		egt tat gac o Arg Tyr Asp 4		15766
Asn Leu T			Ala Pro A	gcc acg aac Ala Thr Asn 4565		15814
		_	_	aat agg gcg Asn Arg Ala 4580		15862
	la Glu Val	-	Val Asp M	atg ctg ttc Met Leu Phe 595		15910
		· ·		gca ctg gtg Ala Leu Val		15958
				gtg cgt gat Val Arg Asp 4		16006
	Ser Glu Ser		Asp Ala	ggc agt cag Gly Ser Gln 4645	-	16054
_				gtt cag aca Val Gln Thr 4660		16102
			Arg Ile	atg gca aat Met Ala Asn 675		16150
		Gln Val Il		ggc gag gct Gly Glu Ala		16198

caa gtg cgc gta ttg cac tgg gag atc ggc aag ccg gat gac ctc gat Gln Val Arg Val Leu His Trp Glu Ile Gly Lys Pro Asp Asp Leu Asp 4700 4705 4710	16246
gag gac tcg gtg cgt tac agt tac gat aac ctg gtg ggc agc agc cag Glu Asp Ser Val Arg Tyr Ser Tyr Asp Asn Leu Val Gly Ser Ser Gln 4715 4720 4725	16294
ctg gag ctg gac aga gag ggt tac ctt atc agt gag gag gag ttc tac Leu Glu Leu Asp Arg Glu Gly Tyr Leu Ile Ser Glu Glu Glu Phe Tyr 4730 4735 4740	16342
ccg tat ggc gga acg gct gtt ctg acg gcg cga agt gag gtt gag gct Pro Tyr Gly Gly Thr Ala Val Leu Thr Ala Arg Ser Glu Val Glu Ala 4745 4750 4755 4760	16390
gac tac aaa act atc cga tac tca ggc aag gag cgt gac gcg acg ggg Asp Tyr Lys Thr Ile Arg Tyr Ser Gly Lys Glu Arg Asp Ala Thr Gly 4765 4770 4775	16438
ctg gat tat tac ggt tat cgg tat tac cag cca tgg gca ggg cgc tgg Leu Asp Tyr Tyr Gly Tyr Arg Tyr Tyr Gln Pro Trp Ala Gly Arg Trp 4780 4785 4790	16486
ctc tcc acg gac ccg gca ggc acg gtg gac ggg ctg aac ctg ttc cgc Leu Ser Thr Asp Pro Ala Gly Thr Val Asp Gly Leu Asn Leu Phe Arg 4795 4800 4805	16534
atg gtg cgg aat aat ccc gtc acg ctg ttt gac agc aac ggg cgg atc Met Val Arg Asn Asn Pro Val Thr Leu Phe Asp Ser Asn Gly Arg Ile 4810 4820	16582
agt act ggt cag gag gcc aga cga tta gtg ggg gaa gca ttt gtt cat Ser Thr Gly Gln Glu Ala Arg Arg Leu Val Gly Glu Ala Phe Val His 4825 4830 4835 4840	16630
ccg tta cac atg cct gtt ttt gaa aga att tct gta gag aga aag att Pro Leu His Met Pro Val Phe Glu Arg Ile Ser Val Glu Arg Lys Ile 4845 4850 4855	16678
tca atg agc gta agg gaa gct ggc att tat act att tca gcg ctg ggt Ser Met Ser Val Arg Glu Ala Gly Ile Tyr Thr Ile Ser Ala Leu Gly 4860 4865 4870	16726
gaa ggt gca gca aaa ggc cat aat att cta gag aaa acc att aaa Glu Gly Ala Ala Ala Lys Gly His Asn Ile Leu Glu Lys Thr Ile Lys 4875 4880 4885	16774
ccc ggt tcc ctg aag gct atc tat ggt gat aaa gct gag tca att ctt Pro Gly Ser Leu Lys Ala Ile Tyr Gly Asp Lys Ala Glu Ser Ile Leu 4890 4895 4900	16822
gga ctg gca aaa cgt agc ggt ctc gtt ggc cga gta gga cag tgg gat Gly Leu Ala Lys Arg Ser Gly Leu Val Gly Arg Val Gly Gln Trp Asp 4905 4910 4915 4920	16870
gca tca ggt gta cgt gga att tat gcg cac aac aga ccg ggt ggt gag	16918

Ala Ser Gly Val Arg Gly Ile Tyr Ala His Asn Arg Pro Gly Gly Glu 4925 4930 4935	
gat ttg gtt tat cct gtc agc ctg cag aat act tct gcc aat gaa att Asp Leu Val Tyr Pro Val Ser Leu Gln Asn Thr Ser Ala Asn Glu Ile 4940 4945 4950	1696 6
gtt aat gca tgg ata aaa ttt aaa atc atc acg ccc tac acc ggg gat Val Asn Ala Trp Ile Lys Phe Lys Ile Ile Thr Pro Tyr Thr Gly Asp 4955 4960 4965	17014
tat gac atg cac gat att att aaa ttc tct gat ggg aaa ggg cat gtg Tyr Asp Met His Asp Ile Ile Lys Phe Ser Asp Gly Lys Gly His Val 4970 4980	17062
cct aca gcg gaa agt agt gag gaa aga gga gta aaa gat cta att aat Pro Thr Ala Glu Ser Ser Glu Glu Arg Gly Val Lys Asp Leu Ile Asn 4985 4990 4995 5000	17110
aaa ggt gtt gcg gag gtc gat cct tcc aga ccc ttt gag tat aca gcg Lys Gly Val Ala Glu Val Asp Pro Ser Arg Pro Phe Glu Tyr Thr Ala 5005 5010 5015	17158
atg aat gtt att cgc cat gga cca cag gtg aac ttt gtt ccc tat atg Met Asn Val Ile Arg His Gly Pro Gln Val Asn Phe Val Pro Tyr Met 5020 5025 5030	17206
tgg gaa cat gag cac gat aaa gtc gtt aat gat aat ggt tat ctg ggg Trp Glu His Glu His Asp Lys Val Val Asn Asp Asn Gly Tyr Leu Gly 5035 5040 5045	17254
gtg gta gct agc ccg ggg ccg ttc ccg gta gcg atg gta cat cag ggg Val Val Ala Ser Pro Gly Pro Phe Pro Val Ala Met Val His Gln Gly 5050 5055 5060	17302
gaa tgg act gtt ttt gac aac agt gaa gaa ctg ttt aat ttc tat aaa Glu Trp Thr Val Phe Asp Asn Ser Glu Glu Leu Phe Asn Phe Tyr Lys 5065 5070 5075 5080	17350
tct aca aat aca cct ctt cct gaa cac tgg tcc caa gat ttt atg gac Ser Thr Asn Thr Pro Leu Pro Glu His Trp Ser Gln Asp Phe Met Asp 5085 5090 5095	17398
aga ggg aaa gga ata gtc gca act cct cgg cat gct gaa ctt ctt gat Arg Gly Lys Gly Ile Val Ala Thr Pro Arg His Ala Glu Leu Leu Asp 5100 5105 5110	17446
aaa cga cga gtc atg tac taa tcgtaacgat ttcctgcctt acccaaagta Lys Arg Arg Val Met Tyr 5115	17497
tacagecegg tgagacattt tetetgtete atttgggttg tttttgtete atetgeat	gt 17557
tatgtcttcc ctcatctaaa gtctaacgag acatttttag caaaatggca ctttacgg	tt 17617
atgttcgcgt ttcaaccgac ggtccggatt ttactctgta aatacagaca cttcgcgc	ag 17677
cctgctgcga aattatccgt gcgaaaaaag ccagcggcag cagccgggat ggacgaaa	tg 17737

aactgcaget tetgetgget tttttgegge caggeaacat getgatggtt aegtgagttg 17797 ateggetgee accaaaaagt eeggagegtg eggeeeagat egeegeaata ataetgetgt 17857 atggtatttc catcaccact gtatatcgca cactctgggc cttccagaaa ccccataccg 17917 cacaceggtg tgategetgg aageeeeggg cattacegee gtetgtaete gaacaetatt 17977 gtggacttga tggttaggag attgaatcga ccatttttga gatccctaac catagatcgt 18037 agagttgcac actcccagat ggcgtggctt agcgagcgat tatgcttaaa aattcatgtt 18097 ttgctgtgtt tttaatccaa aacctgcttt tcaggcgcac ttatccagct acggggtctg 18157 aagccatcgt ttttttgccg tacgatgtag cctgtcagag agcatttttg tggcgtgctc 18217 gcccgctacg gtaccggcgg caaaacgcag ccggcctttg cagaggatgc actggtacgg 18277 ateggtgeec aggaageett teateageae egegaaceeg ggeegttteg gttteteeeg 18337 taccgtcatc tccagcgcgt cgtaaacctt cggcagcagc gtgcccgttt gcggttggcc 18397 agaaaaccat agtaacgcac cattttaaaa tgccgtgcag ggatatggct gacgtaacgc 18457 tgcagcatct cctcctggct gattttctgg cgtttgtgct gctgcgtacg gtgatcgtaa 18517 tactgatgca ccacggcccc gccgcggtag tggcgtagct gagaagccgc caccggcggg 18577 cgcttcaggt accgggccag gtatttcacg ctgcgccagg cgccgcgggt ctttttggca 18637 aaattcactt tccaggggcg gcggtattgc gcatgcaggg tcttcgttgc ggatatggcc 18697 gagacccggc agggcgccag gattgatgcg cagcaggtga acgacggcat tgcgccagat 18757 ggettecace tetttetttt taaagaacag etgeegeeag aegtggtgtt tgaegteaag 18817 accgccgcgg gtaacggaga cgtggatatg cggatgttga ttgagctgcc ggccttaggt 18877 gtggagegeg caaaaaatge eggeetegat geeetgeegg egtgeeeage ggageatgge 18937

PCT/NZ00/00174

- (2) INFORMATION FOR SEQ ID NO: 2:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 144 amino acid residues
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: Linear
 - (ii) MOLECULE TYPE: PROTEIN (ORF 1)
 - (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
- Met Lys Ile Ser Ser Arg Gly Ile Ala Leu Ile Lys Glu Phe Glu Gly
 1 5 10 15
- Leu Arg Leu His Ala Tyr Arg Cys Ala Ala Asp Val Trp Thr Val Gly 20 25 30
- Tyr Gly His Thr Ala Gly Val Thr Lys Gly Asp Ile Ile Thr Val Asp 35 40 45
- Glu Ala Gln Thr Met Leu Thr Asn Asp Ile Thr Val Phe Glu Arg Ala 50 55 60
- Val Ser Gln Ala Val Ala Val Pro Leu Asn Gln Ser Gln Tyr Asp Ala 65 70 75 80
- Leu Val Ser Leu Val Phe Asn Ile Gly Gln Gly Asn Phe Lys Arg Ser 85 90 95
- Thr Leu Leu Lys Lys Leu Asn Lys Gln Asp Tyr Val Gly Ala Gly Asn 100 105 110
- Glu Phe Leu Arg Trp Thr Arg Ala Asn Gly Lys Val Leu Pro Gly Leu 115 120 125
- Ile Arg Arg Glu Ala Glu Arg Val Leu Phe Glu Lys Leu Gly
 130 135 140

Ala

- (2) INFORMATION FOR SEQ ID NO: 3:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 191 amino acid residues
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: Linear
 - (ii) MOLECULE TYPE: PROTEIN (ORF 2)
 - (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Met Ser Pro Ser Pro Leu Thr Gly Ala Ala Leu Met Glu Thr Lys Met

1 5 10 15

Lys Ile His Tyr Gln Val Ala Ala Val Val Leu Thr Gly Val Met Val
20 25 30

Trp Gly Leu Ser His Trp Arg Tyr Thr Val Gly Tyr His Ala Ala Asp
45

Thr Gln Trp Gln Gln Arg Gln Ala Glu Gln Glu Arg Ala Asp Ala Leu 50 60

Ala Leu Leu Ala Ala Glu Thr Arg Glu Arg Lys Trp Glu Gln Gln Arg
65 70 75 80

Gln Thr Asp Met Asn Lys Val Ala Ile His Ala Glu Glu Glu Leu Ala 85 90 95

Ala Ala Arg Asp Ala Ala Asp Ala Gln Arg Thr Gly Gln Arg Leu
100 105 110

Gln His Thr Val Thr Thr Leu Gln Arg Gln Leu Ala Ser Arg Glu Thr 115 120 125

Arg Arg Leu Ser Ala Ala Thr Ala Ile Gly Thr Asp Asp Leu Gly Gly
130 140

Gln Pro Gly Val Leu Phe Ala Glu Leu Phe Arg Arg Ala Asp Gln Arg 145 150 155 160

Ala Gly Glu Leu Ala Ala Tyr Ala Asp Arg Thr Arg Val Lys Trp Gln
165 170 175

Ala Cys Gly Arg Ala Tyr Gln Ala Ala Thr His Glu Ala Glu Lys 180 185 190

(2) INFORMATION FOR SEO ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2376 amino acid residues
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: Linear
- (ii) MOLECULE TYPE: PROTEIN (SepA)
- (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
- Met Arg Gln Asp Ile Met Tyr Asn Ile Asp Asp Ile Leu Glu Lys Val
- Asn Ala Pro Arg Ala Arg Leu Ser Glu Glu Asn Asp Thr Ala Val Thr
 20 25 30
- Leu Thr Asp Leu Phe Ser Arg Ser Phe Pro Glu Val Lys Lys Ile Thr
 35 40 45
- Gly Asp Ser Leu Ser Trp Gly Glu Val Cys Tyr Leu Tyr Ser Gln Ala 50 55 60
- Gln His Glu Gln Lys Glu Asn Arg Leu Thr Glu Ser Arg Ile Leu Ala 65 70 75 80
- Arg Ala Asn Pro Leu Leu Val Asn Ala Val Arg Leu Gly Ile Arg Gln 85 90 95
- Ala Ala Gly Ser Arg Ser Tyr Asp Asp Trp Phe Gly Ser Arg Ala Asp 100 105 110
- Arg Phe Ala Arg Pro Gly Ser Val Ala Ser Met Phe Ser Pro Ala Ala 115' 120 125
- Tyr Leu Thr Glu Leu Tyr Arg Glu Ala Lys Asp Leu His Pro Asp Thr 130 135 140
- Ser Leu Phe Arg Leu Asp Ile Arg Arg Pro Asp Leu Ala Ala Leu Ala 145 150 155 160
- Leu Ser Gln Asn Asn Met Asp Asp Glu Leu Ser Thr Leu Ser Leu Ser 165 170 175
- Asn Glu Leu Leu Tyr Arg Gly Ile Gly Ala Ala Glu Gly Leu Asp Asp 180 185 190

and and only

As	o Se		/al 195	Arg	Glu	Leu	Leu	Ala 200	Gly	Tyr	Arg	Leu	Thr 205	Gly	Leu	Thr
Pre	21	r H	lis	Trp	Ala	Tyr	Glu 215	Ala	Ala	Arg	Gln	Ala 220	Ile	Leu	Val	Gln
As ₁	p Pro) 1	Thr	Leu	Met	Gly 230	Phe	Ser	Arg	Asn	Pro 235	Asp	Val	Ala	Gln	Leu 240
Me	t As	p I	Pro	Ala	Ser 245	Met	Leu	Ala	Ile	Glu 250	Ala	Asp	Ile	Ser	Pro 255	Glu
Le	а Ту:	rc	3ln	11e 260	Leu	Ala	Glu	Glu	11e 265	Thr	Thr	Asp	Ser	Tyr 270	Glu	Ala
Let	ı Tr		Ser 275	Lys	Asn	Phe	Gly	Asp 280	Met	Pro	Pro	Ser	Ser 285	Leu	Leu	Ser
Ту	29	⊋ <i>₽</i> O	Ala	Leu	Ala	Thr	Phe 295	Tyr	Asp	Leu	qaA	Tyr 300	Asp	Glu	Leu :	
Se:	r Le	1 I	Leu	Ser	Leu	Arg 310	Leu	Asp	Phe	Ser	Asn 315	Pro	Asn	Asn	Glu	Tyr 320
Ту	r Il	≥ <i>}</i>	Asn	Ser	Gln 325	Leu	Ser	Val	Val	Thr 330	Leu	Asn	Glu	Ser	Thr 335	Gly
Let	ıIl	e 1	Chr	Ile 340	His	His	Tyr	Leu	Arg 345	Thr	Leu	Gly	Gly	Asp 350	Ser	Gln
Gli	n Ile	e <i>p</i>	Asn 355	Pro	Glu	Leu	Ile	Pro 360	Tyr	Gly	A sp	Gly	Thr 365	Tyr	Leu	Tyr
Ası	37		Ser	Val	Val	Ser	Thr 375	Ile	Ser	Glu	Asp	Ser 380	Phe	Lys	Leu	Gly
Se:	r Le	ı (3ly	Ser	Asn	Ser 390	Ser	Asn	Leu	Tyr	Ser 395	Gly	Asp	Tyr	Gln	Leu 400
Glı	ı Ly:	s C	3ly	Val	Arg 405	Tyr	Ser	Ile	Pro	Val 410	Glu	Ile	qaA	Glu	Gly 415	Lys
Let	ı Ası	a A	qa/	Gly 420	Ile	Thr	Ile	Gly	Leu 425	Ser	Arg	Lys	Gly	Gly 430	Gly	Tyr
Ту	r Se:		thr 135	Val	naA	Phe	Thr	Leu 440	Ile	Glu	Tyr	Asp	Pro 445	Ala	Ile	Phe
116	45	ı I	ŗλε	Leu	Asn	Lys	Val 455	Ile	Arg	Leu	Tyr	Lys 460	Ala	Thr	Gly	Met
Th:	r Th	c P	Ala	Glu	Ile	Tyr 470	Gln	Ile	Thr	Asn	Ile 475	Leu	Asn	naA	Gly	Leu 480
Th	r Ile	e <i>P</i>	/ap	His	Ala 485	Val	Leu	Ser	Lys	Ile 490	Phe	Leu	Val	Arg	Tyr 495	Leu
Me	Ar	g ŀ	lis	Tyr	Gln	Leu	qaA	Val	Ala	Arg	Ser	Leu	lle	Leu	Сув	Asn

510 500 505 Gly Thr Ile Ser Asp Gln Ala Phe Ser Gly Glu Thr Gly Leu Phe Thr 520 Thr Leu Phe Asn Thr Pro Pro Leu Asn Gly Gln Leu Phe Ser Ala Asp 535 Asp Thr Pro Leu Asp Leu Arg Ser Glu Ala Pro Glu Asp Ala Phe Arg 555 Leu Ser Val Leu Lys Arg Ala Phe Asn Ile Ser Ala Ser Gly Leu Ser 570 Thr Leu Trp Gln Leu Ala Ser Gly Asp Ser Ser Ala Gly Phe Ser Cys 585 Ser Ala Asp Asn Ile Ala Ala Leu Tyr Arg Val Lys Leu Leu Ala Asp 600 Ile His Asp Leu Ser Ala Gly Glu Leu Ser Met Leu Leu Ser Val Ser Pro Phe Ser Gly Val Ala Ala Gly Ser Leu Ser Asp Asn Glu Leu Thr Gln Phe Leu Tyr Gln Thr Thr Trp Leu Thr Glu Gln Gly Trp Thr Val Ser Asp Val Phe Leu Met Leu Thr Thr Gln Tyr Gly Thr Leu Leu Thr Pro Asp Ile Glu Asn Leu Leu Ala Ser Leu Arg Asn Gly Leu Ser 680 Gly Arg Glu Leu Phe Pro Glu Thr Leu Pro Gly Asp Gly Ala Pro Phe 695 Ile Ala Ala Met Gln Leu Asp Ala Thr Asp Thr Ala Lys Ala Met Leu Thr Trp Ala Asp Gln Leu Lys Pro Glu Gly Leu Thr Leu Thr Glu 730 Phe Ile Leu Leu Val Met Asn Ala Pro Asn Asp Glu Gln Ala Gly 745 Gln Met Ala Gly Phe Cys Gln Ala Leu Trp Gln Leu Ala Leu Ile Ile Arg Ser Thr Gly Leu Ser Thr Arg Glu Leu Thr Leu Leu Val Ser Gln 775 Pro Gly Arg Phe Arg Thr Gly Trp His His Leu Pro His Asp Leu Pro 795 Ala Leu Arg Asp Ile Thr Arg Phe His Ala Val Val Asn Arg Ser Gly

810

- Ser His Ala Gly Glu Val Leu Thr Ala Leu Glu Thr Gly Glu Leu Ser 820 825 830
- Ser Ala Leu Leu Ala Arg Ala Leu Ser Gln Asn Glu Gln Asp Val Thr 835 840 845
- Gly Ala Leu Ala Gln Val Arg Gly Ala Gly Glu Gln Asp Asn Ser Val 850 855 860
- Phe Thr Ser Trp Glu Glu Val Asp Gln Ala Glu Gln Trp Leu Asp Met 865 870 875 880
- Ser Glu Thr Leu Ser Ile Thr Pro Ser Gly Leu Ala Ser Leu Ile Ala 885 890 895
- Leu Lys Tyr Ile Asn Val Ser Asp Asp Ser Ala Pro Leu Tyr Ser Gln
 900 905 910
- Trp Gln Val Val Ser Gly Leu Leu Gln Ala Gly Leu Lys Ser Ser Gln
 915
 920
 925
- Ser Ser Ala Leu His Asp Tyr Leu Glu Glu Gly Thr Ser Ser Ala Leu 930 935 940
- Cys Ala Tyr Tyr Leu Arg Asn Leu Ala Pro Asn Met Val Ser Gly Arg 945 950 955 960
- Asp Asp Leu Phe Gly Tyr Leu Leu Leu Asp Asn Gln Val Ser Ala Lys 965 970 975
- Val Lys Thr Thr Arg Ile Ala Glu Ala Ile Ala Gly Ile Arg Leu Tyr 980 985 990
- Ile Asn Arg Ala Leu Asn Gly Ile Glu Leu Ser Ala Met Ala Glu Val 995 1000 1005
- Arg Gly Arg Gln Phe Phe Thr Asp Trp Asp Thr Phe Asn Lys Arg Tyr 1010 1015 1020
- Ser Thr Trp Ala Gly Val Ser Glu Leu Val Tyr Tyr Pro Glu Asn Tyr 025 1030 1035 1040
- Leu Asp Pro Thr Val Arg Ile Gly Gln Thr Gly Met Met Asp Thr Leu 1045 1050 1055
- Leu Gln Ser Val Ser Gln Ser Ser Ile Asn Arg Asp Thr Val Glu Asp 1060 1065 1070
- Ala Phe Lys Thr Tyr Leu Thr Thr Phe Glu Gln Ile Ala Asn Leu Asn 1075 1080 1085
- Thr Val Ser Gly Tyr His Asp Asn Ala Ser Met Thr Gln Gly Thr Thr 1090 1095 1100
- Trp Tyr Val Gly Arg Ser Ile Thr Asp Gln Thr Asn Trp Tyr Trp Arg
 105 1110 1115 1120

- Ser Ala Asn His Ser Lys Ile Gln Asp Ser Met Met Pro Ala Asn Ala 1125 1130 1135
- Trp Thr Gly Trp Thr Lys Ile Asn Cys Gly Met Asn Pro Trp Ser Asp
- Leu Val Cys Ser Val Phe Phe Asn Ser Arg Leu Tyr Val Val Trp Val
 1155 1160 1165
- Glu Glu Asn Gln Ser Ala Asp Thr Glu Ala Glu Ser Thr Thr Thr 1170 1175 1180
- Gln Gln Ser Tyr Thr Leu Lys Leu Ser Phe Arg Arg Tyr Asp Gly Thr 185 1190 1195 1200
- Trp Ser Ser Pro Val Ser Phe Asp Ile Thr Gly Asn Ile Ala Phe Pro 1205 1210 1215
- Glu Thr Gln Gly Met His Val Thr Cys Asn Pro Leu Thr Glu Gln Leu 1220 1225 1230
- Tyr Cys Ala Phe Tyr Ser Val Thr Ser Lys Pro Asp Phe Asp Asn Ala 1235 1240 1245
- Gln Leu Ile Ser Val Asp Asn Asp Met Thr Leu Asn Val Ile Ser Asp 1250 1260
- Ile Gly Ile Phe Lys Ser Val Ser His Glu Phe Asn Thr Ser Thr Glu 265 1270 1275 1280
- Lys Phe Ile Asn Asn Val Phe Ser Asp Pro Ser Ala Asn Tyr Phe Val
- Ser Ala Thr Ser Leu Ile Asp Asp Val Ile His Ser Asp Phe Ser Leu 1300 1305 1310
- Leu Asn Ser Lys Thr Thr Ser Thr Val Phe Thr Asn Glu Asp Ser Ser 1315 1320 1325
- Leu Leu Thr Pro Glu Leu His Ile Thr Ala Asn Val Ser Cys Phe Val 1330 1335 1340
- Ser Thr Ala Gly Ile Ala Thr Gln Ser Thr Ile Glu Lys Phe Val Gln 345 1350 1355 1360
- Ala Gly Ile Glu Phe Glu Glu Ile Asn Phe Tyr Ala Gly Gln Ala Ala 1365 1370 1375
- Gly Gly Phe Asp Gly Phe Val Gly Val Asp Val Ser Asn Ser Lys Val 1380 1385 1390
- Tyr Gln Val Gly Lys Glu Ala Val Gly Val Thr Val Lys Ser Tyr Ser 1395 1400 1405
- Val Thr Gly Val Ser Gly Ser Val Glu Leu Phe Ile Asp Ser Ser Asn 1410 1415 1420
- Lys Tyr Phe Ser Gly Ile Leu Ser Asp Lys Met Ile Thr Ala Leu Ile

1430 1440 425 1435 Ser Gly Ser Thr Ser Lys Val Asn Tyr Val Ser Ser Ile Gly Ser Gln 1445 1450 Asp Phe Trp Ser Val Lys Ser Leu Met Pro Ala Leu Gln Ile Tyr Glu 1460 1465 Leu Ile Asp Asp Ile Ile Leu Thr Ser Gly Val Asn Gly Thr Glu Ile 1480 Lys Ser Trp Pro Ser Ala Glu Trp Tyr Asn Asp Lys Leu Ser Leu Gln 1495 1500 Ser Gly Asn Asn Leu Phe Asn Thr Lys Ser Leu Ser Phe Thr Val Asn 1510 1515 Thr Ser Asp Ile Val Glu Asp Glu Phe Asp Val Thr Phe Thr Phe Thr 1530 Ala Val Asp Gln Asn Asn Val Val Leu Ala Ala Arg Thr Ala Ile Leu Thr Val Ile Arg Asn Ile Asn Asn Asp Thr Ser Val Ile Ala Leu Arg 1560 Lys Asn Thr Arg Gly Ala Gln Tyr Ile Arg Phe Thr Ala Gly Asn Asp Val Ala Leu Ile Arg Leu Asn Thr Leu Phe Ala Arg Gln Leu Val Asp 1590 Arg Ala Asn Thr Gly Ile Asp Thr Ile Leu Ser Met Glu Thr Gln Arg 1610 1605 Leu Thr Glu Pro Ala Leu Glu Glu Gly Ser Asp Val Phe Met Asp Phe 1625 Ser Gly Ala Asn Ala Leu Tyr Phe Trp Glu Leu Phe Tyr Tyr Thr Pro 1635 1640 Met Met Val Phe Gln Arg Leu Leu Gln Glu Gln His Phe Pro Glu Ala 1655 Thr Arg Trp Leu Gln Tyr Val Trp Asn Pro Ala Gly His Val Val Asn 1675 1670 Gly Val Leu Gln Asn Tyr Thr Trp Asn Val Arg Pro Leu Glu Glu Asp 1690 Thr Gly Trp Asn Asp Ser Pro Leu Asp Ser Ile Asp Pro Asp Ala Ile 1705 Ala Gln Tyr Asp Pro Met His Tyr Lys Val Ala Thr Phe Met Ser Tyr Leu Asp Leu Leu Ile Ala Arg Gly Asp Ala Ala Tyr Arg Leu Leu Glu

- Arg Asp Thr Leu Asn Glu Ala Arg Met Trp Tyr Val Gln Ala Leu Asn 745 1750 1755 1760
- Leu Leu Gly Asp Glu Pro Tyr Ile Ser Phe Asp Ala Asp Trp Ser Ala 1765 1770 1775
- Leu Thr Leu Gly Asp Ala Ala Ser Glu Val Thr Arg Arg Asp Tyr Gln
 1780 1785 1790
- Glu Ala Leu Leu Ala Val Arg Arg Leu Val Pro Ala Pro Glu Thr Arg 1795 1800 1805
- Thr Ala Asn Ser Leu Thr Ala Leu Phe Leu Pro Gln Gln Asn Glu Val 1810 1815 1820
- Leu Lys Gly Tyr Trp Gln Thr Leu Ala Gln Arg Leu His Asn Leu Arg 825 1830 1835 1840
- His Asn Leu Ser Ile Asp Gly Gln Pro Leu Ser Leu Ser Val Tyr Ala 1845 1850 1855
- Thr Pro Ser Glu Pro Ser Ala Leu Gln Ser Ala Val Val Asn Ser Ala 1860 1865 1870
- Gln Gly Ala Ala Leu Pro Ala Ala Val Met Pro Leu Tyr Ser Phe 1875 1880 1885
- Pro Val Met Leu Glu Asn Ala Arg Gly Met Val Ser Leu Leu Thr Gly
 1890 1895 1900
- Phe Gly Asn Thr Leu Leu Gly Ile Thr Glu Arg Gln Asp Ala Glu Ala 905 1910 1915 1920
- Leu Ala Lys Leu Leu Gln Thr Gln Gly Ser Glu Leu Ile Arg Gln Gly
 1925 1930 1935
- Leu Arg Gln Gln Asp Asn Val Leu Glu Glu Ile Asp Ala Asp Ile Ala 1940 1945 1950
- Ala Leu Glu Glu Ser Arg Arg Gly Ala Gln Met Arg Phe Glu Arg Tyr 1955 1960 1965
- Lys Val Leu Tyr Glu Ala Asp Val Asn Thr Gly Glu Lys Gln Ala Met 1970 1975 1980
- Asp Leu Tyr Leu Ser Ser Ser Val Leu Ser Ala Ser Thr Ala Ala Leu 985 1990 1995 2000
- Phe Leu Ala Glu Ala Ala Asp Met Leu Pro Asn Ile Tyr Gly Leu 2005 2010 2015
- Ala Val Gly Gly Ser Arg Tyr Gly Ala Leu Phe Lys Ala Thr Ala Ile 2020 2025 2030
- Gly Ile Gln Val Ser Ser Asp Ala Thr Arg Ile Ser Ala Asp Lys Ile 2035 2040 2045

- Ser Gln Ser Glu Val Tyr Arg Arg Arg Glu Glu Trp Glu Ile Gln 2050 2055 2060
- Arg Asp Ser Ala Gln Ser Asp Val Ala Gln Ile Asp Ala Gln Leu Ala 065 2070 2080
- Ala Met Ala Val Arg Arg Glu Gly Ala Glu Leu Gln Lys Thr Tyr Leu 2085 2090 2095
- Glu Thr Gln Gln Thr Gln Ala Gln Ala Gln Leu Ala Phe Leu Gln Ser 2100 2105 2110
- Lys Phe Asn Asn Thr Ala Leu Tyr Ser Trp Leu Arg Gly Arg Leu Ser 2115 2120 2125
- Ala Ile Tyr Tyr Gln Phe Tyr Asp Leu Ala Val Ser Arg Cys Leu Met 2130 2140
- Ala Gln Gln Ala Trp Gln Trp Asp Lys Phe Glu Thr Arg Ser Phe Ile 145 2150 2155 2160
- Gln Pro Gly Ala Trp Met Gly Ala Asn Ala Gly Leu Leu Ala Gly Glu 2165 2170 2175
- Thr Leu Met Leu Asn Leu Ala Gln Met Glu Gln Ala Trp Leu Thr Gly
 2180 2185 2190
- Asp Glu Arg Ala Ile Glu Val Thr Arg Thr Val Cys Leu Ser Glu Val 2195 2200 2205
- Tyr Thr Ser Leu Ala Glu Asp Ala Ala Phe Ser Leu Ala Asp Lys Val 2210 2215 2220
- Val Glu Leu Val Ser Asn Gly Ser Gly Ser Ala Gly Thr Lys Ser Asn 225 2230 2235 2240
- Gly Leu Gln Met Asp Gln Gln Gln Leu Glu Ala Thr Leu Lys Leu Ala 2245 2250 2255
- Asp Leu Gly Ile Gly Asn Asp Tyr Pro Val Ser Leu Gly Thr Met Arg 2260 2265 2270
- Arg Ile Lys Gln Ile Ser Val Thr Leu Pro Ala Leu Val Gly Pro Tyr 2275 2280 2285
- Gln Asp Val Arg Ala Val Leu Ser Tyr Gly Gly Ser Met Val Met Pro 2290 2295 2300
- Arg Gly Cys Ser Ala Leu Ala Val Ser His Gly Met Asn Asp Ser Gly 305 2310 2315 2320
- Gln Phe Gln Leu Asp Phe Asn Asp Pro Arg Tyr Leu Pro Phe Glu Gly
 2325 2330 2335
- Leu Pro Val Asp Asp Thr Gly Thr Leu Thr Leu Ser Phe Pro Asp Ala 2340 2350
- Asp Gly Lys Gln Gln Ala Met Leu Leu Ser Leu Ser Asp Ile Ile Leu 2355 2360 2365
- His Ile Arg Tyr Thr Ile Ile Ser

- (2) INFORMATION FOR SEQ ID NO: 5:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1429 amino acid residues
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: Linear
 - (ii) MOLECULE TYPE: PROTEIN (SepB)
 - (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Met Gln Asn His Gln Asp Met Ala Ile Thr Ala Pro Thr Leu Pro Ser 1 5 10 15

Gly Gly Gly Ala Val Thr Gly Leu Lys Gly Asp Ile Ala Ala Gly 20 25 30

Pro Asp Gly Ala Ala Thr Leu Ser Ile Pro Leu Pro Val Ser Pro Gly
35 40 45

Arg Gly Tyr Ala Pro Thr Gly Ala Leu Asn Tyr His Ser Arg Ser Gly 50 60

- Asn Gly Pro Phe Gly Ile Gly Trp Gly Ile Gly Gly Ala Ala Val Gln 65 70 75 80
- Arg Arg Thr Arg Asn Gly Ala Pro Thr Tyr Asp Asp Thr Asp Glu Phe
 85 90 95
- Thr Gly Pro Asp Gly Glu Val Leu Val Pro Ala Leu Thr Ala Ala Gly
 100 105 110
- Thr Gln Glu Ala Arg Gln Ala Thr Ser Leu Leu Gly Ile Asn Pro Gly
 115 120 125
- Gly Ser Phe Asn Val Gln Val Tyr Arg Ser Arg Thr Glu Gly Ser Leu 130 135 140
- Ser Arg Leu Glu Arg Trp Leu Pro Ala Asp Glu Thr Glu Thr Glu Phe 145 150 155 160
- Trp Val Leu Tyr Thr Pro Asp Gly Gln Val Ala Leu Leu Gly Arg Asn 165 170 175
- Ala Gln Ala Arg Ile Ser Asn Pro Thr Ala Pro Thr Gln Thr Ala Val 180 185 190
- Trp Leu Met Glu Ser Ser Val Ser Leu Thr Gly Glu Gln Met Tyr Tyr 195 200 205
- Gln Tyr Arg Ala Glu Asp Asp Gly Cys Asp Glu Ala Glu Arg Asp 210 215 220
- Ala His Pro Gln Ala Gly Ala Gln Arg Tyr Pro Val Ala Val Trp Tyr 225 230 235 240
- Gly Asn Arg Gln Ala Ala Arg Thr Leu Pro Ala Leu Val Ser Thr Pro 245 250 255
- Ser Met Asp Ser Trp Leu Phe Ile Leu Val Phe Asp Tyr Gly Glu Arg 260 265 270
- Ser Ser Val Leu Ser Glu Ala Pro Ala Trp Gln Thr Pro Gly Ser Gly 275 280 285
- Glu Trp Leu Cys Arg Gln Asp Cys Phe Ser Gly Tyr Glu Phe Gly Phe 290 295 300
- Asn Leu Arg Thr Arg Arg Leu Cys Arg Gln Val Leu Met Phe His Tyr 305 310 315 320
- Leu Gly Val Leu Ala Gly Ser Ser Gly Ala Asn Asp Ala Pro Ala Leu 325 330 335
- Ile Ser Arg Leu Leu Leu Asp Tyr Arg Glu Ser Pro Ser Leu Ser Leu 340 345 350
- Leu Glu Asn Val His Gln Val Ala Tyr Glu Ser Asp Gly Thr Ser Cys 355 360 365

Ala Leu Pro Ala Leu Ala Leu Gly Trp Gln Thr Phe Thr Pro Pro Thr 370 375 380

Leu Ser Ala Trp Gln Thr Arg Asp Asp Met Gly Lys Leu Ser Leu Leu 385 390 395 400

Gln Pro Tyr Gln Leu Val Asp Leu Asn Gly Glu Gly Val Val Gly Ile 405 410 415

Leu Tyr Gln Asp Ser Gly Ala Trp Trp Tyr Arg Glu Pro Val Arg Gln
420 425 430

Ser Gly Asp Asp Pro Asp Ala Val Thr Trp Gly Ala Ala Ala Leu 435 440 445

Pro Thr Met Pro Ala Leu His Asn Ser Gly Ile Leu Ala Asp Leu Asn 450 455 460

Gly Asp Gly Arg Leu Glu Trp Val Val Thr Ala Pro Gly Val Ala Gly
465 470 475 480

Met Tyr Asp Arg Thr Pro Gly Arg Asp Trp Leu His Phe Thr Pro Leu
485 490 495

Ser Ala Leu Pro Val Glu Tyr Ala His Pro Lys Ala Val Leu Ala Asp 500 505 510

Ile Leu Gly Ala Gly Leu Thr Asp Met Val Leu Ile Gly Pro Arg Ser 515 520 525

Val Arg Leu Tyr Ser Gly Lys Asn Asp Gly Trp Asn Lys Gly Glu Thr 530 535 540

Val Gln Gln Thr Glu Arg Leu Thr Leu Pro Val Pro Gly Val Asp Pro 545 550 555

Arg Thr Leu Val Ala Phe Ser Asp Met Ala Gly Ser Gly Gln Gln His 565 570 575

Leu Thr Glu Val Arg Ala Asn Gly Val Arg Tyr Trp Pro Asn Leu Gly 580 585 590

His Gly Arg Phe Gly Gln Pro Val Asn Ile Pro Gly Phe Ser Gln Ser 595 600 605

Val Thr Thr Phe Asn Pro Asp Gln Ile Leu Leu Ala Asp Thr Asp Gly 610 615 620

Ser Gly Thr Thr Asp Leu Ile Tyr Ala Met Ser Asp Arg Leu Val Ile 625 630 635 640

Tyr Phe Asn Gln Ser Gly Asn Tyr Phe Ala Glu Pro His Thr Leu Leu 645 650 655

Leu Pro Lys Gly Val Arg Tyr Asp Arg Thr Cys Ser Leu Gln Val Ala
660 665 670

Asp Ile Gln Gly Leu Gly Val Pro Ser Leu Leu Leu Thr Val Pro His

675 680 685 Val Ala Pro His His Trp Val Cys His Leu Ser Ala Asp Lys Pro Trp 695 700 Leu Leu Asn Gly Met Asn Asn Met Gly Ala Arg His Ala Leu His 710 Tyr Arg Ser Ser Val Gln Phe Trp Leu Asp Glu Lys Ala Glu Ala Leu Ala Ala Gly Ser Ser Pro Ala Cys Tyr Leu Pro Phe Thr Leu His Thr Leu Trp Arg Ser Val Val Gln Asp Glu Ile Thr Gly Asn Arg Leu Val Ser Asp Val Leu Tyr Arg His Gly Val Trp Asp Gly Gln Glu Arg Glu 775 Phe Arg Gly Phe Gly Phe Val Glu Ile Arg Asp Thr Asp Thr Leu Ala Ser Gln Gly Thr Ala Thr Glu Leu Ser Met Pro Ser Val Ser Arg Asn Trp Tyr Ala Thr Gly Val Pro Ala Val Asp Glu Arg Leu Pro Glu Thr Tyr Trp Gln Asn Asp Ala Ala Ala Phe Ala Asp Phe Ala Thr Arg Phe Thr Val Gly Ser Gly Glu Asp Glu Gln Thr Tyr Thr Pro Asp Asp Ser Lys Thr Phe Trp Leu Gln Arg Ala Leu Lys Gly Ile Leu Leu Arg Ser Glu Leu Tyr Gly Ala Asp Gly Ser Ser Gln Ala Asp Ile Pro Tyr Ser 885 890 Val Thr Glu Ser Arg Pro Gln Val Arg Leu Val Glu Ala Asn Gly Asp 905 Tyr Pro Val Val Trp Pro Met Gly Ala Glu Ser Arg Thr Ser Val Tyr Glu Arg Tyr His Asn Asp Pro Gln Cys Gln Gln Gln Ala Val Leu Leu Ser Asp Glu Tyr Gly Phe Pro Leu Arg Gln Val Ser Val Asn Tyr Pro 950 955 Arg Arg Pro Pro Ser Ala Asp Asn Pro Tyr Pro Ala Ser Leu Pro Ala 965 Thr Leu Phe Ala Asn Ser Tyr Asp Glu Gln Gln Ile Leu Arg Leu

- Gly Leu Gln Gln Ser Ser Ala His His Leu Val Ser Leu Ser Glu Gly
 995 1000 1005
- His Trp Leu Leu Gly Leu Ala Glu Ala Ser Arg Asp Asp Val Phe Thr
 1010 1015 1020
- Tyr Ser Ala Asp Asn Val Pro Glu Gly Gly Leu Thr Leu Glu His Leu 025 1030 1035 1040
- Leu Ala Pro Glu Ser Leu Val Ser Asp Ser Gln Val Gly Thr Leu Ala 1045 1050 1055
- Gly Gln Gln Val Trp Tyr Leu Asp Ser Gln Asp Val Ala Thr Val 1060 1065 1070
- Ala Ala Pro Pro Leu Pro Pro Lys Val Ala Phe Ile Glu Thr Ala Val 1075 1080 1085
- Leu Asp Glu Gly Met Val Ser Ser Leu Ala Ala Tyr Ile Val Asp Glu 1090 1095 1100
- His Leu Glu Gln Ala Gly Tyr Arg Gln Ser Gly Tyr Leu Phe Pro Arg 105 1110 1115 1120
- Gly Arg Glu Ala Glu Gln Ala Leu Trp Thr Gln Cys Gln Gly Tyr Val 1125 1130 1135
- Thr Tyr Ala Gly Ala Glu His Phe Trp Leu Pro Leu Ser Phe Arg Asp 1140 1145 1150
- Ser Met Leu Thr Gly Pro Val Thr Val Thr Arg Asp Ala Tyr Asp Cys 1155 1160 1165
- Val Ile Thr Gln Trp Gln Asp Ala Ala Gly Ile Val Thr Thr Ala Asp 1170 1180
- Tyr Asp Trp Arg Phe Leu Thr Pro Val Arg Val Thr Asp Pro Asn Asp 185 1190 1195 1200
- Asn Leu Gln Ser Val Thr Leu Asp Ala Leu Gly Arg Val Thr Thr Leu 1205 1210 1215
- Arg Phe Trp Gly Thr Glu Asn Gly Ile Ala Thr Gly Tyr Ser Asp Ala 1220 1225 1230
- Thr Leu Ser Val Pro Asp Gly Ala Ala Ala Leu Ala Leu Thr Ala 1235 1240 1245
- Pro Leu Pro Val Ala Gln Cys Leu Val Tyr Val Thr Asp Ser Trp Gly 1250 1255 1260
- Asp Asp Asp Asn Glu Lys Met Pro Pro His Val Val Leu Ala Thr 265 1270 1275 1280
- Asp Arg Tyr Asp Ser Asp Thr Gly Gln Gln Val Arg Gln Gln Val Thr 1285 1290 1295

- Phe Ser Asp Gly Phe Gly Arg Glu Leu Gln Ser Ala Thr Arg Gln Ala 1300 1305 1310
- Glu Gly Asn Ala Trp Gln Arg Gly Arg Asp Gly Lys Leu Val Thr Ala 1315 1320 1325
- Ser Asp Gly Leu Pro Val Thr Val Ala Thr Asn Phe Arg Trp Ala Val 1330 1335 1340
- Thr Gly Arg Ala Glu Tyr Asp Asn Lys Gly Leu Pro Val Arg Val Tyr 345 1350 1355 1360
- Gln Pro Tyr Phe Leu Asp Ser Trp Gln Tyr Val Ser Asp Asp Ser Ala 1365 1370 1375
- Arg Gln Asp Leu Tyr Ala Asp Thr His Phe Tyr Asp Pro Thr Ala Arg 1380 1385 1390
- Glu Trp Gln Val Ile Thr Ala Lys Gly Glu Arg Arg Gln Val Leu Tyr 1395 1400 1405
- Thr Pro Trp Phe Val Val Ser Glu Asp Glu Asn Asp Thr Val Gly Leu 1410 1415 1420

Asn Asp Ala Ser 425

- (2) INFORMATION FOR SEQ ID NO: 6:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 973 amino acid residues
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: Linear
 - (ii) MOLECULE TYPE: PROTEIN (SepC)
 - (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met Ser Thr Ser Leu Phe Ser Ser Thr Pro Ser Val Ala Val Leu Asp 1 5 10 15

Asn Arg Gly Leu Leu Val Arg Glu Leu Gln Tyr Tyr Arg His Pro Asp 20 25 30

Thr Pro Glu Glu Thr Asp Glu Arg Ile Thr Cys His Gln His Asp Glu
35 40 45

Arg Gly Ser Leu Ser Gln Ser Ala Asp Pro Arg Leu His Ala Ala Gly
50 55 60

Leu Thr Asn Phe Thr Tyr Leu Asn Ser Leu Thr Gly Thr Val Leu Gln 65 70 75 80

Ser Val Ser Ala Asp Ala Gly Thr Ser Leu Glu Leu Ser Asp Ala Ala 85 90 95

Gly Arg Ala Phe Leu Ala Val Thr Gly Ala Gly Thr Glu Asp Ala Val 100 105 110

Thr Arg Thr Trp Gln Tyr Glu Asp Asp Thr Leu Pro Gly Arg Pro Leu 115 120 125

Ser Ile Thr Glu Gln Val Thr Gly Glu Ala Ala Gln Ile Thr Glu Arg 130 135 140

Phe Val Tyr Ala Gly Asn Thr Asp Ala Glu Lys Ile Leu Asn Leu Ala 145 150 155 160

Gly Gln Cys Val Ser His Tyr Asp Thr Ala Gly Leu Val Gln Thr Asp 165 170 175

Ser Ile Ala Leu Ser Gly Val Pro Leu Ala Val Thr Arg Gln Leu Leu 180 185 190

Pro Asp Ala Ala Gly Ala Asn Trp Met Gly Glu Asp Ala Ser Ala Trp
195 200 205

Asn Asp Leu Leu Asp Gly Glu Thr Phe Phe Thr Gln Thr His Ala Asp 210 215 220

Ala Thr Gly Ala Val Leu Ser Ile Thr Asp Ala Lys Gly Asn Leu Gln 225 230 235 240

Arg Val Ala Tyr Asp Val Ala Gly Leu Leu Ser Gly Ser Trp Leu Thr
245 250 255

Leu Lys Asp Gly Thr Glu Gln Val Ile Val Ala Ser Leu Thr Tyr Ser 260 265 270

Ala Ala Gly Lys Lys Leu Arg Glu Glu His Gly Asn Gly Val Val Thr 275 280 285

Ser Tyr Ile Tyr Glu Pro Glu Thr Gln Arg Leu Thr Gly Ile Lys Thr 290 295 300

Glu Arg Pro Ser Gly His Val Ala Gly Ala Lys Val Leu Gln Asp Leu 305 310 315 320

Arg Tyr Thr Tyr Asp Pro Val Gly Asn Val Leu Ser Val Asn Asn Asp 325 330 335

Ala Glu Glu Thr Arg Phe Trp Arg Asn Gln Lys Val Val Pro Glu Asn 340 345 350

Thr Tyr Ile Tyr Asp Ser Leu Tyr Gln Leu Val Ser Ala Thr Gly Arg 355 360 365

Glu Met Ala Asn Ala Gly Gln Gln Gly Asn Asp Leu Pro Ser Ala Thr 370 375 380

Ala Pro Leu Pro Thr Asp Ser Ser Ala Tyr Thr Asn Tyr Thr Arg Thr 385 390 395 400

Tyr Arg Tyr Asp Arg Gly Gly Asn Leu Thr Gln Met Arg His Ser Ala

Pro Ala Thr Asn Asn Asn Tyr Thr Thr Asp Ile Thr Val Ser Asp Arg
420 425 430

Ser Asn Arg Ala Val Leu Ser Thr Leu Ala Glu Val Pro Ser Asp Val 435 440 445

Asp Met Leu Phe Ser Ala Gly Gly His Gln Lys His Leu Gln Pro Gly
450 455 460

Gln Ala Leu Val Trp Thr Pro Arg Gly Glu Leu Gln Lys Val Thr Pro

Val Val Arg Asp Gly Gly Ala Asp Asp Ser Glu Ser Tyr Arg Tyr Asp 485 490 495

Ala Gly Ser Gln Arg Ile Ile Lys Thr Gly Thr Arg Gln Thr Gly Asn 500 505 510

Asn Val Gln Thr Gln Arg Val Val Tyr Leu Pro Gly Leu Glu Leu Arg

Ile Met Ala Asn Gly Val Thr Glu Lys Glu Ser Leu Gln Val Ile Thr 530 535 540

Val Gly Glu Ala Gly Arg Ala Gln Val Arg Val Leu His Trp Glu Ile

545 550 555 560 Gly Lys Pro Asp Asp Leu Asp Glu Asp Ser Val Arg Tyr Ser Tyr Asp 570 Asn Leu Val Gly Ser Ser Gln Leu Glu Leu Asp Arg Glu Gly Tyr Leu 585 Ile Ser Glu Glu Glu Phe Tyr Pro Tyr Gly Gly Thr Ala Val Leu Thr 600 Ala Arg Ser Glu Val Glu Ala Asp Tyr Lys Thr Ile Arg Tyr Ser Gly 615 Lys Glu Arg Asp Ala Thr Gly Leu Asp Tyr Tyr Gly Tyr Arg Tyr Tyr 635 Gln Pro Trp Ala Gly Arg Trp Leu Ser Thr Asp Pro Ala Gly Thr Val 650 Asp Gly Leu Asn Leu Phe Arg Met Val Arg Asn Asn Pro Val Thr Leu 665 Phe Asp Ser Asn Gly Arg Ile Ser Thr Gly Gln Glu Ala Arg Arg Leu 680 Val Gly Glu Ala Phe Val His Pro Leu His Met Pro Val Phe Glu Arg 695 Ile Ser Val Glu Arg Lys Ile Ser Met Ser Val Arg Glu Ala Gly Ile 705 710 715 Tyr Thr Ile Ser Ala Leu Gly Glu Gly Ala Ala Lys Gly His Asn 730 Ile Leu Glu Lys Thr Ile Lys Pro Gly Ser Leu Lys Ala Ile Tyr Gly 745 Asp Lys Ala Glu Ser Ile Leu Gly Leu Ala Lys Arg Ser Gly Leu Val Gly Arg Val Gly Gln Trp Asp Ala Ser Gly Val Arg Gly Ile Tyr Ala His Asn Arg Pro Gly Gly Glu Asp Leu Val Tyr Pro Val Ser Leu Gln Asn Thr Ser Ala Asn Glu Ile Val Asn Ala Trp Ile Lys Phe Lys Ile Ile Thr Pro Tyr Thr Gly Asp Tyr Asp Met His Asp Ile Ile Lys Phe 825 Ser Asp Gly Lys Gly His Val Pro Thr Ala Glu Ser Ser Glu Glu Arg 835 840 Gly Val Lys Asp Leu Ile Asn Lys Gly Val Ala Glu Val Asp Pro Ser 855 860

±655,115

Arg Pro Phe Glu Tyr Thr Ala Met Asn Val Ile Arg His Gly Pro Gln 865 870 880

Val Asn Phe Val Pro Tyr Met Trp Glu His Glu His Asp Lys Val Val 885 890 895

Asn Asp Asn Gly Tyr Leu Gly Val Val Ala Ser Pro Gly Pro Phe Pro 900 905 910

Val Ala Met Val His Gln Gly Glu Trp Thr Val Phe Asp Asn Ser Glu 915 920 925

Glu Leu Phe Asn Phe Tyr Lys Ser Thr Asn Thr Pro Leu Pro Glu His 930 935 940

Trp Ser Gln Asp Phe Met Asp Arg Gly Lys Gly Ile Val Ala Thr Pro 945 950 955 960

Arg His Ala Glu Leu Leu Asp Lys Arg Arg Val Met Tyr 965 970

United States Patent & Trademark Office Office of Initial Patent Examination -- Scanning Division



Application deficien	cies found during	scanning:	
□ Page(s)	of		were not present
for scanning.		(Document title)	
☐ Page(s) present for scanning.	of	(Document title)	were not

· Scanned copy is best available. Figure, are to dark